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Local barometric pressure changes at the apical surface of the skin have been reported to alter 
the mechanical and physiological properties of the cutaneous tissue. However, how skin 
changes induced by barometric pressure alter percutaneous penetration require further 
investigation. The aim of this study was to understand the effects of local barometric pressure 
changes upon cutaneous drug delivery with a view to understand if such an approach could 
be used to design a novel medicinal product. To accomplish this, one of the most widely used 
test systems for studying in vitro skin permeability, the Franz diffusion cell, was adapted to 
operate under sub-atmospheric pressure. Three relevant agents (tetracaine, diclofenac 
diethylamine and aciclovir) were selected, based upon their different physicochemical 
properties, and a suitable analytical method was developed for each molecule. The model 
agents were shown to aggregate in solution and the process of aggregation appeared to retard 
penetration into the skin. In vitro hypobaric driven delivery was shown to be an effective 
means to achieve ‘targeting’ of diclofenac diethylamine and aciclovir within the epidermal 
tissue after topical application of the aggregated agents. The calculated epidermal ‘targeting’ 
potential was 4 and 1.4 for each model agent, respectively. The mechanical and 
morphological changes in the hypobaric stressed skin showed that the ‘targeted’ drug 
deposition to the epidermal layer was accompanied by an enlargement of the follicular 
infundibula (p < 0.001), reduced corneocyte size (p < 0.001) and skin thinning (p < 0.05). 
These findings suggested that both enhanced follicular and passive stratum corneum transport 
played a role in the manner which hypobaric pressure improved cutaneous penetration. Local 
hypobaric stress application to the skin was also shown to induce a haemodynamic response 
(i.e. a significant increase in blood flow (p < 0.001)), which together with the ability to alter 
skin drug diffusion significantly enhanced cutaneous and systemic bioavailability (p < 0.01) 
of a model macromolecule. These results demonstrated that the application of topical 
barometric stress represented a promising technology to deliver molecules into the skin and it 
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1.1 General introduction 
 
Drug delivery via the skin is one of the most commonly employed routes of medicinal 
compound administration (Cross and Roberts, 2004). The cutaneous tissue can be used to 
deliver therapeutic agents within the skin strata (topical delivery) and to the systemic 
circulation (transdermal delivery). This route of administration offers several attractive traits 
such as the provision of a drug reservoir that can be removed from the body and the 
possibility of a convenient and pain free means to provide controlled release of a drug over 
24 h from a single application (Guy and Hadgraft, 2003; Williams, 2003; Prausnitz et al., 
2004; Bronaugh and Maibach, 2005; Joshi and Raje, 2002; Roberts et al., 2002).  
 
Despite its frequent use in modern medical practise, drug delivery via the skin has yet to 
achieve its full potential (Prausnitz and Langer, 2008). This is due to the fact that the skin’s 
stratified structure provides a formidable resistance to drug movement and currently available 
formulation technologies still struggle to provide targeted drug administration. The skin’s 
main function is to prevent xenobiotic permeation and regulate transcutaneous water loss 
(Potts and Francoeur, 1991; Delgado-Charro and Guy, 2001). The outermost “horny layer” of 
the skin, the stratum corneum (SC), confers the greatest regulation potential for most agents 
due to its anatomy. In the SC, corneocytes are embedded within a lipid matrix and the 
architecture of this skin layer is commonly associated with a “brick and mortar” wall, as it 
gives a sense of both the SC’s structure and function. The SC and the multiple layers which 
are formed in the underlying epidermal tissue exhibit a selective permeability that only 
allows relatively small lipophilic compounds to efficiently penetrate into the dermis (< 500 
Da, Log P 0.8 - 3 (Naik et al., 2000; Barry, 1983)). The development of mathematical models 
to describe and predict skin permeability has strengthened the knowledge of how the 
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chemistry of drugs can be manipulated to increase passive permeability of agents into the 
skin. In addition, these models have contributed to the development of a broad range of 
strategies which facilitate compound penetration into the skin, including passive 
enhancement delivery methods (e.g. chemical enhancers, supersaturated systems) and 
physical enhancement methods (e.g. iontophoresis, sonophoresis). However, even using these 
drug delivery technologies trying to preferentially locate an agent in specific strata of the skin 
remains a challenge. 
 
The ability to enhance drug delivery into the skin and then localise agents within specific 
strata of the cutaneous tissue (where the site of action lies) is desirable in a wide range of 
clinical conditions, including the treatment of neoplasias, inflammatory conditions or 
microbial infections (Brown et al., 2006). Inducing barometric stress to the apical surface of 
the skin affects its mechanical properties and the local vasculature and these changes could 
have a significant impact upon drug diffusion and localisation within the cutaneous tissue 
(Wojciechowski et al., 1985; Arora et al., 2008; Banga, 2011). Childers et al., (2007) has 
already demonstrated that a sub-atmospheric pressure of 500 mBar resulted in thinning of the 
epidermis and enlargement of blood vessels embedded in the dermis, hence this may be one 
means skin strata localised drug delivery could be achieved. However, the potential of this 
technology to enhance drug delivery via the skin is at the present poorly understood and this 
field warrants further investigation. It was the aim of this PhD project to investigate this area 
in greater depth and to facilitate this, the first task was to review the current understanding of 
the fundamental physiology of the skin layers and the manner in which drug transport is 
controlled across this barrier. 
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1.2 Skin structure and routes of permeation 
 
The skin’s highly complex structure and physiological organization dictates the pathway for 
drug permeation across the different strata. Therefore, several methods of enhancing drug 
delivery into the skin, including using barometric pressure, attempt to induce reversible 
alterations in the skin’s structure. Hence, it is thought to be a valuable activity to review the 
current understanding of the skin structure and function at the start of the PhD project.  
 
The skin is the largest and most readily accessible organ of the human body with a total 
weight of more than 3 kg and a surface area of 1.5 - 2 m2 (Cevc, 1997). The main function of 
the skin is to act as a protective barrier from the outside environment. This protective 
function is achieved mainly by its physiological structure. The skin is a multilayered organ 
that structurally comprises two distinct main components: a stratified avascular outer cellular 
epidermis (SC and viable epidermis (VE)) and an underlying acellular dermis consisting of 
connective tissue (Figure 1.1). The properties of the skin strata are different and hence drug 
permeation through these barriers differs. The knowledge of the specific anatomy helps the 














Figure 1.1. A diagrammatical representation of a cross-section through human skin showing 
the different cell layers and appendages, taken from (Williams, 2003). 
 
1.2.1   Stratum corneum 
 
The SC, or horny layer, is the outermost layer of the epidermis, which is often the focus for 
most delivery strategies that attempt to increase percutaneous penetration, as it presents a 
highly restrictive barrier. The thickness of this layer ranges between 10 and 20 µm (Bouwstra 
et al., 2003; Huang et al., 2005). Its “brick and mortar” structure (Figure 1.2) consists of 10-
25 rows of dead keratinocytes (corneocytes) embedded in a lipid matrix (Bouwstra et al., 
1997; Norlen, 2008). The corneocytes represent the “bricks”, which are flattened, elongated, 
dead cells, lacking nuclei and other organelles (Benson, 2005). It is important to note that the 
corneocytes are not brick shaped, but rather are polygonal, elongated and flat (0.2 -1.5 µm 
thick and 34 – 46 µm in diameter) (Benson, 2005).  














Figure 1.2. The “brick and mortar” structure of the SC, modified from (Williams and Barry, 
1992). 
 
The cells are joined together by desmosomes that maintain the cohesiveness of this layer 
(Menon, 2002). The heterogeneous structure of the SC is composed of approximately          
75 - 80 % proteins, 5 – 15 % lipids and 5 – 10 % unidentified on a dry weight basis 
(Williams, 2003). The intercellular lipid matrix provides the “mortar” for the “bricks”. This 
mortar chiefly comprises of ceramides, cholesterol, triglycerides and fatty acids, arranged 
into lipid lamellae. These lamellae are predominantly organised into bilayers (Michaels et al., 
1975). The “brick and mortar” structure is primarily responsible for the SC’s ability to act as 
the main barrier of the skin. It functions to regulate both the permeation of xenobiotic 
compounds into the skin and endogenous compounds out of this tissue (Elias, 2005), but 
simply crossing the SC does not lead to strata localisation of therapeutic agents as increasing 
transport across the SC can result in more drug passage to the epidermal and dermal tissue. 
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Drug diffusion across the SC is achieved via an intercellular (i.e. restricted to the lipid matrix) 
or transcellular (i.e. through the corneocytes and lipid matrix) transport (Figure 1.3). 
Diffusion through these routes is dependent upon the drug’s affinity with the lipid matrix, 
with the internal environment of the corneocyte and upon the ability to permeate the 
corneocyte envelop (Barry, 1987; Friberg et al., 1990). The intercellular route is believed to 
be the dominant means of entry for most drugs (Yotsuyanagi and Higuchi, 1972; Potts and 
Francoeur, 1991; Tanner and Marks, 2008). However, via both routes penetration of the SC is 
a multistep process that involves partitioning into, diffusion through and partitioning out of 
the tissue. The transcellular route provides a larger area for diffusion and at the same time a 
shorter route to bypass the SC, but it also involves more partitioning and diffusion steps than 
the intercellular route.  After partitioning into and diffusing through the relatively aqueous 
corneocytes, the drug following the transcellular route must partition into the surrounding 
lipid envelope and subsequently partition in and out of the multiple lipid bilayers that 
separate the corneocytes (Hadgraft and Guy, 1989). Drug enhancement strategies such as 
barometric stress can alter these passive diffusion pathways via the SC and/or it can modify 
the transappendageal cutaneous route (Figure 1.3) as discussed later. If passage of a molecule 










Figure 1.3. Permeation routes through the SC: 1) via the lipid matrix between the corneocytes 
(i.e. intercellular route) and across the corneocytes and lipid matrix (i.e. transcellular route), 
2) via the sweat glands and 3) via de hair follicle (taken from (Daniels, 2007)). 
 
1.2.2 The viable epidermis 
 
Strategies to enhance drug delivery rarely act directly upon the VE as it lies below the SC, but 
this layer is the main site of action for a wide range of drugs applied to the skin for local 
action (Brown et al., 2006). Its properties are different to the SC and therefore if one wishes 
to localise a drug in this strata, its anatomy and penetration routes must be compared to the 
SC. 
 
The VE consists of a keratinized stratified squamous epithelium. The thickness of the 
epidermis ranges from 100 to 150 µm (Menon, 2002). The predominant cells are the 
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keratinocytes (Menon, 2002), which produce sulphur containing proteins, keratins and 
various lipids while differentiating and then gradually converting from live to dead fully 
keratinised cells as the cells move towards the skin’s surface (Huang et al., 2005). The other 
non-keratinocyte cells present in the VE are the Langerhans’ cells, which are involved in 
keratinocyte proliferation and skin sensitisation, and melanocytes, which generate and supply 
melanin granules to the keratinocytes (Barry, 2007). The keratinocytes are organized in layers 
above the basement membrane, reaching to the outer surface, which correspond to the 
consecutive steps of the vectorial process of keratinocyte maturation/differentiation (Figure 
1.1). The stratum basale is a single layer of columnar or cuboid cells that are attached to the 
underlying irregular basement membrane by hemidesmosomes and laterally to each other and 
to the overlying stratum spinosum cells by desmosomes. The basal cells are constantly 
undergoing mitosis causing the off-spring to be displaced outward to keep the epidermis 
replenished as the SC cells are constantly being sloughed from the surface epidermis. This 
continual renewal of the epidermis takes place every 20 – 30 days (Delgado-Charro and Guy, 
2001). The succeeding outer layer is the stratum spinosum, which consists of several layers of 
irregular polyhedral cells that become flattened as they reach the surface. These cells are 
connected to the adjacent stratum spinosum cells and the stratum basale cells below by 
desmosomes (Huang et al., 2005). The presence of numerous tonofilaments differentiates 
them morphologically from the other cell layers. The subsequent layer is the stratum 
granulosum, which comprises of numerous layers of flattened cells lying parallel to the 
epidermal - dermal junction. This layer contains irregularly shaped keratohyalin granules 
(Huang et al., 2005). These granules are thought to play a role in keratinization and barrier 
function. Another characteristic of this stratum is the presence of lipid containing lamellar 
granules. The three strata described above form the VE. Then, the stratum lucidium is the 
transition layer that consists of thin, translucent and homogenous strata. It is found only in 
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distinct anatomical areas of exceptionally thick skin and in hairless regions (e.g. plantar and 
palmar surfaces). It is formed of several layers of fully keratinized, closely compacted, dense 
cells devoid of nuclei and cytoplasmic organelles. Their cytoplasm contains protein-bound 
phospholipids and a keratin-like protein (Huang et al., 2005). Most researchers tend to view 
the stratum lucidum as the lower portion of the SC and thus bracket them together (note: 
Figure 1.1 does not show the stratum lucidum).  
 
The fact that drug diffusion across the VE is heavily influenced by diffusion through an 
aqueous domain that is restricted by proteins and keratinocyte tight junctions (Bazzoni and 
Dejana, 2002; Brandner et al., 2006) means that hydrophobic drugs can be trapped in the SC 
without the ability to penetrate into the epidermis. It is primarily the higher water content of 
these strata that makes it a more efficient barrier to lipophilic permeant ingress (Scheuplein, 
1971). Other factors may have a significant impact upon the penetration and retention of 
agents within this layer including drug metabolism and binding to cellular components (Liu 
et al., 1991; Hikima et al., 2002; Roberts et al., 2005). For example, Bhatt et al., (2008) 
reported a higher than expected amount of a lipophilic pesticide in the epidermal tissue (after 
a 48 h exposure) due to protein binding. The contribution of such processes is not always 
very clear, however it is generally accepted that they can have a significant impact on the 
amount of drug that can permeate into the underlying dermal tissue. Altering skin thickness 
and cutaneous blood flow by modifying barometric pressure applied to the skin may modify 
the properties of the VE and hence this could facilitate drug localisation in this layer or 
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1.2.3 The dermis 
 
Immediately beneath the epidermis sits the dermis, which is the thickest component of the 
skin, up to 1 - 2 mm in depth (Bouwstra et al., 2003). Its upper layer, the 100 - 200 µm thick 
papillary dermis, consists of thin collagen bundles, elastin fibres, fibrocytes, water, 
electrolytes, plasma proteins and polysaccharides - polypeptide complexes (Jakubovic et al., 
1992). Below this layer is the thicker reticular dermis, made up predominantly of collagen 
and elastin networks (Jakubovic et al., 1992). While collagen bundles provide structural 
support, elastin fibres are more flexible and serve to anchor the epidermis to the dermis. The 
elastin adherence helps the skin to return to its original morphology after being stretched. 
Protected by the epidermal layer, the dermis houses the blood vessels, lymphatics and 
peripheral nervous system network within the skin, as well as the various skin appendages 
(Jepps et al., 2013). Underneath the reticular dermis lies the hypodermis (subcutaneous fat 
tissue), which may have a thickness of up to several millimetres (Jepps et al., 2013). It 
consists of fat microlobules and collagen bundles; it also houses the blood vessels, lymphatics 
and nerves. Its main functions are to store energy, to provide thermal insulation and to 
connect the skin to the underlying structures of the muscle and bone (Ritschel and Hussain, 
1988; Jakubovic, 1992; Grams et al., 2005). The dermal layer is the site of absorption of 
permeated solutes into the systemic circulation. Microvascular flow through the skin can vary 
by 100-fold depending on exogenous conditions, making it one of the most highly perfused 
organs in the body. The structural organization of the dermal microvasculature has been 
described in detail in the literature (Braveman, 1990).  
 
Drug diffusion across the dermis is achieved in the same manner as described above for the 
VE, it acts as an aqueous barrier. However, the high vascularization of this layer has a 
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significant impact upon drug transport and localization of actives. In addition, to the local 
vasculature, the dermis presents several sites for binding and retention of molecules. The co-
administration of vasoactive agents (known to alter drug absorption into the systemic 
circulation) has provided further knowledge of the function of the local vasculator in drug 
penetration and distribution (Riviere et al., 1991; Singh et al., 1994). Theoretically, 
vasodilatation should allow a greater absorption of drug into the systemic circulation and 
vasoconstriction is expected to have a contrary effect. Such effects have been experimentally 
confirmed for a variety of drugs such as lidocaine and flurbiprofen when co-administered 
with vasoactive agents (Riviere et al., 1991; Sugibayashi et al., 1999). Increased drug 
distributions at contralateral sites due to vasodilation (Cross et al., 1999) and the opposite 
effect due to vasoconstriction (Higaki et al., 2005) have also been reported. The skin 
appendages located within the dermal tissue may play a significant role upon percutaneous 
penetration; hence it is thought to be a valuable activity to review their anatomy and 
physiology. 
 
1.2.4 Skin appendages  
 
The skin appendages present a desirable means to target drug delivery directly to the 
epidermal and dermal tissue due to the possibility of avoiding the tortuous route through the 
SC (Delgado-Charro and Guy, 2001) (Figure 1.3). There are three main types of skin 
appendages, which traverse the skin and terminate in the dermis: hair follicles, sebaceous 
glands and sweat glands (eccrine and apocrine). The follicular opening extends to the 
sebaceous duct that connects the follicle with the sebaceous gland (Figure 1.1). This gland 
produces sebum that consists of free fatty acids, cholesterol, cholesterol esters, squalene, 
waxes and triglycerides (Valiveti et al., 2008) that fills the infundibulum and serves different 
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roles such as lubricating the skin surface and maintaining the surface pH at around 5 
(Williams, 2003; Barry, 2007). The follicle is covered by an epithelium layer that is a 
continuance of the SC and its thickness is gradually reduced along the structure (Scheuplein 
et al., 1971; Grams et al., 2005; Schaefer et al., 2001). The heavily vascularized network that 
surrounds the follicular structure could have a significant impact upon drug diffusion of a 
permeant following this route (Jepps et al., 2013; Jacobi et al., 2006). Eccrine sweat glands 
are tubular structures which possess a coiled section located at the lower dermis (Figure 1.1). 
These glands produce sweat to help cool the body by evaporation, improve grip and sensitize 
the skin (Ritschel and Hussain, 1988; Jakubovic et al., 1992; Montagna et al., 1992). The 
apocrine glands resemble the eccrine glands however they are ten times larger than the latter 
and open to the infundibulum (Washington, 2001). Both the eccrine and apocrine glands are 
highly vascularized (Ellis, 1961; Hurley, 2001).  
 
Among the different transappendageal pathways (Figure 1.3), the follicular route has been 
shown to provide encouraging results upon epidermal and dermal drug targeting and hence 
has received a great deal of attention over the past 10 years (Knorr et al., 2009). Initially, 
these appendages were regarded to not significantly contribute to drug penetration because 
they represent only 0.1% of the total surface of the skin (Scheuplein, 1967). However, the 
low percentage of the available surface area is an underestimation of the actual surface area 
available for permeation, since the hair follicles extend deep through the skin surface past the 
dermis and hence allow drug delivery to this skin strata (Babiuk et al., 2000). In addition, the 
possibility of interfollicular drug diffusion directly into the viable epidermis and the presence 
of a heavily vascularized network around the follicular route may have a significant impact 
upon drug localisation within the cutaneous tissue (Jepps et al., 2013; Jacobi et al., 2006; 
Rancan et al., 2009). In fact, there have been some reports that suggest that the 
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transappendageal route may play an important role upon the permeation of actives, especially 
hydrophilic and large molecules (Huang et al., 2005; Wilke et al., 2006).  
 
1.3 Parameters that influence percutaneous penetration 
 
1.3.1 The influence of permeant characteristics 
 
The permeant characteristics play an important role in the process of traversing the cutaneous 
tissue and mainly it is the interaction between the permeant and the tissue that dictate the rate 
of penetration and residence of the drug in a particular skin strata. The journey across the 
cutaneous tissue for many xenobiotics is not exclusively by one route; rather it involves 
utilisation of the intercellular, transcellular and transappendageal pathways to varying 
extents. The permeant characteristics influence the way the molecules approach the process 
of skin penetration and therefore this has an impact on any strategies to enhance transport and 
localise agents within specific strata of the cutaneous tissue. 
 
The effect of partition coefficient (usually expressed as Log P, defines the ratio of partition 
between octanol/water), molecular size, hydrogen bonding and solubility have been 
considered to be the major characteristics that influence cutaneous drug delivery (Scheuplein 
and Blank, 1971; Michaels et al., 1975; Roberts, 1996). However, the relationship between 
permeant’s physicochemical characteristics and hypobaric driven delivery has not yet been 
reported in the literature and this is one aspect of percutaneous administration that warrants 
further investigation. Hence, an understanding of the principal physicochemical 
characteristics that may influence drug permeation through the skin is required. There has 
been much academic debate as to which of these physicochemical characteristics are the most 
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important when one wishes to design a drug that will traverse the skin effectively. Barry, 
(1987) reported that the route of permeation through the skin is mainly determined by the 
permeant’s partition coefficient as this is a good prediction of the route a molecule may move 
through the skin. Polar or hydrophilic molecules (Log P < 1) are thought to transport through 
the skin via the transcellular route (Williams, 2003) whereas lipophilic compounds (Log P > 
1) are expected to travel along the intercellular route (Williams, 2003; Hadgraft et al., 1998). 
For highly hydrophilic, charged and large molecules the transappendageal route may be of 
more importance (Huang et al., 2005; Wilke et al., 2006). To achieve a good level of skin 
permeation an intermediate partition coefficient (Log P octanol/water between 1 and 3) has been 
reported to be ideal since it allows drug diffusion through the lipophilic lipid matrix of the SC 
and subsequent clearance into the lower hydrophilic VE and dermis. Molecular size has also 
been reported to be an important drug characteristic that influences the diffusion coefficient 
of a permeant (Potts and Guy, 1992). An inverse relationship between molecular size and 
percutaneous permeation has been established and some studies suggest that molecular size is 
the main determinant of permeant diffusion across the skin (Magnusson et al., 2004). It has 
been proposed that ideally a drug administered to the skin should display a molecular size of 
less than 500 Da (Bos and Meinardi, 2000). The hydrogen-bonding capacity of drugs has also 
been considered to have a significant role to play in percutaneous permeation (Roberts, 
1976). The introduction of one hydrogen bounding group to a permeant was reported to 
significantly limit its ability to cross the skin, whereas the addition of extra groups resulted in 
less pronounced effects relative to the first binding site (Roberts, 1996).  
 
Another important characteristic of a permeant is the solubility in the application vehicle. 
Since most topical products are formulated with a polar external phase, a certain degree of 
aqueous solubility is usually required since the flux of a drug moving across the cutaneous 
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tissue is dependant to some extent on the drug concentration in the application vehicle (as 
described in Section 1.5). In some cases, however, drug flux can still be obtained with only a 
small amount of dissolved drug in a topical delivery system, as this can be in equilibrium 
with precipitated drug within the vehicle. The undissolved drug can provide a drug reservoir 
at the apical surface of the skin because the movement through the barrier is typically quite 
slow, hence a constant rate of delivery can be achieved (Gupta et al., 1992). ). The degree of 
ionisation of the permeant in the application vehicle can also influence percutaneous 
penetration. Unionized microspecies permeate easily through the SC due to their hydrophobic 
characteristics, whereas the ionized form displays low affinity to lipid domains and this 
usually results in poor permeation as described by the pH-partition hypothesis (Shore et al., 
1957). However, despite the lower affinity of the ionised molecules to the SC, such molecules 
have been shown to pass through the skin and this may be related to their high aqueous 
solubility which may help the permeation through the cutaneous tissue (Barry, 2007). In 
addition, charged molecules can cross the skin via the transappendageal route (Horita et al., 
2014; Barry, 1987). It is important to either measure or predict the manner in which the 
inherent properties of a drug will influence its transport through the skin, as normally it is 
difficult to change these characteristics without creating a new drug entity. Therefore, any 
attempts to enhance drug delivery or target specific skin strata must be tailored to the 
particular drug which wishes to be administered. 
 
1.3.2 The influence of temperature, skin anatomy and physiology 
 
Temperature, hydration of the SC and regional variation can also affect cutaneous penetration 
and localisation of a therapeutic agent within specific skin strata. One approach to enhance 
skin permeability is the application of heat (Mitragotri, 2006). For example, exposure to 
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prolonged moderate heating has been reported to enhance fentanyl skin penetration by 4-fold 
(Shomaker et al., 2000). However, controlling the application of heat during medical practise 
can be problematic and some heat patches have caused burning due to extreme variations of 
temperature in the products (Park et al., 2008).  Hydration of the skin caused by topical 
formulation or transdermal patch occlusion of the skin tissue has been reported to increase 
skin permeability by 5 to 10-fold due to increasing the fluidity of the cells within the SC (Van 
Den Merwe and Ackermann, 1987). This effect can also be observed indirectly by an increase 
in the movement of water from the VE to the SC, commonly defined as transepidermal water 
loss (TEWL) (Blank et al., 1984). Other factors, such as drug metabolism, protein binding 
and blood flow can influence skin penetration and residence of actives within specific skin 
strata (as seen in Section 1.2). In addition, a different SC thickness, variation of the density of 
sebaceous glands, hair follicles and water content may result in different transport rates 
across several areas of the body. Prausnitz et al., (2012) suggested the rank of regional 
permeability to be as follows: << palm/sole < trunk/extremities < face/scalp << scrotum.  
 
1.4 The prediction of percutaneous drug delivery 
 
The evaluation of the effects of topical barometric stress upon percutaneous penetration and 
drug residence within specific skin strata should ideally be assessed under similar 
circumstances to those observed when administering a formulation to a patient. However, this 
approach would be extremely complicated and costly. The fundamental linking of the skin 
structure and the factors that alter drug penetration and residence within the cutaneous tissue 
drove the need for the development of predictive models and experimental methodologies (in 
vitro and in vivo) to determine the ability of novel technologies to enhance drug delivery via 
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the skin. As such, a series of laboratory based methods to determine the effects of hypobaric 
driven delivery upon percutaneous penetration including mathematical modelling, in vitro 
and in vivo techniques were employed in this project.  
 
1.4.1 Mathematical models 
 
The passive transport rate of a therapeutic agent through a confluent barrier can be described 
by mathematical representations of the chemical penetration process. Although the latter is 
typically measured at a set barometric pressure, this term is not typically included within the 
standard mathematical models that aim to describe drug passage across the cutaneous tissue. 
Nevertheless, the effects of skin changes (e.g. membrane thinning and blood flow) induced 
by barometric stress upon cutaneous drug penetration may be understood through 
mathematical representation of this process.  
 
Although the penetration of therapeutic agents through the heterogeneous structure of the 
skin is a multifactorial process, scientists have simplified the approaches taken to understand 
the transport process (Barry, 1983). For example, one approach is to suggest that the main 
barrier for skin permeation lies in the non-viable SC and since solute transport across this 
layer is primarily by passive diffusion (Scheuplein and Blank, 1971) then solute mass transfer 
across the cutaneous tissue can be described by Fick’s first law. This equation relates the 
amount of solute (Q), that is transported across the skin barrier of area, A, over a period of 
time, T, with a constant concentration gradient, ΔCs, the diffusion coefficient in the skin 
barrier, D, and the path length, h (equation 1.1). 
 
𝑄 = 𝐷𝐷𝐷𝐷𝐷𝑠/ℎ                                                                                                    (Equation 1.1) 
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The main assumptions of this model are that the SC barrier is a pseudo-homogeneous 
membrane and that its intrinsic barrier characteristics do not change during the solute transfer 
process. In the percutaneous penetration process, steady-state can only be achieved after the 
lag time (L) for permeant diffusion has passed. The lag time can be determined by the x-
intercept of the linear portion of the cumulative solute amount as a function of time (Figure 
1.4) and is dependent upon the diffusion coefficient in the skin barrier (D) and the barrier 
thickness (h) and is given by (equation 1.2) as demonstrated by Crank, (1975). 
 
𝐿 = ℎ2/6𝐷                                                                                                            (Equation 1.2) 
 
Equation 1.1 is often represented as steady-state flux, JSS, as follows (equation 1.3). 
 
JSS = Q/(AT) = D 𝐷𝐷𝑠/ℎ                                                                                                                                   (Equation 1.3) 
 
In vitro experiments are performed to generate Jss as displayed in Figure 1.4. Using equation 


























Figure 1.4. The cumulative mass per area (Q/A) permeating the skin as a function of time (t), 
may be modelled using equation 1.3 to obtain steady-state flux (JSS). The lag time can be 
determined by the x-intercept of the linear portion of the cumulative amount (JSS) as a 
function of time. 
 
With the acknowledgment that solute mass transfer across the skin can be described by Fick’s 
first law, Higuchi work revealed the significance of the thermodynamic activity of the 
permeant agent (Higuchi, 1960; Higuchi, 1961). This laid down a seminal principle for 
modern theories to follow in subsequent years. It was proposed that assuming that there is so 
little drug present on the basolateral side of the cell line that diffusion is occurring under ‘sink 
conditions’ the maximum rate of diffusion per unit time,  (Jmax), is proportional to the 
thermodynamic activity (αs) of the compound and not its concentration (equation 1.1). The 
latter can be rewritten in terms of thermodynamic activity, where D is the diffusion 
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coefficient of the drug, Ss is the maximum solubility of a solute in the SC and h is the barrier 
thickness (Higuchi, 1961). 
 
𝐽𝑚𝑚𝑚 = 𝐷𝑆𝑠/ℎ                                                                                                       (Equation 1.4) 
 
According to this relationship, the flux of a compound from saturated solutions is constant, 
regardless of the saturated concentration in a given vehicle because all saturated solutions 
have a thermodynamic activity of 1 (Bronaugh and Maibach, 1989). However, this transport 
model makes several assumptions, including: mass transfer occurring under sink conditions, 
membrane rate controlled movement, the application vehicle does not affect the barrier, 
thermodynamic activity is homogenous throughout the formulation and only one compound 
is transported across the membrane (Higuchi, 1960). It is important to consider that non-
linearity is likely to occur due to the heterogeneity of the cutaneous tissue that permits at least 
two possible routes (polar and non-polar). Several workers have built mathematical models 
that consider two diffusional layers: the non-viable lipophilic SC and the viable hydrophilic 
tissue that presents non-polar and polar routes (Chien, et al., 1989; Anissimov and Roberts, 
1999).  
 
Quantitative structure-permeation relationship (QSPR) models attempt to determine the 
permeability coefficient (commonly presented as kp) which represents the ratio of the steady-
state flux of a permeant (Jss) and the concentration gradient (ΔCv), (equation 1.5). 
 
𝑘𝑝 = 𝐽𝑠𝑠/𝐷𝐷𝑣                                                                                                         (Equation 1.5)   
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In most cases, the quantity of drug present on the basolateral side of the cell line is so little 
that kp is represented by the ratio of Jss and Cv. If one considers that the SC is the main barrier 
for drug permeation, kp is represented by the product of the partition coefficient, K 
(SC/vehicle) and diffusion coefficient of the drug (D), normalized by the barrier thickness (h) 
as proposed by Crank, (1975) (equation 1.6). 
  𝑘𝑝 = 𝐾 .𝐷/ℎ                                                                                                        (Equation 1.6) 
 
Many of the proposed QSPR models are based on the extensive dataset gathered and reported 
by Flynn, (1990). In this work, skin permeability coefficients were obtained from a simple 
algorithm derived from their octanol-water partition coefficients and molecular weight. Potts 
and Guy (1992) when analysing Flynn’s dataset developed the QSPR that is now the most 
commonly used to estimate skin permeability. This mathematical model correlates skin 
permeability coefficient, log kp, with the permeant’s partition coefficient in octanol-water, log 
Poct/w, and molecular weight, MW (equation 1.7). 
 log Kp =  −6.3 + 0.71 . log Poct/w −  0.0061 .MW  (r2= 0.67, n= 93)               (Equation 1.7) 
 
Other mathematical models have been generated including parameters such as hydrogen 
bonding (Abraham et al., 1997; Buchwald and Bodor, 2001), melting point (Barrat, 1995) 
and group contribution approaches (Pugh et al., 1998). These additional factors can be more 
descriptive of the partition coefficient and hence, result in better fits of the model. Recent 
equations to predict skin permeability are based on empirical modelling, primarily using 
molecular descriptors. For example, neural networks are a good predictor for non-linear 
modelling of causal-effect relationships (Lim et al., 2002). 
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1.4.2 In vitro methodologies 
 
Different in vitro techniques have been employed to investigate drug percutaneous 
penetration and localisation within different skin strata. These approaches commonly involve 
the use of diffusion cells fitted with suitable membranes (e.g. silicone membrane, porcine 
skin) that operate under atmospheric pressure conditions. As such, to accomplish the aim of 
this PhD project, these methodologies needed adapting to operate under sub-atmospheric 
pressure and hence allow the transport of permeants across hypobaric stressed skin to be 
investigated. 
 
Percutaneous penetration through a membrane fitted in a diffusion cell can be determined by 
measuring the cumulative drug appearance in the receptor cell (Figure 1.5) as a function of 
time (as shown in Figure 1.4), or a concentration-depth profile of the permeant within the 
different cutaneous layers can be evaluated to determine drug residence within specific skin 
strata. The most commonly employed diffusion cells are the static diffusion upright cells 
commonly designated as “Franz” type diffusion cells (Franz, 1975; Franz, 1978) (Figure 1.5). 
The donor solution traditionally consists of the test permeant in a vehicle (e.g. aqueous, 
buffer or formulation), which is applied to the apical surface of the membrane in order to 
initiate the permeation experiment. The receptor compartment contains the receiver solution 
that is a good solvent for the permeant and does not induce any alteration to the barrier 
properties of the selected membrane (Howes et al., 1996). The receiver solution should also 
allow sink conditions (i.e. not exceeding 10% of the donor concentration and permeant 
saturated concentration in the spent receiver fluid) as this maintains a concentration gradient 
between the donor and receiver solution and hence, providing the driving force for the 
permeation process through the controlling barrier (Howes et al., 1996). To aid the 
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maintenance of sink conditions throughout the experiment, stirring of the receiver solution is 
employed. The receiver solution should be at 37 °C in order to achieve a skin surface 
temperature of 32 °C (to mimic in vivo skin surface temperature (Maddock et al., 1933)). The 
amount of formulation applied in the donor compartment is either an infinite dose (i.e. > 10 
mg.cm-2), typically used when analysing the fundamental permeation behaviour of a test 
molecule or finite dose (i.e. between 2 and 10 µg.cm-2) typically used to mimic the clinical 
application of a topical formulation (Howes et al., 1996). To ensure infinite dose throughout 
the duration of the study, fine suspensions of the permeant are often employed in the donor 
chamber of the Franz diffusion cell, to avoid any drug depletion and hence, guarantee a 
constant concentration gradient over a significant period of time. The selection of the vehicle 
to administer the test compound to the apical surface of the Franz cells is important because 
this process can have a large effect on the results obtained by this method. For most of the in 
vitro experiments aqueous based vehicles are employed because there is little deleterious 
influence of the vehicle upon the structure and barrier properties of the skin. However, 
buffering may be needed when there are issues related to the permeant ionization. The kinetic 
permeation profile is achieved by sampling the receiver fluid at defined time points and 
determining the amount of permeant in the receiver fluid using accurate and sensitive 
methods. Chromatographic methods (e.g. High Performance Liquid Chromatography) are 
most commonly used; however, when the detection sensitivity is a problem radiolabelled 
permeants (e.g. tritium 3H and 14C) can be employed. Skin components may leach during 
permeation studies due to the close contact with the receiver solution and hence, any 



















Figure 1.5. A “Franz” type diffusion cell.  The formulation is placed in the donor 
compartment and the diffusion of the drug through the membrane into the receptor is 
measured by taking samples at different time points through the sampling arm. The receptor 
phase is constantly mixed with a magnetic flea during this procedure. 
 
Since the structure and barrier properties of the skin are maintained following excision 
(Franz, 1975; Franz, 1978; Howes et al., 1996), ex-vivo Franz cell models using human tissue 
have been developed and shown to provide a reliable prediction of the dermal absorption in 
man. Human skin is the most relevant membrane to predict drug delivery across the 
cutaneous tissue; however, due to the cost and lack of availability and variability, alternatives 
have been employed to mimic the skin barrier properties. Investigations employing diffusion 
cells fitted with artificial membranes have been widely used to study the in vitro 
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flux rate of a test compound (Twist and Zatz, 1986; Feldstein et al., 1998; Houk and Guy, 
1988). This technique is cost-effective, the isotropic nature of the membrane results in higher 
reproducibility and the permeation kinetics can be described by simple mathematical models. 
The most commonly used are the polydimethylsiloxane membranes (e.g. silicone) that 
provide a non-porous hydrophobic confluent barrier, which allows the diffusion of water and 
hence, mimicking the TEWL process during permeation studies. Several animal membranes 
have also been used in vitro (Twist and Zatz, 1986; Feldstein et al., 1998; Houk and Guy, 
1988). Due to its availability, rodent and porcine skin are commonly used to perform in vitro 
permeation studies. Porcine skin is the most relevant animal model (apart of primates) to 
human skin in vitro due to its similar histological and biochemical properties, albeit the 
diameter of the follicular opening to the surface is larger (Gray and Yardley, 1975; Jacobi et 
al., 2007). Permeation profiles obtained across porcine skin have been reported to be in good 
agreement when compared with those generated through human skin (Schmook et al., 2001; 
Singh et al., 2002). Among rodents, rat skin has more anatomical similarities to human skin; 
however, rodent skin normally shows higher permeation rates than human skin (Sato et al., 
1991; Nicoli et al., 2008). Other alternatives such as skin equivalents (Schmook et al., 2001; 
Godin and Touitou, 2007; Roy et al., 1993), human reconstructed epidermis (Netzlaff et al., 
2005; Schmook et al., 2001; Godin and Touitou, 2007) and lipids from the SC (Matsuzaki et 
al., 1993) have recently been employed as model membranes to mimic human skin in vivo.  
 
The amount of permeant detected in the receiver solution allows the assessment of the 
penetration process across the skin. In addition, the concentration-depth profile of the drug 
within the different strata of the skin may be used to determine the kinetics and contribution 
of each diffusional layer to the permeation process. Drug deposition profile is time dependent 
and varies with the permeant’s physicochemical properties. Different techniques have been 
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employed and described in the literature to determine the amount of drug retained in the SC, 
VE and dermis, but the most reported one is tape stripping, which determines drug 
concentration within the SC (Pellett et al., 1997; Shah, 1998; Pershing et al., 1990; 
Stinchcomb et al., 1999). During tape stripping of the skin the SC layers are progressively 
removed by successive tape applications. The drug is extracted from the strips using a 
suitable solvent and quantified using an appropriate sensitive analytical method such as 
HPLC or scintillation counting (Tsai et al., 1999; Schwarb et al., 1999; Wester et al., 1998). 
This procedure is non-invasive and has been employed in bioequivalence testing (Pershing et 
al., 1994; Shah et al., 1998). In order to remove the SC homogeneously, a roller (Weigmann 
et al., 1999), a constant weight (Shah et al., 1998) or a spatula (Marttin et al., 1996) can be 
used to allow the application of the tape under similar pressure conditions, as this improves 
the contact between the tape and the SC. In addition, the velocity of tape stripping should be 
maintained constant throughout the procedure to ensure that the amount of SC adhered to the 
tape is uniform (Landemann et al., 2009). The first strip is often discarded since this 
represents unabsorbed drug on the skin surface (Landemann et al., 2009) and the drug is 
quantified. After removal of the SC by tape stripping the VE is separated from the dermis, 
each skin layer is finely minced with scissors or using a tissue homogenizer and the drug is 
extracted using a suitable solvent. Then, the amount of drug is quantified with an appropriate 
sensitive method (e.g. HPLC or scintillation counting for radiolabeled compounds). Several 
techniques to separate the epidermis from the dermis have been reported such as by gentle 
teasing with the needle-type forceps (Lehman et al., 1988; Lehman and Malany, 1989), with 
a scalpel (Surber et al., 1991; Ferreira et al., 1995; Ayub et al., 2007; Argenta et al., 2014) 
and employing a freezing microtome (Kammerau et al., 1975; Schaefer and Stuttgen, 1976). 
Every method employed should be shown to be reproducible and the drug recovery extraction 
procedures need to be developed and validated prior to the start of the experiments. The 
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regulatory guidelines define 100 ± 15% as of the drug amount that should be recovered at the 
end of each experiment (Health and consumer protection directorate-general, 2006). The in 
vitro assessment of cutaneous drug delivery is often used to support in vivo measurements 
because it is cheaper, faster and there are no concerns with ethical issue or housing animals 
(Russell and Guy, 2009). However, it is recognized that in vivo studies usually must be 
completed to validate science concepts, such as the effects of topical barometric stress 
described in this PhD thesis, as they provide realistic measurement of the penetration process 
in intact skin (e.g. the cutaneous microvascular flow is present). 
 
1.4.3 In vivo methodologies 
 
Inducing barometric stress to the apical surface of the skin affects the cutaneous 
microcirculation and local blood flow changes could have a significant impact upon drug 
diffusion and localisation within specific skin strata (Wojciechowski et al., 1985; Arora et al., 
2008; Banga, 2011; Childers et al., 2007). Animal models provide a useful tool to access the 
effects of the cutaneous blood flow upon xenobiotic penetration into the cutaneous tissue 
(Godin and Touitou, 2007). Briefly, the formulation is administered during a fixed period of 
time to a specific area of the skin and the cutaneous absorption is determined by measuring 
the amount of drug present in the skin layers and/or in the blood or urine. The data can be 
used to determine the systemic bioavailability of the drug and/or its metabolites in the plasma 
or urine (Akrill et al., 2002; Brooke et al., 1998; Roberts and Cross, 1999; Singh and Roberts, 
1994).  
 
Other method that has been proposed to study the pharmacokinetics of cutaneous absorption 
is microdialysis (Kreilgard, 2000; Morgan et al., 2003; Schnetz et al., 2001). The technique 
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consists on the passive diffusion through a semipermeable dialysis membrane of a 
microdialysis probe that is inserted into the dermis parallel to the site of interest. The probe is 
slowly perfused with a site compatible physiological solution, mimicking the blood flow 
(Kreilgard, 2000; Morgan et al., 2003; Schnetz et al., 2001). The technique presents several 
advantages such as avoidance of reference exposure, possibility to study skin metabolism and 
several sampling sites can be studied at the same time (Kezic, 2008). However, this technique 
is not suitable for the study of large or highly protein-bound compounds due to the low 
recovery rates (Kezic, 2008). Further, the insertion of the probe causes a skin reaction that 
may influence the cutaneous absorption process (Kezic, 2008). 
 
Tape stripping can also be employed to study in vivo topical absorption. The fundamentals of 
this methodology are similar to that previously described in in vitro studies (Section 1.4.2). 
Since the SC is the main barrier for drug absorption, it is anticipated that the 
pharmacokinetics of cutaneous absorption across this layer are related to topical 
bioavailability (Russell and Guy, 2009). Different topical administration times may be 
employed or stripping of the SC delayed after removal of the formulation to assess SC 
clearance and derive pharmacokinetic parameters (Russell and Guy, 2009). A good 
relationship has been demonstrated between the reservoir effect of the SC and percutaneous 
absorption of drugs (Rougier et al., 1983). In addition, this effect was found to be 
independent of the main factors likely to influence cutaneous absorption such as contact time, 
animal species or dose applied (Rougier and Lotte, 1993).  
 
Another commonly used in vivo technique to predict cutaneous absorption is to assess a 
biological/pharmacological response (Mckenzie and Stoughton, 1962; Barry and Woodford, 
1976; Pershing et al., 2002; Mura et al., 2007). A drawback of employing this methodology 
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is that it is only appropriated for drugs that exhibit an easily measurable response. One 
example of a pharmacological response is the effect of an anti-inflammatory drug on the 
carrageenan induced paw edema (Halici et al., 2007). Several spectroscopic methods such as 
attenuated total reflectance Fourier transform infrared spectroscopy (Klimich and Chandra, 
1986; Naik et al., 1995), remittance spectroscopy (Feather et al., 1989; Sennhenn et al., 
1993), fluorescence spectroscopy (Sennhenn et al., 1993; Jansen et al., 1974) photothermal 
spectroscopy (Sennhenn et al., 1993; Kolmel et al., 1986) and confocal Fourier transform 
Raman spectroscopy (Caspers et al., 2002)  have also been employed in vivo to determine the 
kinetics of dermal absorption. 
 
1.4.4 In vitro vs in vivo data 
 
The relationship between in vitro and in vivo diffusion studies is of fundamental importance 
to evaluate the effects of the physiological processes (e.g. cutaneous microcirculation under 
differential barometric pressure) that dominate the diffusion partition process in vivo, since 
these processes are not apprehended employing in vitro methodologies. Several workers have 
attempted to establish the relationship between in vivo and in vitro data by performing the 
comparison between the amount of permeant detected in the receiver solution in in vitro 
studies and comparing to the amount of drug absorbed and eliminated in the urine in the in 
vivo studies (Bronaugh and Maibach, 1985; Bronaugh and Franz, 1986; Wester et al., 1992; 
Dick et al., 1995; Dick et al., 1997; Cnubben et al., 2002; Mavon et al., 2007; Griffin et al., 
1999; Griffin et al., 2000). Generally, in these comparative studies there is a good agreement 
between in vitro and in vivo data; however some of the in vitro results were shown to 
underestimate in vivo cutaneous absorption (Bronaugh and Maibach, 1985; Bronaugh and 
Franz, 1986; Cnubben et al., 2002; Wojciechowski et al., 1985). These results were coupled 
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with the lack of the physiologic processes that have a significant impact in the in vivo 
situation such as the local vasculature (Wojciechowski et al., 1985), the existence of a lag 
time in the drug excretion process (Cnubben et al., 2002) and drug metabolism (Bronaugh 
and Maibach, 1985; Bronaugh and Franz, 1986).  On the other hand, an overestimation of the 
in vivo permeation absorption was reported in some studies. This was linked with an in vivo 
SC drug reservoir effect that prevented drug absorption (Griffin et al., 1999; Griffin et al., 
2000; Dick et al., 1997) and drug permeation through the subcutaneous fatty layer (Griffin et 
al., 1999; Griffin et al., 2000). 
 
1.5 Strategies to enhance percutaneous drug delivery 
 
In this PhD project, barometric pressure has been proposed as a new method to enhance 
cutaneous drug delivery. To move this concept forward, it is important to acknowledge the 
considerable efforts that have already been made to overcome this barrier such that best 
practise in the evaluation of the new technology is taken onwards. Many of the challenges 
related with the development of percutaneous enhancement strategies already published in 
the literature are associated with achieving an appropriate balance between effective delivery 
and safety. Often, this requires “targeted” localisation and this is not easy to achieve using a 
delivery system that is low cost and easy to use for patients (Prausnitz and Langer, 2008). 
The strategies that have been documented to date in research publications can be broadly 
classified accordingly to their overall approach, namely: chemical, biochemical and physical 
percutaneous drug delivery enhancement strategies such as the application of topical 
barometric stress. Each of these will be described in the text below in order to contemplate 
the position of barometric pressure among the other technologies. 
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1.5.1 Chemical enhancement 
 
Mass transport across the skin can be altered by chemical enhancers that aim to manipulate 
the environment in which the permeant crosses the skin and they generally influence one or 
more than one of the parameters described by Equation 1.4 and 1.6. For example, chemical 
penetration enhancement can be achieved by increasing the partitioning into the SC, the 
solubility in the vehicle (K), the ability of the permeant to diffuse through the membrane (D) 
or the drug thermodynamic activity. The major benefits of chemical enhancers are their cost-
effectiveness; their easy incorporation into a topical formulation and the lack of dependence 
of a delivery device. The primary limitation of chemical enhancers is related to the skin’s 
response to the application of the chemicals, as these agents can alter the barrier properties 
and cause local sensitization, irritation and occasionally systemic toxicity. Chemical 
enhancers are known to be effective for the delivery of small molecules, but they have a 
limited capacity to enhance the passage of large molecules into the skin. However, drug 
enhancement strategies such as barometric stress may overcome this issue by promoting 
percutaneous penetration of macromolecules, as discussed later. 
 
The most widely used chemical penetration enhancer is water. Formulations with high water 
content or systems that encourage skin hydration via occlusion have been shown to enhance 
the permeation of both hydrophilic and hydrophobic drugs (Williams, 2003; Bronaugh and 
Maibach, 2005). However, the mechanism by which water promotes increased percutaneous 
permeation is not fully understood. Several mechanisms have been proposed such as an 
increased mobility of the lipid bilayers (Barry, 1987), the existence of a water phase within 
the intercellular domain or water uptake by the corneocytes, but no firm conclusion has been 
made about the activity of this molecule (Marjukka et al., 1999). Chemical enhancers are 
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commonly divided in different classes including solubilizers (e.g. propylene glycol and 
ethanol), fatty acids or esters (e.g. oleic acid), surfactants (e.g. sodium lauryl sulphate) and 
terpenes (e.g. menthol). The enhancement of drug solubility is often fundamental to the 
mechanism of action of penetration enhancers in the case of poorly soluble permeants. This is 
of importance as low solubility in the donor vehicle can lead to drug depletion (Williams, 
2003) as described previously in Section 1.5.2. Ethanol and propylene glycol are commonly 
used as solubilizers. These two molecules can also act as chemical enhancers by increasing 
SC permeability and hence, enhancing drug partitioning through the skin (Megrab et al., 
1995). Oleic acid is one of the most cited chemical enhancers and it has been shown to 
increase the permeation of molecules such as 5-aminolevulinic (Pierre et al., 2006) and 6-
mercaptopurine (Koyama et al., 1994). The permeation enhancement effect of oleic acid is 
proposed to be coupled with an interaction with the SC lipids resulting in increased bilayer 
fluidity (Ongpipattanakul et al., 1991). Sodium lauryl sulphate is an anionic surfactant that 
has been reported to enhance cyclosporin A deposition within the skin (Liu et al., 2006) and 
lorazepam transdermal permeation (Nokhodchi et al., 2003). This enhancement effect has 
been shown to be elicited by disrupting proteins and lipids of the SC (Barry, 1987).  The most 
widely terpene employed as a chemical enhancer is menthol. Terpenes are non-aromatic 
compounds derived from essential oils that display relatively high Log P values (Trommer 
and Neubert, 2006). Menthol has been reported to enhance transdermal delivery of several 
molecules such as propanol hydrochloride (Kunta et al., 2000) and testosterone (Kaplun-
Frischoff and Touitou, 2000). Its mechanism of action is suggested to be attributed to a 
reversible disruption of the intercellular packing of SC lipids (Kang et al., 2007; Williams 
and Barry, 1991). Liposomes, emulsions, micelles and deformable vesicles have also been 
employed as “chemical” enhancers with a supramolecular structure that can be used to 
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increase drug solubility in the formulation and facilitate partitioning into the skin (Prausnitz 
and Langer, 2008).  
 
1.5.2 Biochemical enhancement 
 
Biochemical approaches increase skin permeability by targeting the lipid matrix of the SC or 
by altering its metabolism. The majority of the published work in this field has used peptides 
that disrupt or penetrate the outermost layer of the skin. For example, the use of an 11-amino 
acid synthetic peptide identified by phage display screening has been reported to increase the 
transdermal delivery of insulin and human growth hormone in an animal model (Chen et al., 
2006). These workers suggested that its main mechanism of action was related to an 
enhanced transappendageal peptide transport that led to an improved drug deposition within 
the cutaneous tissue. Magainin, a naturally occurring pore-forming peptide was reported to 
increase skin permeability by selectively disrupting the lipid bilayers of the SC (Kim et al., 
2007; Kim et al., 2008). The use of a polyarginine heptamer has been reported to enhance 
cyclosporine A topical delivery by acting as a transporter and localizing the drug within the 
epidermis and dermis (Rothbard et al., 2000). The use of metabolic inhibitors aim to increase 
the efficacy of standard enhancers by biochemically inhibit the metabolic process in vivo and 
hence delaying barrier recovery (Prausnitz et al., 2012). As a consequence, these approaches 
raise some concerns regarding skin integrity and reversibility and to date, their contribution to 
medical practise has been limited due to safety issues. Nevertheless, the emergence of such 
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1.5.3 Physical enhancement 
 
Since the main obstacle to achieve an effective xenobiotic percutaneous penetration resides in 
the SC, significant efforts have been made to overcome and/or circumvent this barrier by 
physical manipulation, such as the application of mechanical barometric stress described 
herein.  The main benefit of such approaches is the opportunity to significantly expand the 
range of drugs that can be delivered (Arora et al., 2008; Banga, 2011), but the physical 
manipulation of the skin generally requires a device that can be costly to produce and pose 
potential constraints for self-administration by patients. In addition, avoiding damage to 
deeper tissue layers remains a problem when physically manipulating the skin with a device 
and this has limited the use of these technologies in medical practise. It is suggested in this 
PhD that the application of topical hypobaric stress could potential represent a cost-effective 
and simple to use safe technology to enhance percutaneous drug penetration. Physical 
enhancement methods can be classified accordingly to their overall mode of action, namely: 
electrically assisted delivery, miscellaneous and mechanical methods. 
 
1.5.3.1 Electrically assisted delivery 
 
Iontophoresis and electroporation are two examples of electrically assisted physical 
enhancement methods that have been employed to deliver small molecules and 
macromolecules through the SC (Banga, 1998). Iontophoresis uses a continuous low voltage 
current field that provides an electrical driving force for mass transfer across the SC (Banga, 
1998; Kalia et al., 2004). Enhanced drug delivery is achieved by one or a combination of the 
following mechanisms: electro-osmosis (neutral molecules), electro-repulsion (charged 
molecules) or electro-perturbation (both neutral and charged molecules). An amplification of 
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mass transport via the follicular route is believed to be the primary mechanism of action for 
iontophoretic drug delivery (Batheja et al., 2006). The main benefit of iontophoresis is the 
possibility of tightly modulating the rate of drug delivery over time. It has been applied in 
clinical practise for the delivery of lidocaine and fentanyl in pain management (Mayes and 
Ferrone, 2006) and water to treat hyperhidrosis (Kreyden, 2004). In contrast to iontophoresis 
that utilizes low voltage, electroporation applies relatively high voltage pulses for very short 
periods of time in order to temporarily increase skin permeability by the formation of 
aqueous pores (Prausnitz et al., 1993; Denet et al., 2004). Mass transport through the pores is 
achieved by three mechanisms: iontophoresis during the pulse, electro-osmosis or by simple 
diffusion across the pores (Williams, 2003). Electroporation is currently being employed in 
clinical practise for the delivery of therapeutic agents to treat skin cancer (Gehl, 2008). 
However, both approaches involve the use of costly devices that are often cumbersome and 
need to be operated by trained personnel and therefore pose problems regarding patient self-
administration and compliance. 
 
1.5.3.2 Miscellaneous methods 
 
Ultrasound utilises high frequency acoustic waves to deliver drugs across the skin. Enhanced 
transdermal delivery is accomplished by two mechanisms: thermal and non-thermal. Skin 
absorption of ultrasonic energy leads to an increase skin temperature that may facilitate drug 
permeation and increase microvascular blood flow (Mitragotri, 2005). The non-thermal 
mechanism is believed to be the most prominent in increasing skin permeability. It forms 
gaseous cavities that lead to the disruption of the SC (Mitragotri, 2005). In a similar 
approach, pulses from a high power laser and high frequency alternating current have been 
employed to create sub-microscopic defects within the SC to increase skin permeability 
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(Doukas and Kollias, 2004; Sintov et al., 2003). Ultrasound is currently being used in clinical 
practise as a pre-treatment in local anaesthesia as it improves the onset time of lidocaine 
action (Spiliopoulos et al., 2011). The major drawbacks of such approaches are similar to that 
previously described above for electrically assisted delivery (Section 1.5.3.1).  
 
1.5.3.3 Mechanical methods 
 
Microneedle based devices provide a very effective means of delivering drugs across the SC 
with minimal discomfort for the patient, which avoid the inherent disadvantages commonly 
associated with needles (i.e. needle phobia, pain). This technology creates micro-scale 
perforations that are large enough to allow mass transport of small molecules, 
macromolecules and nanoparticles (Wermeling et al., 2008; Cosman et al., 2010; McAllister 
et al., 2003). Despite offering compelling opportunities in the transdermal delivery field some 
issues still need to be addressed. For example, the long-term effect of repeated application of 
these devices and the potential of increased susceptibility to bacterial infection remains 
unclear. Skin stretching after the pre-treatment with a microneedle device has been proposed 
to enhance transdermal drug delivery (Cormier et al., 2001, Neukermans et al., 2001). These 
workers suggest that a tension of ca. 0.01 to 10 mP generates the transient formation of 
micropathways that allows drug movement across the barrier, but the sole use of the 
expandable skin stretching technique was described as being inefficient as an enhancing 
method. Tape stripping (described in Section 1.4.2) and skin abrasion represent simple 
techniques that have been employed to remove the outermost layer of the skin. The removal 
of successive layers of the SC by an adhesive tape has been reported to enhance in vivo 
dermal permeation of several molecules such as 5-aminolevulinic acid and hexyl 
aminolevulinate (van den Akker et al., 2000). Although cost-effective such an approach is 
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considered to have poor patient acceptability and this has limited its clinical use. Skin 
abrasion using sandpaper has also been shown to be an effective and simple method to 
facilitate vaccine delivery across the skin, but again similar patient acceptability issues exist 
(Prausnitz and Langer, 2008). The application of local hyperbaric pressure (e.g. 250 mBar) 
has also been shown to enhance the skin permeability (Trefel et al., 1993). However, no 
mechanistic studies were reported. The application of topical hypobaric stimuli has been 
typically used to generate a suction blister that allows the removal of the epidermis while 
leaving the dermal layer intact (Svedmann, 1995). Since the dermal local vasculator and 
nociceptor nerves are not affected by this technique, transdermal invasivity is thus avoided. 
Clinical studies have shown the possibility of trans-epidermal delivery of morphine and 
vasopressin using this technique. The pharmacokinetic profile evaluation of both drugs was 
reported to be in good agreement to that registered by continuous intravenous injection 
(Svedmann et al., 1996; Svedmann et al., 1991). Laser Doppler measurements of the de-
epithelialised dermis also revealed a marked increase in the skin microvascular blood flow. 
This effect was considered to further contribute to the efficient transdermal delivery of the 
test compounds. The de-epithelialised skin area was reported to recover its normal 
appearance within 6 weeks without any sign of tissue trauma. The approximate 2.5 h time 
length that is required to induce a suction blister (Gupta et al., 1999) is one of the major 
limitations of this method. However, this can be reduced to 15 - 70 min by warming the skin 
to 38 °C (Svedmann et al., 1996). If this system was as fast and efficient as intravenous 
catheter insertion its application in medical practise would be practical. Moreover, the risk of 
epidermal infection is less serious than the consequences of systemic sepsis (Down and 
Harvey, 2003). However, the effect of local hypobaric pressure upon xenobiotic penetration 
into the cutaneous tissue has not yet been reported in the literature. Therefore, the ability of 
this technology to deliver therapeutic agents into the skin requires further investigation. 
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1.6 Aim and Scope 
 
The exposure of humans to barometric pressure changes (normally ca. 1010 mBar) can be 
considered both on the macro (whole body exposure) and micro scale (i.e. application of 
suction). Whole body exposure changes in atmospheric pressure are more common than may 
be first perceived. For example, passengers on commercial air flights are exposed to 
hypobaric pressure, approximately 820 mBar, for the duration of the flight. Although aircraft 
vary in size and flight altitudes the lowest levels of pressure that a human should experience 
during a commercial flight is 750 mBar (Muhm et al., 2007). The greater the altitude the 
more extreme the pressure changes and therefore space flight simulations use hypobaric 
pressures of 15 mBar to understand the physiological changes that humans experience during 
this process (Baisch et al., 2000). Physiological changes in blood circulation and respiration 
under hypobaric pressure have been well documented as a consequence of the humans 
exposure to whole body barometric pressure changes, but the influence of these changes on 
the barrier physiology and the bodies natural defence mechanism to xenobiotic insult does 
not appear to have been studied. Whole body exposure to barometric pressure changes would 
be expected to have very different effects to local hypobaric pressure changes induced by 
methods such as suction because the latter generates a pressure differential which could draw 
molecules across the barrier and have less profound effects on whole body physiology.  
 
There have been reports of how local air suction effects cutaneous microvascular flow and 
the mechanical properties of the skin.  For example, Childers and his colleagues (2007) 
demonstrated that a hypobaric pressure of ca. 500 mBar resulted in thinning of the epidermis 
and enlargement of blood vessels embedded in the dermis. Pedersen and Jemec (2006) 
applied hypobaric pressures between 400 and 600 mBar generated from a suction cup device 
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and reported a significantly increased TEWL with concomitant decrease in the SC water 
content. In another study, a marked increase in TEWL, disorganization of the intercellular 
lipid bilayers and rupture of the corneosomes was shown after stretching of the skin 
(Rawlings et al., 1995; Leveque et al., 2002). However, a link between skin changes induced 
by barometric pressure alteration and xenobiotic percutaneous penetration needs further 
study. 
 
As such, the aim of this study was to investigate the effects of local barometric pressure 
changes upon percutaneous penetration with a view to understand if such an approach could 
be used to design a novel medicinal product. In order to achieve this aim four objectives were 
defined: 1) to build a pressure diffusion cell that could generate a barometric pressure change 
at the skin surface, 2) to determine the effects of local barometric pressure changes upon the 
mechanical and physiologic properties of the skin, 3) to investigate the relationship between 
in vitro cutaneous bioavailability under differential barometric pressure and the drug’s 
physicochemical properties and 5) to assess the in vivo effects of local barometric pressure 
changes upon microvascular blood flow, drug pharmacokinetics and tissue distribution. To 
achieve these objectives there was initially a need to select the test agents, develop analytical 
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In order to assess the effects of local barometric pressure changes upon xenobiotic 
percutaneous penetration three model agents were selected from distinct therapeutic classes, 
namely: tetracaine (local anaesthetic), diclofenac diethylamine (Cox-2 inhibitor) and aciclovir 
(nucleoside analogues). These agents were selected based upon their different 
physicochemical properties, their ease of assay and cost. The strategy of employing 
penetrants that display a range of physicochemical properties to assess the ability of different 
methodologies to enhance membrane permeability has previously been described in the 
literature (Guy and Hadgraft, 1988; Aungst et al., 1990). For example, a series of proteins, 
peptides and oligonucleotides have been employed to investigate skin permeation 
enhancement by high velocity powder injection (Burkoth et al., 1999) and the flux of model 
compounds with different degrees of lipophilicity, including indomethacin and nalbuphine 
has been used to determine transdermal drug delivery enhancement by the application of a 
erbium:YAG laser (Lee et al., 2001). Using more than one model penetrant allows a more 
complete understanding of how novel technologies designed to facilitate barrier transport 
function work by establishing any relationships between the physicochemical properties of a 
penetrant and its transmembrane flux. 
 
Tetracaine is an effective amino ester type local anaesthetic that is indicated for anaesthesia 
before venepuncture or venous cannulation (Scott et al., 1972). Tetracaine has been shown to 
pass through the skin (Liu et al., 2005; Foldvari, 1994). As a powder tetracaine is a white or 
light yellow waxy solid and it is very slightly soluble in water and soluble in organic 
solvents. It has pKa’s of 2.24 and 8.39 (Iglesias-Garcia et al., 2010).  
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Table 2.1. Physicochemical properties of the model penetrants used in the present study and 
their chemical structures.  Log P (o/w) octanol-water partition coefficient; TC – tetracaine; 
DDEA – diclofenac diethylamine; ACV – aciclovir. 
 
 
Diclofenac diethylamine is a non-steroidal and anti-inflammatory drug and it is prescribed for 
patients affected by dermatitis (Stuttgen, 1988) and rheumatic diseases (Heyneman et al., 
2000). It is classified formally as a non-selective cyclooxygenase inhibitor but it does possess 
a slightly preferential cyclooxygenase 2 inhibition activity (Giuliano et al., 1988). Diclofenac 
diethylamine is the most preferable diclofenac salt for percutaneous delivery due to its high 
solubility in aqueous solutions and has been shown to provide a good permeation rate across 





















































(Brand et al., 2001) 
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2005). Aciclovir is indicated for initial and recurrent labial and genital herpes simplex 
infections (Spruance et al., 2002) and has been shown to permeate the skin (Yeo et al., 1998, 
Spruance et al., 2002, Freeman et al., 1986; Piret et al., 2000), albeit with difficulty. This 
molecule is a white to almost white crystalline powder. It is sparingly to slightly soluble in 
water and dissolves in dilute solutions of mineral acids and alkali hydroxides and has a pKa 
of 9.25 (Freeman et al., 1986).  
 
In order to assess the effects of barometric pressure upon the ability of the three model agents 
to pass through a membrane an analytical method for each was required and a sound transport 
methodology needed to be set up for the specific aims of this work. Tetracaine has been 
previously determined using sequential injection analysis with permanganate induced 
chemiluminescence detection with a limit of detection (LOD) of 0.1 µg.mL-1 (Pasekova et al., 
2000). Elsewhere, a LOD of tetracaine has been reported to be as low as 1.32 ng.mL-1 using 
electrochemistry (Wang et al, 2002). Kitade et al., (1995) reported a LOD value of 1.26 
ng.mL-1 when phosphometry was employed as the analytical method. In addition, the LOD 
has been reported to be 1.20 µg.mL-1, 50 µg.mL-1, 0.003 µg.mL-1, 0.008 µg.mL-1 and 0.012 
µg.mL-1 using spectrofluorometry, capillary electrophoresis, resonance Rayleigh scattering, 
frequency doubling scattering and second-order scattering, respectively (Nevado et al., 2000; 
Al-Otaibi et al., 2009; Qin et al., 2009). Likewise, the separation and characterisation of 
diclofenac diethylamine has been reported in a wide range of matrices such as plasma, blood 
and pharmaceutical preparations using several techniques such as gas chromatography with 
electron capture detection, gas chromatography/mass spectrometric with selected ion 
monitoring, protein precipitation and HPLC with electrochemical detection  with reported 
LOD of 0.2 ng.mL-1, 0.5 ng.mL-1,  25 ng.mL-1 and 10 ng.mL-1, respectively (Schneider et al., 
1986; Borenstein et al., 1996; El-Sayed et al., 1988; Torrez-Lopez et al., 1997). Aciclovir has 
Chapter 2: Analytical verification of HPLC methods and transmembrane                              45 




been quantified in pharmaceutical preparations, plasma and urine by chemiluminiscence, 
micellar electrokinetic chromatography, capillary electrophoresis and reverse phase HPLC 
with reported LOD of 0.2 mg.mL-1, 3 µg.mL-1, 0.15 mg.mL-1 and 20 ng.mL-1, respectively 
(Yang et al., 2004; Neubert et al., 1998; Zhang et al., 2000; Bangaru et al., 2000). Of these 
previously reported method options, HPLC coupled to ultraviolet (UV) detection was 
selected as the method to be implemented for each of the three model agents because the 
quantification of tetracaine, diclofenac diethylamine and aciclovir by HPLC is reported to be 
reproducible, accurate and sensitive, with sample retention times not longer than 15 min. 
LOD values for tetracaine in the literature are typically reported to be less than 1 µg.mL-1 
using HPLC-UV and limit of quantification (LOQ) values are reported to be ca. 3 µg.mL-1 
(Wang et al., 2003; Al-Otaibi et al., 2014; Murtaza et al., 2002; Qin et al., 2010). Likewise, 
LOD and LOQ values of 0.25 µg.mL-1 and 0.75 µg.mL-1 respectively have been reported for 
diclofenac diethylamine (Bilal et al., 2011). Elsewhere a LOD and LOQ for diclofenac 
diethylamine has been reported to be 1.1 µg.mL-1 and 3.38 µg.mL-1 (Vemula et al., 2013).  A 
LOD and LOQ less than 0.8 µg.mL-1 and 1.5 µg.mL-1  was reported for aciclovir (Boulieu et 
al., 1997; Darville et al., 2007; Tzanavaras et al., 2006; Bangaru et al., 2000; Basavaiah et 
al., 2003). Despite the higher sensitivity showed by some of the other reported analytical 
methods, HPLC-UV was deemed to be relatively inexpensive, quick, easy to perform and 
convenient. The most popular method for the detection of compounds separated by HPLC is 
UV radiation because of its versatility, reliability, sensitivity, low-cost and suitability for the 
detection of components that contain a UV active chromophore (Meyer, 2004).  
 
The membrane transport method of choice for topically applied products is currently the 
Franz diffusion cell (Franz, 1975; Franz, 1978) in a range of pharmaceutical development 
contexts. They provide a useful tool that allows the systematic investigation of the 
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permeation process in vitro (Reid et al., 2008, Iervolino et al., 2001, Moser et al., 2001). 
However, significant discrepancies in results are occasionally reported. For example, 
testosterone steady-state fluxes through sections of a polydimethylsiloxane membrane were 
reported to have a coefficient of variation of 32% when 63 replicates were tested (Khan et al., 
2005). Likewise, sequential intra-laboratory measurements of solute permeation across a 
silicone membrane resulted in coefficient of variation of 45.5%, 30.7%, 15.1% and 13.1% for 
adenosine, aldosterone, corticosterone and estradiol, respectively (Frum et al., 2007). In other 
study involving 18 different laboratories, the steady-state flux of methlyparaben was reported 
to have a coefficient of variation of 35% (Chilcott et al., 2005). Thus, there is a need to 
develop experimental Franz cell methods that are robust and that can provide an accurate 
assessment of transmembrane penetration. For this work, the influence of tetracaine system 
pre-equilibration time, membrane thickness and degree of ionization of the molecules in the 
donor solution upon the passive diffusion process was investigated. Only this molecule was 
used initially to design an optimal method for diffusing testing as it was thought to be the 
most problematic of the three and hence it was expected that a method for tetracaine could 
easily be adapted for the other two agents. It has been reported that tetracaine may be prone 
to hydrolytic degradation (Menon and Norris, 1980), it could interact with membranes 
(Zhang et al., 2007; Frezzatti et al., 1986; Hata et al., 2000; Racansky et al., 1988) and it has 
previously been shown to self-associate in solution (Guerin et al., 1980; Umemura et al., 
1981). Therefore, the aim of the work presented in this chapter was twofold: first, to 
demonstrate that HPLC methods for the determination of tetracaine, diclofenac diethylamine 
and aciclovir were ‘fit for purpose’. Secondly, to investigate suitable conditions to assess the 
in vitro tetracaine permeation through a model membrane in order to subsequently assess the 
influence of barometric pressure upon percutaneous penetration. 
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Acetonitrile and methanol both HPLC grade, grade A glass pipettes, clear glass HPLC vials 
crimpable lids and 0.45 µm nylon filter papers were purchased from Fischer Scientific 
(Leicester, UK). Tetracaine base and aciclovir base both BP grade (99.9%) were supplied by 
Sigma Aldrich (Dorset, UK). Diclofenac diethylamine BP grade (99.9%) was obtained from 
Chemos Group (Regenstauf, Germany). Concentrated hydrochloric acid and sodium 
hydroxide was from Fluka (Dorset, UK). Sodium acetate and potassium dihydrogen 
phosphate were provided by Alfa Aesar (Heysham, UK). Silicone membranes with a 




2.3.1 HPLC assay method verification 
 
A liquid chromatography pump (P680 HPLC pump, Dionex, Surrey, UK) connected to a UV-
visible detector (PDA-100 photodiode array detector, Dionex, Surrey, UK) with an ASI-100 
automated sample injector (Dionex, Surrey, UK) was used for the quantitative determination 
of each drug molecule (Table 2.2). The HPLC system was connected to a computer with 
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Table 2.2. HPLC-UV conditions for the model penetrants tetracaine (TC), diclofenac 
diethylamine (DDEA) and aciclovir (ACV). HPLC – high performance liquid 
chromatography; UV – ultraviolet; ACN - Acetonitrile; MeOH - Methanol; NaCOOH - 
Sodium acetate; RT – room temperature. 
 
 
Stock solutions of tetracaine, diclofenac diethylamine and aciclovir (100 µg.ml-1 in 20:25:55 
ACN:MeOH:NaCOOH, 40:25:35 ACN:MeOH:NaCOOH and 4:96 MeOH:NaCOOH, 
respectively) were prepared by dissolving 10 mg of the solid penetrant in 100 ml of the 
relevant solvent. From the stock solutions, standard dilutions were made to obtain varying 
concentrations of each penetrant and calibration curves were produced for the three model 
agents using five standard concentrations. The mean peak area versus concentration (n = 5) 
Parameter TC DDEA ACV 
Column specification Phenomenex® 
LunaTM 5 µm C18 
column (250 x 4.6 
mm) 
Phenomenex® 
LunaTM 5 µm C18 
column (250 x 4.6 
mm) 
Phenomenex® 
Luna™ 5 µm C18 
column (250 x 2.0 
mm)  
Injection volume (µl) 60 60 60 
Mobile phase composition 20% ACN, 25% 
MeOH and 55% 
(0.1M NaCOOH 
pH4) 
40% ACN, 25% 
MeOH and 35% 
(0.1M NaCOOH 
pH4) 
4% MeOH and 96% 
(0.1M NaCOOH 
pH4) 
Flow rate (ml/min) 1 1 1 
Run Time (min) 10 12 13 
Temperature (°C)  RT RT RT 
Detection UV ( λ ) 310 220 254 
Detection sensitivity 0.025 0.025 0.025 
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was plotted for the five concentrations and a regression model was applied. The peak 
symmetry (As) was calculated (n = 15) using equation 2.1. 
 
2d
WA 0.05s =                                                     (Equation 2.1) 
 
where W0.05 is the width of the peak at one-twentieth of the peak height, d equals the distance 
between the perpendicular dropped from the peak maximum and the leading edge of the peak 
at one-twentieth of the peak height. A peak symmetry of 1 was considered ideal as this 
represents a perfectly symmetrical peak. The theoretical plates (estimation of the column 










=                                                  (Equation 2.2) 
 
Where t is the retention time of peak and Wh/2 equals the width of peak at half the peak 
height. The LOD (the lowest concentration of analyte in a sample that can be detected but not 
necessarily quantified) and the LOQ (the minimum injected amount of analyte that gives 
precise measurements), for each penetrant was calculated according to equations 2.3 and 2.4 
respectively. 
 
LOD = YB + 3sB                                     (Equation 2.3) 
 
LOQ = YB + 10sB                                     (Equation 2.4) 
 
Where sB was equal to the standard deviation of the y estimate and YB was the intercept from 
the regression equation. 
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The precision of each HPLC method was determined by assay repeatability (intra-day) and 
assessment of the intermediate precision (inter-day). Intra-day precision was obtained by 
evaluating the variance between three standard curves assayed from the same standard 
solutions (five injections per standard) of each model penetrant. The intermediate precision of 
the test molecules was determined by comparing three calibration curves of each penetrant 
using independently prepared standard solutions (five injections per standard) on three 
separate days.  
 
The accuracy of the tetracaine, diclofenac diethylamine and aciclovir HPLC assays were 
determined by assaying freshly prepared solutions of known concentration. The ability of 




A(%)Accuracy =                                     (Equation 2.5) 
 
Where A is the actual (measured) concentration and T is equal to the theoretical analyte 
concentration 
 
2.3.2 Tetracaine chemical stability assessment 
 
The chemical stability of tetracaine was assessed as it was to be used in the transport study 
method development. Initially the ability of the HPLC method to detect chemical instability 
was determined using a method to hydrolytically degrade tetracaine. This was achieved by 
adding a 0.1 mg aliquot of the drug to 0.1 M HCl solution at pH 1.1 (acid degradation 
solution) and to a 0.1 M NaOH solution at pH 13.2 (base degradation solution). After this 
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procedure each solution was stored at room temperature and at 90 ˚C in a water bath (Grant 
Instruments, Cambridge, UK). At regular time intervals, 250 µL of each solution was made 
up with mobile phase before being analysed by HPLC. The results were interpreted 
accordingly to the percentage variation in peak area (% ∆) and the appearance of new peaks 
in the chromatogram which were thought to represent degradation products. The main 
mechanism for tetracaine degradation in solution is hydrolytic degradation and the main 
degradation product is p-n-butylaminobenzoic acid (Menon et al., 1981). The HPLC method 
employed in the analysis was identical to the one described in Section 2.3.1. 
 
2.3.3 Tetracaine permeation studies 
 
The permeation experiments were carried out in previously calibrated upright Franz cells 
with an average receiver volume of 9.8 mL and an average surface area of 2.1 cm2 
(University of Southampton, UK). Tetracaine saturated solutions at pH 4 and pH 10 with 
increasing suspension pre-equilibration times were used as the donor solutions (24 h, 120 h 
and 576 h). Pre-equilibration time corresponded to the period in which the donor solutions 
were left to equilibrate at room temperature prior to the permeation studies. Different 
thickness silicone membranes (0.05 mm, 0.12 mm and 0.25 mm) were used as the controlling 
barrier. The silicone membrane was cut to fit the Franz cell with scissors and mounted on the 
cell with a 13-mm magnetic flea in the receiver chamber. The top of the cell was positioned 
over the membrane and the cell was sealed by wrapping parafilm around the two sections. 
The cell was then inverted, filled immediately with previously sonicated 0.1 M acetate buffer 
solution (n = 5) and with 0.1 M phosphate buffer solution (n = 5). To ensure there was no 
leakage, the cells were inverted and visually checked. Leaking cells were excluded from the 
experiments.  Each diffusion cell was placed on a submersible stirring plate in a pre-heated 
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water bath (Grant Instruments, Cambridge, UK) set at 37 ˚C, to obtain 32 ˚C at the membrane 
surface (Maddock et al., 1933). The cells were left to equilibrate for 30 min before 
application of the donor solution, which consisted of tetracaine saturated solutions at pH 4 
(0.1 M acetate buffer solution) and pH 10 (0.1 M phosphate buffer solution). Drug 
permeation was monitored by removal of 1 mL samples out of the sampling arm of the cell, 
which was placed into an HPLC vial. One millilitre of thermostatically regulated receptor 
solution was then added to the diffusion cell receiver fluid to replace the withdrawn sample. 
Membrane thickness was measured before and after the transport experiments using a Venier 
micrometer  (No. 436.1 Series 0 - 25 mm) purchased from Starrett  (Jedburgh, UK), in order 
to check for swelling which would indicate vehicle-matrix interaction (Dias et al., 2001). 
Cumulative amounts of drug penetrating the unit surface area of the membrane (µg.cm-2) 
were corrected for sample removal and plotted against time (min). Flux (J) was taken from 
the line of best fit with a linearity of R2 ≥ 0.99 over at least five values for determined 
concentrations which exceeded the HPLC assay limits of detection. Lag time was determined 
by the intercept of the steady-state flux with the x axis and it was provided in min. 
 
2.3.4 Statistical analysis 
 
Statistical evaluation was carried out using a statistical package for social sciences software 
(SPSs version 16.0, SPSS Inc., Chicago, USA). All data were checked in terms of normality 
(Kolmogorov-Smirnov test) and homogeneity of variances (Levene's test) prior to analysis. 
Permeation results were analysed using one way analysis of variance tests (i.e. one-way 
ANOVA and one-way AVOVA post-hoc Tukey test). Box plot statistical tests were 
performed on the permeation data obtained from each cell in a single experiment to identify 
the outliers which were then removed from the calculation of the average. All other data were 
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analysed using either two-way ANOVA followed by Bonferroni’s comparison post-hoc test 
or Student's t-test.  Statistically significant differences were defined when p < 0.05. All values 
were expressed as mean ± standard deviation (SD). The number of replicates was 3 in the 
chemical stability assessment and 5 in the permeation studies. 
 
2.4 Results and Discussion 
 
2.4.1 HPLC assay method verification 
 
Tetracaine, diclofenac diethylamine and aciclovir displayed well resolved peaks with 
retention times of ca. 7.6 min, 10.9 min and 8.9 min respectively (Figure 2.1). The mean peak 
symmetry (As) for tetracaine, diclofenac diethylamine and aciclovir was within the 
recommended limit proposed by the International Conference on Harmonisation (ICH, 1995) 
(Table 2.5) with values of 1.05 ± 0.2, 0.92 ± 0.1 and 1.21 ± 0.3, respectively (n = 15 ± SD in 
all cases). The column efficiency (where N represents theoretical plate number) for each 
model agent was within the limit recommended by the ICH guidelines (Table 2.5) as follows: 
tetracaine N = 3010 ± 102, diclofenac diethylamine N = 4090 ± 190 and aciclovir N = 2900 ± 
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Figure 2.1. Typical liquid chromatographs of a) 100 µg/ml tetracaine (TC) in 20:25:55 
ACN:MeOH:NaCOOH, b) 100 µg/ml diclofenac diethylamine (DDEA) in 40:25:35 
ACN:MeOH:NaCOOH, and c) 100 µg/ml aciclovir (ACV) in 4:96 MeOH:NaCOOH. 
 
The standard calibration curves of tetracaine, diclofenac diethylamine and aciclovir were 
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Figure 2.2. Intra-day HPLC calibration curves showing mean peak areas as a function of 
concentration of a) tetracaine in 20:25:55 ACN:MeOH:NaCOOH b) diclofenac diethylamine 
in 40:25:35 ACN:MeOH:NaCOOH and c) aciclovir in 4:96 MeOH:NaCOOH. Data 
represents mean ± SD (n = 18). Error bars represent mean ± SD but are too small to be seen. 
 
This is in accordance with the ICH guidelines that recommend the use of at least a five point 
calibration curve that displays a linearity > 0.99, to demonstrate the capacity of an analytical 
a) b) 
c) 
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method to generate results that are directly related to the concentration of an analyte present 
(Table 2.5). The LOD and LOQ values for each compound were calculated from summated 
intra-day calibration curves (three standard curves). The LOD for tetracaine, diclofenac 
diethylamine and aciclovir was 3.26 µg.mL-1, 3.14 µg.mL-1 and 2.78 µg.mL-1, respectively 
whilst the LOQ values were 9.76 µg.mL-1, 8.92 µg.mL-1 and 10.58 µg.mL-1, respectively. 
The LOQ values calculated in the present study for the three model penetrants were found to 
be in the same range as those reported in the literature. For example, the LOQ values for 
tetracaine were reported to be ca. 3 µg.mL-1 (Wang et al., 2003; Al-Otaibi et al., 2014; 
Murtaza et al., 2002; Qin et al., 2010), likewise, the LOD for diclofenac diethylamine and 
aciclovir was found to be in the same range as the published values of ca. 3.38 µg.mL-1  and 
1.5 µg.mL-1 , respectively (Vemula et al., 2013; Boulieu et al., 1997; Darville et al., 2007; 
Tzanavaras et al., 2006; Bangaru et al., 2000; Basavaiah et al., 2003).  
 
In all cases the differences in peak area for the independently prepared solutions were not 
statistically different from one another (p > 0.05). For tetracaine, diclofenac diethylamine and 
aciclovir the intra-day and inter-day variability was <  1% and <  2% for all concentrations, 
respectively (Table 2.3) and these values were below the limits recommended by the ICH 
guidelines (Table 2.5).The mean accuracy of the tetracaine (n = 6), diclofenac diethylamine 
(n = 5) and aciclovir (n = 6) assays was 97.9 ± 2.3%, 96.7 ± 0.2% and 99.7 ± 1.1% at the 
concentrations tested from the calibration range (Table 2.4). The accuracy of the three 
analytical methods, determined by the extent to which theoretical concentrations of the model 
agents agreed with the true analyte concentrations was within the ICH guideline 
recommended values (Table 2.5). As a consequence of this data the three developed and 




Table 2.3. Variance (repeatability and intermediate precision) of the tetracaine (TC), diclofenac diethylamine (DDEA) and aciclovir 

















CV of the intra-day 
(%, n = 15) 
CV of the inter-day 
(%, n = 15) 
 TC DDEA ACV TC DDEA ACV 
100 0.32 0.42 0.08 0.51 0.61 0.4 
50 0.41 1.31 0.3 0.82 2.93 0.5 
16 0.45 0.62 0.6 0.91 1.38 0.5 
10 0.54 1.11 0.4 1.12 1.33 1.3 
1 1.13 1.21 0.02 2.4 2.61 2.5 
0.5 1.11 __ 0.5 1.3 __ 3.5 
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Table 2.4. Assay accuracy for tetracaine (TC), diclofenac diethylamine (DDEA) and aciclovir (ACV). Accuracy was determined at 6 



























100 97.1 100 96.4 100 99.2 
50 98.3 50 97.5 50 101.2 
16 97.9 16 97.3 16 98.3 
10 98.1 10 96.4 10 98.9 
1 98.6 1 96.1 1 99.5 
0.5 97.5 0.5 -- 0.5 101.3 
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Table 2.5. A summary of the assay validation data for tetracaine (TC), diclofenac diethylamine (DDEA) and aciclovir (ACV)  
and comparisons to the ICH guidelines for analytical method validation (ICH,1995). 
 
Validation parameter Compound 
Recommend 
level/limit by ICH 
 TC DDEA ACV  
System suitability     
   Linearity (R2, n = 3 calibrations, ± SD) 0.998 ± 2×10-5 0.999 ± 4 ×10-5 0.999 ± 3×10-4 > 0.99 
   Peak symmetry, As (n = 15 ± SD) 1.05 ± 0.2 0.92 ± 0.1 1.21 ± 0.3 < 2, Ideal As = 1 
   Theoretical plate number, N (n = 15 ± SD) 3010 ± 102 4090 ± 190 2900 ± 98 N > 2000 
   Limit of Detection (µg.mL-1) 3.26 3.14 2.78 --- 
   Limit of Quantification (µg.mL-1) 9.76 8.92 10.58 --- 
Precision     
   Intra-day variability (repeatability, % CV) 0.58 0.48 0.31 < 1 % 
   Inter-day variability (intermediate precision) < 2 % < 2 % < 2 % < 5 % 
Accuracy (% ± SD, n = 6 for TC and ACV and n 
= 5 for DDEA) 
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2.4.2 Tetracaine chemical stability assessment 
 
Forced degradation studies revealed that a degradant was generated upon base hydrolysis of 
tetracaine (0.1 M NaOH pH 13.2) at room temperature (Figure 2.3) and 90 °C at 30 min, 1h 







Figure 2.3. Tetracaine (TC) base hydrolysis degradation product (DP) at room temperature at 
30 min sampling time. 
 
Upon base hydrolysis at room temperature tetracaine lost 3 % of its original peak area after 
30 min, 70 % after 1 h and only the degradation product was eluted after 24 h (Table 2.6). 
Tetracaine fully degraded to its degradation product for all experiments performed at 90 °C. 
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Table 2.6. Percentage variation (% ∆) in peak area for tetracaine at different temperatures in 
0.1 M NaOH at pH 13.2.  
 
A degradant was also generated upon acid hydrolysis of tetracaine using 0.1 M HCl pH 1.1 at 







Figure 2.4. Tetracaine (TC) acid hydrolysis degradation product (DP) at 90 °C 24 h sampling 
time. 
 
Upon acid hydrolysis tetracaine lost 7 % of its original peak area at the 24 h sampling time 
when stored at 90 °C whereas at room temperature no degradation was detected (Table 2.7). 
The retention time for the degradation product was similar to that observed upon base 
hydrolysis at 5.57 ± 0.1 min. It has been reported in the literature that the mechanism for 
tetracaine degradation in solution is hydrolytic degradation and the main degradation product 
is p-n-butylaminobenzoic acid (Menon et al., 1981). The HPLC method was able to detect 
Treatment Temperature Duration % ∆ in peak area 
0.1 M NaOH Room temperature 30 min 3 
  Room temperature 1 h 70 
  Room temperature 24 h Only the degradation product was eluted 
  90 °C 30 min Only the degradation product was eluted 
  90 °C 1 h Only the degradation product was eluted 
  90 °C 24 h Only the degradation product was eluted 
DP 
TC 
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tetracaine chemical degradation and the fact that the tetracaine peak was sensitive to 
degradation was deemed suitable to use as an indicator for detecting the chemical stability of 
the drug in subsequent work. 
 
Table 2.7. Percentage variation (% ∆) in peak area for tetracaine at different temperatures in 




2.4.3 Tetracaine permeation studies 
 
In order to assess percutaneous penetration of a model compound through a controlling 
barrier, mass transport studies should be conducted under sink conditions (i.e. not exceeding 
10% of the donor concentration and permeant saturated concentration in the spent receiver 
fluid). These conditions are deemed essential since they guarantee a concentration gradient 
between the donor and receiver solution and hence, the driving force for the permeation 
process through the barrier (Howes et al., 1996). The analysis of membrane thickness and 
donor solution pre-equilibration time effects on drug passive transport was limited to some 
extent, which resulted in receiver fluid saturation going beyond 10 % on occasion and an 
inability to measure permeation lag time on other occasion. 
Treatment Temperature Duration % ∆ in peak area 
0.1 M HCl Room temperature 1 h No significant variation  
  Room temperature 2 h No significant variation 
  Room temperature 24 h No significant variation 
  90 °C 1 h No significant variation 
  90 °C 2 h No significant variation 
  90 °C 24 h 7 
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At pH 10, sink conditions were exceeded when a 0.12 mm thick silicone membrane was 
employed as the controlling barrier (14.4% of saturated solubility was recorded) (Table 2.9), 
but sink conditions were maintained in the receptor fluid at pH 4 for all test systems (a 
maximum of 0.36% of the drugs saturated solubility was recorded at the end of the study) 
(Table 2.8). The rapid transport through the 0.05 mm thick silicone membrane at both pHs 
did not produce a reasonable lag time and hence, this data was considered unreliable as an 
equilibrium that could generate a steady-state flux. As a consequence of these issues, only the 
transport data generated through a 0.25 mm thick silicone membrane was used to optimise 
the transport method in the Franz cells.  
 
The overall passive transport during steady-state through the 0.25 mm thick membrane of 
unionised tetracaine (pH 10) was significantly higher (p < 0.05) than that of ionised tetracaine 
(pH 4). For example, at 24 h donor solution pre-equilibration time, steady-state flux across a 
0.25 mm thick membrane was 18.7 ± 2.14 μg.cm−2.min−1 vs 2.6 ± 0.5 μg.cm−2.min−1 at pH 10 
and 4, respectively (Table 2.8 and 2.9). The difference in permeation in the two different pH 
environments was suggested to be attributable to the different ionisation of tetracaine in the 
vehicles employed for the transport studies. The silicone membrane used in these 
experiments was lipophilic and as at pH 10 the calculated distribution coefficient (Log D) of 
tetracaine is significantly higher than at pH 4 (Log D of 2.78 and -0.77, source: Marvin 
Sketch, ChemAxon, Cambridge, USA) it is expected that the transport at pH 10 will be 
higher. Interestingly, lag time was significantly greater (p < 0.01) at pH 10 despite its better 
partition and penetration through the barrier when compared to that registered at pH 4 (Figure 
2.5). Moreover, lag time was statistically higher (p < 0.01) at pH 4 with an increase in donor 
solution pre-equilibration time from 24 h to 120 h (Figure 2.5). A further increase in donor 











   Table 2.9. Summary indicies for Franz cell permeation studies at pH 10. Data represents mean ± SD (n = 5). Chemical  





Pre-equilibration time (h) 24 24 24 120 576 
Membrane thickness (mm) 0.05 0.12 0.25 0.25 0.25 
Flux (µg /cm2 /min) 4.0 ± 0.3 3.8 ± 0.4 2.6 ± 0.5 1.5 ± 0.3 1.6 ± 0.9 
Lag time (min)  none 5 ± 1.1 4 ± 1.1 7 ± 0.8 10 ± 0.5 
Sink conditions Fulfilled Fulfilled Fulfilled Fulfilled Fulfilled 
Chemical degradation Not detected Not detected Not detected Not detected Not detected 
Pre-equilibration time (h) 24 24 24 120 576 
Membrane thickness (mm) 0.05 0.12 0.25 0.25 0.25 
Flux (µg /cm2 /min) 7.28  ± 1.8 24.4 ± 2.9 18.7 ± 2.14 16 ± 1.3 __ 
Lag time (min)  none 7 ± 1.1 16 ± 2.3 13 ± 3.1 __ 
Sink conditions conditions Fulfilled Not fulfilled Fulfilled Fulfilled __ 
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The reasons behind the changes in steady-state flux with an increase in pre-equilibration time 
were difficult to explain. For example, the rate of mass transfer during steady-state at pH 10 
was statistically equivalent (p > 0.05) across a 0.25 mm thick silicone membrane when 
equilibrated at either 24 h (18.7 ± 2.14 μg. cm-2. min-1) or 120 h (16 ± 1.3 μg.cm-2.min-1) 
(Figure 2.5). However, the rate of mass transfer during steady-state at pH 4 was significantly 
higher (p < 0.05) across a 0.25 mm thick silicone membrane when pre-equilibrated at 24 h 
(2.6 ± 0.5 μg. cm-2.min-1) compared to 120 h (1.5 ± 0.3 μg.cm-2.min-1) (Figure 2.5). A further 
increase in pre-equilibration time did not result in a significantly different (p > 0.05) rate of 
mass transfer at pH 4 (1.6 ± 0.9 μg.cm-2.min-1 at 570 h vs 1.5 ± 0.3 μg.cm-2.min-1 at 120 h). 
Chemical degradation was not observed at pH 4 throughout the experiments, but it was 
observed at pH 10 (Table 2.8 and 2.9). The base derived hydrolysis product was shown in the 
chromatograms, albeit this was believed not to have a significant impact in the analysis of the 
transport data since the hydrolysis product corresponded to < 4% of the total tetracaine peak 
area.  
 
Drug permeation across a confluent barrier such as the silicone membrane employed in this 
study can be described by Higuchi’s equation of mass transport (Section 1.4.1). This equation 
states that all saturated solutions of the same drug should provide the same rate of transport 
given that: mass transfer occurs under sink conditions, the membrane is the rate controlling 
barrier, the application vehicle does not affect the barrier, thermodynamic activity is 





Chapter 2: Analytical verification of HPLC methods and transmembrane                              66 

















Figure 2.5. Tetracaine permeation profiles across a 0.25 mm silicone membrane at increasing 
suspension pre-equilibration time at pH 4 and pH 10. The inset graph represents lag time 
versus pH. Each point represents mean ± standard deviation (n = 5). ** p < 0.01 and *** p < 
0.001 (Two-way ANOVA with Bonferroni post-hoc test).  
 
The experimental setup was designed to investigate the conditions where tetracaine 
permeation could be explained by the Higuchi model. However, the lower transport rate with 
an increased donor solution pre-equilibration time (from 24 h to 120 h) did not follow this 
theoretical model. This was not thought to be due to violation of sink conditions, as they were 
maintained when the 0.25 mm silicone membrane was employed in the transport studies (no 
more than 10% of the total drug solubility was exceeded during the permeation studies 
(Howes et al., 1996)). All the saturated donor solutions with increasing pre-equilibration time 
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showed linear permeation over the time period studied and this indicated that the membrane 
was the rate limiting step of the drug flux (Davis and Hadgraft, 1991). Membrane thickness 
was checked after the transport studies and found to be statistically equivalent (p > 0.05) 
when compared to that registered before the experiments. Hence, water permeation into the 
silicone membrane was thought to be negligible and did not appear to alter its properties 
significantly; therefore the vehicle was unlikely to affect the barrier (Dias et al., 2001). Only 
one drug compound was transported across the membrane and the thermodynamic activity 
was homogenous throughout the formulation as tetracaine donor solution remained saturated 
(as a fine suspension) at the two pHs throughout the permeation study. One hypothesis that 
could explain the decrease in permeation across the greater pre-equilibration time and the 
differences in lag time at both pHs is molecular aggregation. It has been reported in the 
literature that the interaction of tetracaine with lipophilic membranes is complicated by its 
detergent and self-association properties (Frezzatti et al., 1986; Zhang et al., 2007).  
Tetracaine like other local anaesthetics has a high tendency to self-associate in concentrated 
solutions due to formation of intermolecular hydrogen bonds (Guerin et al., 1980; Umemura 
et al., 1981). In addition, it has been described that the ability of a molecule to cross 
membranes decreases when intermolecular association occurs by hydrogen bonding 




Three ‘fit-for-purpose’ HPLC methods were reported in this Chapter. Their use in subsequent 
parts of the thesis was underpinned by experimental results that demonstrated sound 
calibration curve linearity, specificity, repeatability and precision in accordance with the 
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guidelines set by the ICH. The verified tetracaine HPLC method was therefore used to 
develop the in vitro permeation assay. A 120 h donor solution pre-equilibration time and a 
0.25 mm thick silicone membrane were considered to be the optimal conditions to determine 
tetracaine transport because using this setup the data was not limited by drug depletion, 
receiver fluid saturation or chemical degradation. It was hypothesized that molecular 
aggregation was influencing tetracaine transport permeation behavior and the next phase of 























The effects of molecular aggregation 

















Pharmacologically active compounds can display amphiphilic properties and this can lead to 
molecular aggregation in solution. Aggregate formation can have a significant impact on the 
pharmacological effects of a molecule as it can alter the passive diffusion process, thus 
modifying its ability to localisation at a receptor site. The aggregation of amphiphilic 
molecules occurs above critical aggregation concentration (CAC) and it generates a cluster of 
molecules which can present different physicochemical properties to the parent entity 
(Florence and Attwood, 1998; Potts and Guy, 1995). Diffusion speed is typically retarded and 
interactions with administration vehicles and biological membranes can be altered when a 
molecule aggregates (Schreier et al., 2000; Rossetti et al., 2011; Ueda et al., 2012). However, 
the physical interactions between the aggregated and non-aggregated entities, the multiple 
routes molecules can take through a barrier and the potential for both the unaggregated and 
aggregated drug to pass through the barrier means that that influence of molecular 
aggregation upon membrane transport is a complex field of study that warrants further 
investigation. 
 
One example of a molecule that is known to aggregate in solution is tetracaine. Its self-
association is thought to be driven by intermolecular tertiary amine hydrogen bonding and 
amine-ester hydrogen bonding (Guerin et al., 1980). Tetracaine topical bioavailability is 
reported to be relatively good for a skin product at 15% (Hadgraft, 1999; Thomas and Finnin, 
2004; O’Brien et al., 2005), but it has a slow onset of topical anaesthesia (30 to 60 min) 
which hinders its effective clinical use in certain contexts (Lubens et al., 1974; Escribano et 
al., 2005; Heavner, 2008). Attempts to enhance tetracaine diffusion across the skin have been 
reported in the literature (Sang-Chul et al., 2004; Liu et al., 2005; Chao et al., 2008; Swayer 





et al., 2009), but there has been very little investigation into how molecular aggregation 
influences the drug passive diffusion and hence how this contributes to its speed of onset is 
therefore unknown. 
 
Tetracaine is commercially available as a 4% gel (formulation pH ~ 9) and can exist in 
solution as three different microspecies depending on the pH. Tetracaine base (TC) has been 
shown to penetrate the skin (Chekirou et al., 2012), and it is the dominant microspecies above 
pH 9. Below pH 6.5 both the tertiary (TCH+) and secondary amine (TCH22+) are protonated, 
the former of these microspecies (TCH+) prevail at physiological pH of the skin (4.2 - 6.5) 
(Figure 3.1). It is generally accepted that the tetracaine tertiary amine binds to the sodium 
channels, blocking the sodium influx and inhibiting nerve cell depolarization that prevent the 
propagation of nerve cell impulses (Iglesias-García et al., 2010), but which is the most 































Figure 3.1. Schematic representation of tetracaine (TC) ionization equilibrium, exhibiting two 
ionisable groups, the tertiary (TCH+) and secondary amine (TCH22+) (Iglesias-García et al., 
2010). 
 
The purpose of the work in the current Chapter was to understand the properties of the 
tetracaine aggregates that may form in topical preparations, in order to gain a better 
understanding of how the physical attributes of supramolecular masses formed as a 
consequence of drug aggregation influence hydrophobic membrane transport. Tetracaine 
amphiphilic characteristics were manipulated by simply altering the pH of aqueous solutions 
containing the drug when it was above its critical aggregation concentration. This allowed a 
series of aqueous vehicles where the degree of ionization of both the tertiary and secondary 
amine was varied to be presented to two hydrophobic membranes, porcine skin and silicone 





membrane, in the anticipation that different types of drug aggregates and different transport 
rates could be recorded and analysed. Photon correlation spectroscopy was employed to 
determine the critical aggregation concentration at which nanosized aggregates were formed 
and zeta potential measurements provided details regarding electrostatic interactions. Fourier 
transform infrared spectroscopy (FTIR) and proton nuclear magnetic resonance (1H-NMR) 
were employed to investigate the molecular arrangement and intermolecular bonding between 




Acetonitrile and methanol both HPLC grade, grade A glass pipettes, clear glass HPLC vials 
crimpable lids and 0.45 µm nylon filter papers were purchased from Fischer Scientific 
(Leicester, UK). Tetracaine base BP grade (99.9%) and deuterium oxide (99.9 atom %) were 
supplied by Sigma Aldrich (Dorset, UK). Concentrated hydrochloric acid and sodium 
hydroxide was from Fluka (Dorset, UK). Sodium acetate, potassium dihydrogen phosphate 
and 1-Octanol were provided by Alfa Aesar (Heysham, UK). Silicone membranes with a 




3.3.1 Tetracaine pKa determination 
 
The automatic titration system used in this study comprised an autoburette (Dosimat 765 liter 
ml syringe, Metrohm, Buckingham, UK) and pH meter (MP230 Mettler Toledo, Leicester, 





UK) with a pH electrode (Metrohm, Buckingham, UK). A 0.1 M KCl electrolyte solution was 
used to maintain the ionic strength. The temperature of the test solutions was maintained in a 
thermostatic jacketed titration vessel at 25 °C ± 0.1 °C by using a temperature controller 
(Techne TE-8J, Sigma Aldrich, Dorset, UK). The solution under investigation was stirred 
vigorously during the experiment. A pump with speed capability of 20 mL.min-1 (Mini-plus, 
Gilson, Luton, UK) was used to circulate the test solution through a quartz flow cuvette using 
a cuvette with a path length of 0.1 cm. The flow cuvette was mounted on an UV-visible 
spectrophotometer (HP 8453, Agilent, Cheadle, UK). All instruments were interfaced to a 
computer and controlled by a Visual Basic program. Automatic titration and spectral scans 
adopted the following strategy: the pH of a solution was increased by 0.1 pH unit by the 
addition of KOH from the autoburette; when pH readings varied by < 0.001 pH unit over a 3 
s period the spectrum of the solution was then recorded. The cycle was repeated 
automatically until the defined end point pH value was achieved. All the titration data were 
analysed with the pHab program (Gans et al., 1999). The microspecies plot was calculated 
with the HYSS program (Alderighi et al., 1999). 
 
3.3.2 Aggregation characterization 
 
3.3.2.1 Photon correlation spectroscopy characterization 
 
Changes in derived count rate and zeta potential of the donor solutions were tracked using 
photon correlation spectroscopy (Malvern Nanoseries Zetasizer, Malvern Instruments Ltd., 
Malvern, UK). Measurements were taken at a scattering angle of 173°. Refractive index and 
viscosity constants were set at 1.33 and 0.88 mPa.s, respectively. Samples were filtered 
through a 0.45 µm cellulose nitrate filter prior to the analysis. The scattering information was 





determined at increasing tetracaine molar concentrations in acetate buffer (0.1 M) at pH 4, 6, 
7.6, 9 and 10. Control solutions were prepared in the same manner as for the test systems, but 
without the addition of drug. The critical aggregation concentration was determined from the 
discontinuity in the linear model applied to the unattenuated derived count rate data and was 
confirmed by the application of a second derivative function (OriginPro 9.1 Software, 
OriginLab, Northhampton, USA). The size of the molecular aggregates was detected by 
converting the light scattering signal into a hydrodynamic radius using the Stokes–Einstein 
equation given in equation 3.1, where k is the Boltzmann constant, T is the absolute 
temperature and η is the solvent viscosity. The size of the molecular aggregates was 
determined above critical aggregation concentration ca. 87 - 95% of tetracaine saturation in 
each aqueous vehicle at pH 4, 6, 7.6, 9 and 10. The pH was adjusted to the required value 
when necessary by adding NaOH (1 M) or acetic acid. The zeta potential of the aggregate 





                                                                                                               (Equation 3.1) 
 
3.3.2.2 Molecular dynamic studies 
 
Tetracaine self-association was generated from the hydrochloride crystal structure reported 
by Nowell et al., (2002). The atomic co-ordinates and unit cell parameters were obtained 
from the Cambridge Structural Database; entry XISVOK (Thomas et al., 2010). The 
assembly was generated (2 x 2 x 2 unit cells) using the Mercury software (Macrae et al., 





2008) and then visualised using Accelrys Viewerlite v5.0 software (Biovia, San Diego, 
USA). 
 
3.3.2.3 Apparent distribution coefficient 
 
The apparent drug distribution coefficients were measured using a tetracaine saturated acetate 
buffer solution at room temperature with a second phase composed of 1-octanol. A 0.1 M 
acetate buffer solution was employed in the studies at a modified pH of 4, 6, 7.6, 9 and 10 as 
previously described (Valenta et al., 2000). After phase separation the aqueous phase was 
withdrawn and samples were centrifuged at 13000 rpm (Biofuge, Heraeus, Germany) and 
aliquots of the liquid phase were then transferred into vials. The samples were analysed 
employing the tetracaine HPLC method described in Section 2.3.1. The apparent distribution 
coefficient (D) was defined as the ratio of the concentration in octanol (C0) to the total 
concentration of ionized (Ci) and unionized (Cu) moiety in the aqueous phase (equation 3.2). 
The amount of tetracaine detected in the aqueous phase was above the experimentally 
determined critical aggregation concentration for all the test systems. 
 
𝐷 = 𝐶0(𝐶𝑖+𝐶𝑢 )                                                                                                            (Equation 3.2) 
 
3.3.2.4 Fourier Transform Infrared spectroscopy (FTIR) 
 
Tetracaine solutions at pH 4, 6, 7.6, 9 and 10 were prepared in deuterium oxide (D2O) at the 
same concentrations used for molecular aggregates size analysis. D2O was employed in the 
solutions as it dampened the solvent signal in the 1700 - 1300 cm-1 range. The pH was 
adjusted with NaOH (1 M) or acetic acid. The samples were loaded into a demountable 





universal transmission cell system (Omni-Cell, Specac Ltd., UK) fitted with calcium fluoride 
(CaF2) windows and a 25 µm mylar spacer (Specac Ltd., UK). The infrared spectra were 
recorded from 4500 to 1000 cm-1 using a Spectrum One spectrometer (Perkin Elmer Ltd., 
UK) and spectral analysis was performed with Spectrum software version 5.3.1 (Perkin 
Elmer Ltd., UK). After normalization of transmittance, background subtraction and baseline 
correction, the analysis of the spectra was done by analysing the C=O band, as described 
previously (Popova and Hincha, 2003). 
 
3.3.2.5  1H-NMR spectroscopy 
 
Tetracaine solutions at pH 4, 6, 7.6, 9 and 10 were prepared in deuterium oxide at the same 
concentrations used for molecular aggregates size analysis. The spectra of each solution was 
obtained with a Bruker Avance DRX400 NMR spectrometer (Bruker, Coventry, UK). A 600 
µL aliquot of each sample was used for the measurements which were conducted at 400 MHz 
with 5000 scans. The peaks assignments were made and supported using the predicted spectra 
(ChemNMR software, PerkinElmer, Beaconsfield, UK). 
 
3.3.3 Tetracaine transport studies 
 
To eliminate any thermodynamic influence on the drug passive transport across both 
membranes, tetracaine was formulated as a saturated solution, i.e., at a thermodynamic 
activity of unity (Smith, 1990; Hadgraft, 1996), as previously described in Section 2.3.3. The 
fine suspension allowed visual verification if drug saturation had been maintained throughout 
the entire experimental period. The individually saturated solutions at pH 4, 6, 7.6, 9 and 10 
were prepared by adding excess tetracaine to acetate buffer (0.1M) and were left to 





equilibrate for 120 h. The pH of each solution was adjusted to the required value when 
necessary by adding NaOH (0.1 M).  
 
Adult pig ears were obtained from a local abattoir. The ears were removed from the carcass 
after hair removal. Any ears that were obviously damaged were discarded. The ears were 
cleaned with water, the residual water on the skin surface was immediately removed by 
blotting with tissue, visible residual hairs were trimmed carefully and the ears were stored at  
-20 °C (no more than three months before use). Before the experiments the porcine skin was 
defrosted and the subcutaneous fat carefully removed using a scalpel. Both the silicone 
membrane (0.25 mm thick, used as obtained) and the porcine skin were cut into pieces of a 
suitable size and mounted in the Franz diffusion cell (University of Southampton, UK). In 
vitro infinite dose permeation experiments were conducted as method described in Section 
2.3.3 over a period of 6 h and 22h (for the silicone and porcine membrane, respectively). The 
samples were analysed employing the tetracaine HPLC method described in Section 2.3.1. 
 
3.3.4 Statistical analysis 
 
All data were presented as mean ± standard deviation and statistical analysis of data was 
performed using SPSS version 16.0, as described previously in Section 2.3.4. A statistically 
significant difference was determined at a minimal level of significance of 0.05 (p < 0.05). 
The number of replicates was 5 in the permeation studies and 3 in the apparent distribution 









3.4 Results and Discussion 
 
3.4.1 Tetracaine pKa determination 
 
The analysis of the titration data using the pHab program revealed two inflection points at pH 
values of 2.48 ± 0.03 and 8.56 ± 0.02 in the plots of tetracaine solution UV absorbance versus 
its pH and these were considered to be the approximate values of tetracaine pKa’s (Figure 
3.2). The pKa value at 2.48 ± 0.03 was assigned to the protonation on nitrogen of the tertiary 
amine and the pKa value of 8.56 ± 0.02 was assigned to the secondary amine. There was a 
good agreement between the experimentally determined values in this work and those 
described in the literature. For example, Iglesias et al., (2012) reported a tetracaine pKa’s 
values of 3.41 and 8.24. Therefore, the percentage of each microspecies in solution (TC, 
TCH+ and TCH2+2) at increasing pH was calculated using the experimentally determined 
pKa’s (Table 3.1). The commercial topical product displayed an apparent pH of ca. 9 and 
hence it was considered to present tetracaine predominantly as a unionized molecule (TC) 


























Figure 3.2. UV-spectrum of tetracaine (560 µM) between pH 2.36 to pH 10.94 starting in 
20.1 mL of KCL (0.1M) at 25 °C using a cuvette with a path length of 0.1 cm. Total points 
represented is 44.  
 
Table 3.1. Percentage of the microspecies (TC, TCH+ and TCH2+2) in solution with an 








pH % TC % TCH+ % TCH2+2 
4 0.03 93.5 6.47 
6 0.23 99.7 0.07 
7.6 9.88 90.1 0.02 
9 73.4 26.6 negligible 


























3.4.2 Tetracaine aggregation characterization 
 
3.4.2.1 Photon correlation spectroscopy characterization 
 
The critical aggregation concentration of the drug solutions was significantly higher (p < 
0.05) when they contained species with some proportion of both the ionized tertiary and 
secondary amines, i.e. the critical aggregation concentration was 18 ± 1.4 mM at pH 4 
(Figure 3.3) and 3 ± 0.9 mM at pH 7.6 compared to 0.7 ± 0.1 mM at pH 9 and 0.5 ± 0.1 mM 
at pH 10. The two CAC values recorded at pH 9 and 10 were not significantly different (p > 
0.05). This trend in the data indicated that the self-association process was more favourable 
when the unionised tetracaine microspecies were prevalent in the aqueous solutions. 
Tetracaine is commercially available in a 4% (w/w) gel. The drug is partially precipitated in 
the product, presumably to promote maximum thermodynamic activity throughout the entire 
storage and administration period (Escribano et al., 2005; Paudel et al., 2010). It was 
interesting to note that the 4% (w/w) tetracaine commercial gel not only presented the 
molecule to the skin using a two phase system, microscopy analysis showed the presence of 
drug microcrystals (Figure 3.4 a and b), but given the CAC data, it also presented the 




















Figure 3.3. Graph depicting the changes in total light scattering for samples at pH 4. Inset 
graph represents the application of a second derivative function that determined the 
discontinuity in the slope of the derived count rate data. Each point in represents mean ± 
standard deviation (n = 3). 
 
Miller et al., (1993) reported evidence of significant tetracaine molecular aggregation by 
three independent methods: surface tension, specific conductivity and pH in propylene glycol 
and saline (0.9% w/w) vehicles (pH between ca. 6.8 - 8.1). The calculated critical aggregation 
concentration values ranged from 3 mM to 180 mM. These workers attributed these 
differences to the broad range over which self-association begins and the way this affects the 
measured physical properties. Tetracaine self-association in aqueous vehicles at pH 4.5 and 
6.5 has been reported to be ca. 34.5 mM and 69 mM by other workers who used light 









Figure 3.4. Light microscopy (Olympus BX50F, Japan) at a magnification of 40 × a) 
tetracaine commercial product and b) tetracaine test system at pH 9 above critical aggregation 
concentration. 
 
The higher critical aggregation concentration values reported in the literature was attributable 
to a better analytical sensitivity of the technique employed in this work. It should be noted 
that due to the limit of detection of photon correlation spectroscopy, drug aggregates that 
displayed a hydrodynamic radius below 2 nm could not be detected and hence the calculated 
CAC values could be challenged. However, in this case it was assumed that the data collected 









When the donor solutions that were to be subsequently employed in the transport studies 
were analysed, the size of the aggregates present in solution was shown to be significantly 
greater (p < 0.05) when the charge on the tetracaine was reduced, i.e., the average aggregate 
size was 114 ± 8.3 nm at pH 4 whilst it was 188 ± 20.4 nm at pH 9 (Figure 3.5 a). The 
relatively high polydispersity index (≥ 0.25) measured for all test systems can be attributed to 

















Figure 3.5. Graph depicting the changes in a) molecular aggregates size (nm) at increasing 
pH of the donor solution and size distribution above critical aggregation concentration b) at 
pH 4, c) at pH 7.6 and d) at pH 9. Each point represents mean ± standard deviation (n = 3). 
a) b) 
 c) d) 





The zeta potential of the solutions containing more of the charged amine species was also 
significantly higher (p < 0.05) (4.34 ± 1.8 mV at pH 4 vs 0.98 ± 0.2 mV at pH 9). This data 
suggested that the supramolecular structures formed from the ionised tetracaine microspecies 
were displaying the charged moiety on its surface. Molecular modelling of the tetracaine 
aggregate structure using the crystallographic data supported this hypothesis. When tetracaine 
forms crystals the charged amine is most likely to orientate preferentially at the surface of the 
structure rather than the interior, as seen by the positioning of the Cl- ions that form weakly 
bound pairs with N+ (Nowell et al., 2002) (Figure 3.6). Whilst it is accepted that the 
supramolecular formation in solution is not the same process as supramolecular structure 
formation during crystallisation this was thought to be a rational explanation for the trends in 
the zeta potential results. It is also important to note that the formation of molecular 
aggregates by amphiphilic molecules in an aqueous environment is less favoured when 
electrostatic repulsion between the polar head groups is higher. This results in an increase in 
the surface area of the molecule that reduces the capability of intermolecular interactions 
between drug molecules (Tanford, 1980; Israelachvili, 1985). This then correlates well with 





























Figure 3.6. Screenshot of a molecular aggregate composed of 16 tetracaine hydrochloride 
molecules generated from the crystal structure using the Mercury software and visualised 
using Accelrys Viewerlite v5.0. Atom colour scheme: H = white, C = grey, O = red, N = 
blue, Cl = green. 
 
3.4.2.2 Apparent distribution coefficient 
 
The experimentally determined Log D values of tetracaine donor solutions at pH 4, 6, 7.6, 9 
and 10 showed a good agreement with the calculated values at lower pHs, i.e. when both the 
tertiary and secondary amine were ionized (Figure 3.7). The most significant differences were 
surprisingly at the higher pHs of 9 and 10 where the experimental distribution coefficients 
were recorded as 2.1 ± 0.16 and 2.01 ± 0.18 respectively. As that the amount of tetracaine 





detected in the aqueous phase of the partitioning experiments was above the experimentally 
determined critical aggregation concentration for the entire test systems, it was assumed that 
the differences in the predicted and measured values were a consequence of supramolecular 
tetracaine structures. Since the experimental partition coefficient was lower than the predicted 
value, this indicated that molecular aggregates were in fact more hydrophilic than the 
unaggregated tetracaine. It was possible that the aggregates ionized amine at pH 9 and 10 was 
orientated more preferably towards the surface of the supramolecular structure as suggested 
by the molecular simulation images. As such, it can be hypothesized that the process of 
aggregation had a negative impact on the hydrophobicity of the molecules presented to the 
water/oil interface used to determine the distribution coefficient. The presence of an 
organized cluster where the polar region groups are displayed to the outer region may provide 
a higher aqueous solubility due to a decrease in the interfacial tension between the aggregate 
surface and water as previously described for other molecules by Kronberg et al., (2014) and 
























Figure 3.7. Experimental and calculated (Marvin Sketch, ChemAxon, Cambridge, USA) 
distribution coefficients values (Log D) for tetracaine above critical aggregation 
concentration using n-octanol in acetate buffer (0.1 M) at pH 4, 6, 7.6, 9 and 10. Each point 
represents mean ± standard deviation for the experimental data (n = 3). 
 
3.4.2.3 Fourier Transform Infrared spectroscopy 
 
The FTIR spectra at pH 4 was characterized by the presence of the C=O group (1707 cm-1) 
and two vibrational bands at 1597 cm-1 and 1560 cm-1 (Figure 3.8). The two bands between 
1600 and 1550 cm-1 fall within the hydroxyl group absorption frequency and could not be 
directly assigned to any functional group of the monomeric structure. The ‘new’ absorption 
bands were presumably due to intermolecular interactions in solution as a consequence of 
self-association, which may have generated a cluster of molecules with different 
physicochemical properties to the parent entity, as previously reported by other researchers 





(Florence and Attwood, 1998; Potts and Guy, 1995). The appearance of ‘new’ absorption 
bands is not uncommon upon drug-drug interaction and has been shown for other molecules 
(Hinedi et al., 1993). Above pH 4, the stretching vibrational band assigned to the C=O group 
was no longer present (Figure 3.8, data at pH 6 and 10 is not shown for greater visual clarity), 
and there was a significant upfield shift of the vibrational bands assigned to the C-O-H group 
that resulted in a much broader peak as the vehicle pH increased (e.g. 1473 cm-1 at pH 9). 
This suggested that there was an increasingly favourable environment for aggregation driven 
by stronger intermolecular interactions in the solutions at a higher pH. The FTIR data 
suggested that the tetracaine molecules responsible for the supramolecular structure 
formation utilised hydrogen bonds formed through an N-H-O=C association. It was still 
considered a possibility that N-H-N-H association could also play a role in the aggregation 
process (Guerin et al., 1980), but because the IR signals from the amines in water were very 
weak it was impossible to arrive at firm conclusions with regard to the amine involvement in 


























Figure 3.8. Fourier transform infrared (FTIR) transmittance spectra (arbitrary units) of 
tetracaine in deuterium oxide at pH 4, 7.6 and 9 above the experimentally determined critical 
aggregation concentration. 
 
3.4.2.4  1H-NMR spectroscopy studies 
 
There were 9 protons that gave clearly resolved peaks in NMR spectrum (Table 3.2). The 
resonance of the methylene protons H1, H2, H3 of the alkyl chain of the secondary amine and 
the methyl group (H9) attached to the tertiary amine remained essentially unchanged 
regardless of the pH environment of tetracaine. However, the chemical shift of all the other 
protons tended to shift downfield (deshielding effect) with an increasing pH (Figure 3.9). 
 C= O C-O-H 





Table 3.2. Tetracaine proton chemical shifts in D2O at 32 °C (ppm) at pH 4, 6, 7.6, 9 and 10. 
The peak assignment was obtained using (ChemNMR software, PerkinElmer, Beaconsfield, 
















The methylene protons of the alkyl chain adjacent to the oxygen of the ester group (H7) 
displayed the largest frequency change of ~ 1.16 ppm as the pH increased from 4 to 10. In 
addition, both the H6 and H7 protons at either side of the carbonyl group changed in their 
multiplicity at basic pHs. The other significant proton chemical shift change was the 
methylene protons adjacent to the tertiary amine (H8) which moved ca. 0.4 ppm as the pH 
increased from 4 to 10. The chemical shifts of the aromatic protons attached to the benzene 
 pH 4 pH 6 pH 7.6 pH 9 pH 10 
H1 0.88 (t) 0.88 (t) 0.89 (t) 0.89 (t) 0.89 (t) 
H2 1.32 (q) 1.33 (q) 1.33 (q) 1.33 (q) 1.33 (q) 
H3 1.47 (q) 1.48 (q) 1.48 (q) 1.48 (q) 1.48 (q) 
H4 2.92 (t) 3.12 (t) 3.17 (t) 3.16 (t) 3.15 (q) 
H5 6.5 (d) 6.5 (d) 6.73 (d) 6.74 (d) 6.74 (q) 
H6 7.68 (d) 7.68 (d) 7.85 (d) 7.86 (d) 7.86 (q) 
H7 4.35 (t) 4.3 (t) 4.9 (t) 5.56 (q) 5.51 (t) 
H8 3.46 (t) 3.5 (t) 3.57 (t) 3.60 (t) 3.86 (t) 














ring and the methylene protons adjacent to the secondary amine changed, but by relatively 
small amounts, however, there was a change in the multiplicity of these protons at pH 10. 
 
The decrease of the nuclear shielding at increasing vehicle pH could indicate a possible 
change in the free movement of the tetracaine molecules in solution, suggesting that the 
rotation of the methylene protons of the lateral alkyl chains was inhibited by intermolecular 
bonding between tetracaine molecules. Steric hindrance upon molecular interaction between 
local anaesthetics has been previously reported in the literature (Umeda et al., 2007). This 
increasing steric hindrance, which increased with pH, indicated in a similar manner to the 
FTIR data, that when more the non-ionised tetracaine molecules were present in solution a 
more compact supramolecular structured was formed. Previous studies on the interactions of 
model polyamines in supramolecular structures have shown similar results (Sassi et al., 1992; 
Jiang et al., 2002). Both the NMR and IR data suggested that intermolecular interaction was 
stronger at the high pHs and that the two principal functional groups that facilitated this 
interaction was the C=O and NH3+ and therefore, just like previous work by Guerin et al., 
































Figure 3.9. 1H-NMR spectra of tetracaine in deuterium oxide above the experimentally 






























3.4.3 Tetracaine permeation studies 
 
Two membranes were used in this work, a synthetic silicone membrane, which presents a 
homogeneous barrier to diffusion that occurs in the absence of pores (e.g. excluding follicular 
transport), and porcine skin, which is the typical in vivo preclinical model used to characterise 
topically applied medical products, due to its similar permeability and histological 
characteristics to human skin (Sekkat et al., 2001; Tiemessen, 1993). Porcine skin allows 
molecules to pass through its barrier both via the confluent structure presented by the cells in 
the various skin layers and the pores introduced into the skin tissue (e.g. via hair follicles). In 
contrast, the synthetic silicone membrane only allows transport through its barrier via the 
classical partitioning and diffusion process which has been modeled by Higuchi (Section 
1.4.1). By combining the data from a series of test systems using both membranes it was 
hoped that an understanding of how the molecules passed through the barriers could be 
obtained.  
 
The data confirmed that at each pH the synthetic membrane (Figure 3.10 a) and porcine skin 
(Figure 3.10 b) were acting as a rate limiting barrier and hence, the linear portion of the 
permeation data was adequate to calculate steady-state permeation. The experiments applied 
an infinite dose of the drug that was saturated in an aqueous solution which is known not to 
interact with the membrane (as demonstrated in Section 2.4.3) and as the calculation of the 
total drug transport through the membrane in each experiment suggested that no drug 
depletion occurred, it was thought that tetracaine was constantly supplied in the transport 
studies at unity to the barrier. Sink conditions in the receiver compartment were maintained 
for each experiment, i.e., tetracaine concentration in the receiver fluid did not exceed 10% of 
the saturated solubility at each experimental pH (Howes et al., 1996). Therefore, it was 





assumed that the cumulative rate of drug passing the membrane could be considered to be the 




















Figure 3.10. Tetracaine permeation profiles through a) silicone membrane using an infinite 
dose of aggregated drug at pH 4, pH 6, pH 7.6, pH 9 and pH 10 and through b) porcine skin 
using an infinite dose of aggregated drug at pH 4, pH 7.6 and pH 9. The inset graph 
represents lag time versus pH. Each point represents mean ± standard deviation (n = 5). * p < 
0.05 (One-way ANOVA with Tuckey’s HSD test). 
a) 
b) 





The transport data showed in general that the drug flux and penetration lag time increased as 
the solution pH of the donor solutions was increased (Table 3.3 and 3.4). This increase in 
drug flux was thought to be a consequence of the increase in the percentage of unionized 
tetracaine in the donor solution, which had a greater affinity for the membrane. This 
hypothesis correlated well with the distribution data and it suggested that the main 
mechanism of transport was passive diffusion through the confluent barrier presented by the 
cells of the skin rather than transport via the follicular route (Figure 3.10). However, in a non-
aggregated system where the drug does not interact with the membrane, Higuchi and other 
workers have shown that when the permeation rate of a drug increases the membrane 
penetration lag time decreases (Higuchi, 1961; Williams, 2003), in the present study the lag 
time increased. For example, when the unionized fraction increased in the donor solution 
from 0.03% to 73.4% (pH 4 and pH 9 respectively) there was a significant increase (p < 0.05) 
in lag time from 3.1 ± 0.8 min to 14.2 ± 1.1 min through the synthetic membrane (Table 3.3) 
and 123 ± 3.9 to 243 ± 10.9 min through porcine skin (Table 3.4).  
 
Table 3.3. Summary indicies for tetracaine transport studies through a synthetic silicone 
membrane. Data represents mean ± SD (n = 5). **p < 0.01, ***p < 0.001 when compared 












(× 10-3 cm-2.min-1) 
4 2.5 ± 0.3 3.1 ± 0.8 2 ± 0.8 
6 11.1 ± 3*** 5.2 ± 0.7** 1.6 ± 0.3 
7.6 13.6 ± 2.1 1.3 ± 0.4*** 5.3 ± 0.9*** 
9 14.6 ± 1.2 14.2 ± 1.1*** 0.51 ± 0.04*** 
10 17.1 ± 3.3 13.6 ± 0.9 0.63 ± 0.08 





Table 3.4. Summary indicies for tetracaine transport studies through porcine skin. Data 
represents mean ± SD (n = 5). *p < 0.05, ***p < 0.001 when compared with following 







This data was thought to be a consequence of the supramolecular structuring of tetracaine 
having a significant functional effect on the drug transport kinetics. The two most likely 
causes of the increases in lag time were considered to be specific interactions between the 
drug and the barrier (Zhang et al., 2007; Frezzatti et al., 1986; Hata et al., 2000; Racansky et 
al., 1988) and/or the different availabilities of membrane transportable species. However, as 
the aggregate characterization data had already shown that larger, more tightly formed drug 
supramolecular complexes were formed at high pHs, it was assumed that the restriction of the 
freely rapidly diffusing unionized microspecies of tetracaine by the large hydrophobic masses 
that displayed a significantly lower diffusion coefficient (p < 0.001) (Table 3.3 and 3.4), 
which may themselves have difficulty in passing through or leaving the barrier, was the main 
cause of the general trend of an increased lag time as pH of the donor solutions increased as 
previously suggested by Scheuplein et al., 1969. 
 
There was an interesting exception in the general trend of an increase of membrane 
penetration lag time as the donor solution pH was increased, i.e., when tetracaine showed the 
lowest penetration lag time at pH 7.6 through the synthetic membrane. This effect was not 





(× 10-3 cm-2.min-1) 
4 0.96 ± 0.3 123 ± 3.9 0.016 ± 0.003 
7.6 2.17 ± 0.2*** 202 ± 6.7*** 0.001 ± 0.0002*** 
9 1.59 ± 0.3* 243 ± 10.9*** 0.008 ± 0.0001 





observed in the porcine skin. However, as the light scattering data, the partitioning data, the 
IR and the NMR data did not show anything particular in the tetracaine solutions at pH 7.6 
the reason for this effect could not be derived from the current data set. It was therefore 
assumed that at pH 7.6 in the membrane silicone transport data where the optimal self-
assembly configuration of tetracaine was achieved to make a rapidly diffusing species of 
tetracaine available for transport. The discrepancy in the skin and silicone membrane data 
regarding the ability of tetracaine when presented in an aqueous which adjusted to pH 7.6 to 
produce a rapidly penetrating form of the molecule suggested that the manner in which the 
drug was passing the biological barrier was a little more complex that traversing the confluent 
barrier posed by the various strata presented within the skin. This accords with previous work 
which has shown that ionic drug aggregates have the potential to pass the skin via the 
follicular route (Horita et al., 2014; Desai et al., 2010). In the porcine skin the availability of 
multiple transport routes could have resulted in the shorter membrane penetration lag time 
shown in the membrane due to multiple routes of transport permeation in this more complex 




A series of test systems where both tertiary and secondary amine ionization was varied were 
used to investigate the properties of tetracaine aggregates and to assess how the aggregation 
process influences the diffusion behavior through the skin. The results from this Chapter 
demonstrated that the aggregation process was more favourable in the aqueous vehicles at pH 
7.6, 9 and 10 and resulted in a different supramolecular structure formation in solution when 
compared to the aqueous vehicles at pH 4 and 6.  The type of structure formed in the 
application vehicle appeared to be linked to the production of more rapidly diffusing species 





that were initially retarded by their tendency to self-assemble into large hydrophobic 
structures which predicted not to penetrate the barrier directly via the traditional transcellular 
or intercellular routes of skin penetration. The data generated herein supports the hypothesis 
from Chapter 2 that tetracaine self-association affects the partition-diffusion process of this 
agent through a confluent barrier. Although the pH of the commercial formulation favours 
good partition and effective transport through the skin, larger and more compact aggregates 
were more easily formed at pH 9 and this resulted in a slower onset of percutaneous 
penetration. As such, a compromise between aggregate formation and permeation rate for this 
molecule is required or a strategy to modulate drug aggregation should be implemented for 
the commercially available product to improve its delayed onset of action and thus, its 
clinical efficiency. One possible strategy that has received little attention in research is 
hypobaric driven delivery. Therefore, the next phase of this work was designed to determine 
the effects of hypobaric stress upon drug delivery into the skin. 
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Modifying xenobiotic passage into the 
skin through the application of local 
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Depositing therapeutically relevant levels of drugs into the epidermis of the skin remains a 
challenge due to its highly stratified structure which is not conducive to the formation of 
epidermal depots of xenobiotics (Elias, 2005; Michaels et al., 1975). The SC and the multiple 
layers which are formed in the epidermis exhibit selective permeability that only allows 
relatively small lipophilic compounds to penetrate into lower layers (< 500 Da, Log P 0.8 - 3 
(Naik et al., 2000; Barry, 1983)). In an attempt to localize drugs in the epidermal tissue, 
several strategies have been adopted, including sonophoresis, combined with chemical 
enhancers, mechanical abrasion and electrical charge (Mitragotri, 2006; Megrab et al. 1995; 
Prausnitz et al. 2004; Arora et al. 2008; Kalia et al. 2004). These approaches have been 
shown to facilitate cutaneous drug diffusion paths (by a transient alteration of the barrier 
properties and/or manipulation of drug/skin/vehicle interactions), but are often associated 
with skin safety issues which hinders their clinical impact (Prausnitz and Langer, 2008). 
However, to date the effects of local barometric pressure changes on chemical transport 
through the skin seem to be less well characterised.  
 
The application of local hyperbaric pressure (e.g. 1250 mBar) has been shown to enhance the 
skin permeability of caffeine (Trefel et al., 1993), but no mechanistic studies were performed 
to explain these results. There have been some reports of how local hypobaric pressure 
affects the mechanical properties of the skin. For example, Childers et al., (2007) 
demonstrated that the topical application of a sub-atmospheric pressure of ca. 500 mBar 
resulted in thinning of the epidermis and enlargement of blood vessels embedded in the 
dermis. Moreover, it has been reported that the application of local hypobaric pressure 
between 400 and 600 mBar generated from a suction cup device significantly increased 
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TEWL with concomitant decrease in the SC water content (Pedersen and Jemec, 2006). In 
another study, a marked increase in TEWL, disorganization of the intercellular lipid bilayers 
and rupture of the corneosomes was shown after stretching the skin (Rawlings et al., 1995; 
Leveque et al., 2002). However, a link between skin changes induced by barometric pressure 
alteration and the penetration of xenobiotics into the cutaneous tissue has not been reported 
and hence the potential of this method to target topically administered agents into the skin has 
not been broadly considered. 
 
The purpose of the work in this Chapter was to assess the influence of locally applied 
hypobaric stress upon drug deposition within the cutaneous tissue. Tetracaine was chosen as 
the model compound because this molecule is expected to pass into the skin via transcellular, 
intercellular and follicular pathways (Woolfson and McCafferty 1993; McCafferty et al., 
1988; Miller et al., 1993; Foldvari, 1994; Horita et al., 2014; Doliwa et al., 2001). Tetracaine 
donor solution was set above critical aggregation concentration in the transport studies to 
allow the formation of drug nanosized molecular aggregates with an average size of ca. 156.5 
± 15.5 nm (Section 3.4.2.1). The pH was fixed at 7.6, to allow the formation of the ionic form 
(TCH+) and non-ionised form of the drug (TC), since the balance between both microspecies 
in solution resulted in a better permeation through the skin in Chapter 3. It was anticipated 
that at pH 7.6 the molecule would pass into the skin via transcellular, intercellular and 
follicular routes, therefore the effects of barometric pressure in all these routes could be 
picked up in the transport studies. The work adapted one of the most widely used test systems 
for studying in vitro skin permeability, the Franz diffusion cell (Franz, 1975) to operate at a 
sub-atmospheric pressure of 500 mBar. The Franz diffusion cell transport protocol was 
verified using a porous (porcine skin) and non-porous membrane (silicone membrane) as the 
controlling barrier and comparative transport experiments were conducted with the verified 
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experimental set up using porcine skin, as its permeability and histological characteristics 
more closely resemble that of human skin (Sato et al., 1991; Fujii et al., 1997; Dick et al., 
1992; Robert et al., 1991). To confirm if the follicular transport was enhanced by the 
application of barometric stress, ex vivo permeation studies were conducted through rat skin 
in order to study the diffusion behavior of a hydrophilic large molecular weight compound 
fluorescein isothiocyanate-dextran FD-4, M.W.; 4.4 kDa (hydrodynamic radius of 0.45 nm 
(Yuan, 2007)) and FD-10S, M.W.; 10 kDa (hydrodynamic radius of 1.9 nm (Chouinard-
Pelletier et al., 2012)). Rat skin was chosen because this was the animal model selected for 
the subsequent in vivo studies (Chapter 6). Drug transport was understood through 
comparison of the data with multiphoton microscopy, light microscopy and atomic force 
microscopic images to provide information of the mechanical and morphological properties 
of the hypobaric stressed skin. In addition, the mechanism by which hypobaric driven 
delivery promoted drug passage into the cutaneous tissue was further elucidated by 




Acetonitrile and methanol both HPLC grade, grade A glass pipettes, clear glass HPLC vials 
crimpable lids, DPX mounting medium and xylene were purchased from Fischer Scientific 
(Leicester, UK). Tetracaine base BP grade (99.9%), formalin solution neutral buffered 10%, 
DAPI medium, ethanol and FTIC-dextran with average molecular weight of 4 kDa (FD-4) 
and 10 kDa (FD-10S), used without any further purification steps were supplied by Sigma 
Aldrich (Dorset, UK). Concentrated hydrochloric acid and sodium hydroxide was from Fluka 
(Dorset, UK). Sodium acetate was provided by Alfa Aesar (Heysham, UK). Silicone 
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membranes with a thickness of 0.25 mm were purchased from GBUK Healthcare (Selby, 
UK). Deionised water was obtained by purification using an Elgstat water purifier (Elga Ltd, 
Buckingham, UK). Phosphate buffered saline (Dulbecco A) tablets were obtained from Oxiod 
Limited (Hampshire, England). The Tissue-Tek® O.C.TTM compound was purchased from 




4.3.1 Tetracaine permeation studies  
 
A standard Franz diffusion cell (Franz, 1975) was attached to an in-house designed 
aluminium support frame (Figure 4.1) that was able to pressure seal the donor compartment. 
Hypobaric pressure was generated by removing a known volume of air using a syringe and 
changes in barometric pressure were recorded with a manometer (Omni Intruments Ltd., 
Dundee, UK) (Figure 4.2). The system was not completely airtight as the recover chamber 
sampling port was left open and hence, hypobaric pressure was shown to decrease overtime 
(183 ± 5.8 mBar over 420 min). A second syringe was used to correct for pressure decrease 
during the experimental period at ca. 45 min intervals resulting in a barometric pressure that 
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Figure 4.1. Pressure diffusion Franz cell 3 D and 2 D drawings generated in AutoCad LT 
software (Autodesk, Farnborough, UK), a) front view, b) hypobaric chamber, c) front and 
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Figure 4.2. In-house developed pressure cell set up. Hypobaric pressure was created by 
removing a known volume of air using a syringe and changes in barometric pressure were 
recorded with a manometer. 
 
To develop a sound experimental protocol using the in-house developed pressure cell set up a 
series of transport experiments were performed over a 7 h period using donor solutions that 
were prepared by adding excess tetracaine to acetate buffer (75 mM, final pH 7.6 ± 0.3). 
Porcine skin isolated from pig ears sourced from a local abattoir and silicone membranes 
were used as the controlling barrier. The pig ears were cleaned with water prior to use. The 
1 Manometer 
2 Aluminium support frame 
3 Creates hypobaric stress 
4 Corrects pressure decrease 
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residual water on the skin surface was immediately removed by blotting with tissue, visible 
residual hairs were trimmed carefully and the ears were stored at -20 °C (no more than three 
months before the experiments). Freezing has been previously shown not to compromise the 
permeability of porcine skin (Weber, 1993). Porcine skin was defrosted and the subcutaneous 
fat carefully removed using a scalpel. Both the silicone membrane (0.25 mm thick) and the 
porcine skin were cut into pieces of a suitable size and mounted in the Franz diffusion cell 
(University of Southampton, UK). In vitro infinite dose permeation experiments were 
conducted as method described previously in Section 2.3.3 under atmospheric pressure (1010 
mBar) and under hypobaric pressure (500 mBar) using the pressure cell assembly. The 
samples were analysed employing the tetracaine HPLC method described in Section 2.3.1.  
The analysis of the chromatograms showed that matrix interference was negligible (data not 
shown) and drug degradation was not detected (< 2% change in tetracaine peak area) for the 
entire duration of the experimental period. 
 
In the pressure cell protocol, the receptor fluid was replaced by a sponge in order to prevent 
pressure induced solvent back diffusion. The sponge was cut into squares of approximately 4 
cm2 and placed onto the receiver chamber in a manner that ensured intimate contact of the 
sponge with the skin. An identical transport experimental protocol was performed as 
explained above to determine the skin layer deposition. At the end of the 7 h transport 
studies, the skin was removed, washed with distilled water and blotted dry with tissue paper. 
The SC of the skin was removed by tape stripping (ca. 20 strips until the skin was translucent) 
using adhesive tape (Scotch 845 book tape, 3M, Bracknell, UK) as described by Primo 
(2008) and the first strip was considered as part of the applied formulation and hence its 
removal was part of the formulation wash off (Sheth et al., 1987). The remaining tape strips 
were applied sequentially by pressing the adhesive tape onto the skin using a roller to stretch 
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the skin surface (Surber et al., 2001). Once the strips were removed they were collected 
together and weighted, to ensure that a uniform amount of SC was collected throughout the 
procedure. Tetracaine was extracted from the adhesive tape by immersing it in a 90% MeOH 
and 10% NaCOOH (0.1 M at pH 4) solution for 24 h. The adhesive tape was then removed 
from the drug solvent and discarded. The drug solutions were dried down, the residue was 
reconstituted using acetate buffer at pH 7.6 and analysed using the tetracaine HPLC method 
described in Section 2.3.1. The epidermis was separated from the dermis using a scalpel as 
previously reported in the literature (Surber et al., 1991; Ferreira et al., 1995; Ayub et al., 
2007; Argenta et al., 2014). Both the epidermis and dermis were homogenized using a tissue 
homogenizer (Ultra Turrax, Fisher Scientific, Leicester, UK) in a 90% MeOH and 10% 
NaCOOH (0.1 M at pH 4) solution and left in contact with the extraction solution for 24 h. 
Samples were then centrifuged at 17000 rpm (Biofuge, Heraeus, Germany) for 15 min, the 
resultant supernatant was evaporated before the residue was reconstituted using acetate buffer 
at pH 7.6 and analysed employing the tetracaine HPLC method described in Section 2.3.1. To 
assess the extraction recovery efficacy, skin samples were spiked with a known amount of 
drug and the extraction procedure was conducted as previously described. The extraction 
recovery was measured by comparing the amount of drug added and extracted. Tetracaine 
extraction procedure from the receptor compartment, tape strips and skin samples was found 
to have a recovery at 7 h period of  95.3 ± 2.5% , 96.3 ± 4.3% and 98.16 ± 5.8% (n = 5), 
respectively. Drug extraction was within the 100 ± 15% recovery rates, which was in line 
with published regulatory guidelines (Health and consumer protection directorate-general, 
2006). 
 
The effect of local hypobaric stress upon tetracaine cutaneous bioavailability was represented 
by an enhancement ratio (ER), which was calculated according to equation 4.1, where CP and 
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                                                                                                               (Equation 4.1) 
 
4.3.2 Dextran permeation studies  
 
All procedures were conducted in accordance with the U.K. Animal Scientific Procedures 
Act (1986) and Amendments Regulations (2012) and approved by the King’s College 
London Animal Care and Ethics Committee. Sprague-Dawley male rats (6 - 9 weeks old, ca. 
220 - 250 g; Charles River, Kent, UK) were caged in groups of 4 with free access to water 
and food. A temperature of 19 - 22 °C was maintained, with a relative humidity of 45 – 65%, 
and a 12 h light/dark cycle. Animals were acclimatized for 7 days before each experiment. 
Rats were killed by intraperitoneal injection of sodium pentobarbital. The dorsal hair was 
removed using an animal hair clipper and full thickness skin was excised. The excess fat 
adhering to the dermis side was removed carefully with a scalpel. The hairless rat skin was 
cut into pieces of a suitable size and mounted with the SC facing the donor compartment in 
the pressure diffusion cell. The receptor phase, consisting of a sponge, was used in order to 
prevent back diffusion as previously described for porcine skin (Section 4.3.1). A 1 mL 
aliquot of each donor solution (125 uM of FD-4 and FD-10S in phosphate buffer solution at 
pH 7.4) was applied to the apical surface of the skin to initiate the transport studies.  Five 
diffusion cells were used for each experiment. Ex vivo diffusion studies were performed 
under atmospheric pressure (1010 mBar) and under hypobaric pressure (500 mBar). The 
same transport protocol was conducted as described above for porcine skin; however 
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hypobaric pressure was applied for the first hour of a 20 h permeation study, as this 
application protocol was shown to not cause irreversible blistering in the fresh rat skin.  
 
The extraction of the dextran from the sponge and tape strips at the end of the transport 
studies followed the same steps previously described for tetracaine (Section 4.3.1), however 
in this case, FDs were extracted by immersing it for 24 h in phosphate buffer saline solution 
(pH 7.4). The dermal tissue was homogenized in the same drug solvent and centrifuged as 
described above for tetracaine. Extraction procedure for FD-4 and FD-10S at 20 h period 
from the receptor compartment, tape strips and dermal tissue was found to have a recovery of 
92 ± 5.1%  and 90.3 ± 6.3%, 89 ± 8.5% and 90.3 ± 7.1%,  92 ± 5.1% and 90.9 ± 4.1% (n = 5), 
respectively. Drug extraction was within the 100 ± 15% recovery rates, which was in line 
with published regulatory guidelines (Health and consumer protection directorate-general, 
2006). The effect of local hypobaric stress upon dextran cutaneous bioavailability was 
represented by an enhancement ratio (ER) which was calculated according to equation 4.1. 
 
4.3.3 Dextran quantification 
 
The amount of FDs was quantified using a stand-alone fluorescence spectrometer (Varian 
Cary Eclipse fluorescence spectrophotometer, Agilent, Cheadle, UK) at an excitation 
wavelength of 495 nm and fluorescent emission wavelength of 515 nm as previously reported 
in the literature (Fang et al., 2004; Fujiwara et al., 2005; Lee et al., 2011). The assay was 
verified as ‘fit for purpose’ by determination of linearity, precision and sensitivity using the 
methodology described in Section 2.3.1. Linearity was confirmed for concentrations ranging 
from 2.4 to 0.02 µg.ml-1 of standard solutions and correlation coefficients were greater than 
0.998. The limit of quantification was 0.089 and 0.258 µg.ml-1 and the limit of detection was 
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found to be 0.027 and 0.077 µg.ml-1 for the FD-4 and FD-10S respectively. Matrix 
interference was determined to be negligible (i.e., skin lipids that may leach out during the 
permeation studies). 
 
4.3.4 Fluorescence microscopy 
 
After the dextran transport studies, skin samples were carefully cut in half along the diameter 
and subsequently embedded in Tissue-Tek O.C.T. before being sectioned in slices of 20 mm 
thickness in a cryostat microtome (Bright Instruments, Huntingdon, UK). Sectioning was 
performed from the dermis side towards the SC in order to avoid dislocation of the 
fluorescein isothiocyanate-dextran from the skin surface on the samples. Skin sections were 
then mounted using mounting medium with DAPI and covered with glass cover slips. 
Fluorescence photomicrographs were obtained with a Zeiss Axioscope microscope equipped 
with a Nikon Digital Camera (DXM1200; Nikon, Kingston upon Thames, UK) at a 
magnification of 10. Images were acquired in two fluorescence channels to allow the 
visualization of the cellular structures stained by DAPI (blue color) and the dextran 
fluorescence signal (green color) using a filter set having an excitation of 360 and 490 nm 
and emission length at 460 and 526 nm, respectively. Samples without the application of 
fluorescein isothiocyanate-dextran were also tested as controls. Images were processed using 
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4.3.5 Skin morphology and physiology 
 
4.3.5.1 Multiphoton fluorescence microscopy analysis 
 
The multiphoton microscope images were taken using a custom built system developed 
around a FN1 upright microscope (Nikon Instruments, Melville, USA). The excitation source 
was a femtosecond pulsed Titanium:sapphire Chameleon Vision S laser (Coherent Inc., Santa 
Clara, USA) tuned to 800 nm, which was relayed into an afocal galvanometer scanning 
system. This was then projected onto the back aperture of an infinity corrected Nikon air-
objective (NA. 0.5x20; Nikon Instruments, Melville, USA), where it was focused on the 
sample. The emitted fluorescence was collected onto two detection channels housed in a non-
descanned configuration, with bandpass filters of 525 nm ± 30 nm and 593 ± 40 nm, 
respectively.  The detectors used were a HPM-100-50 Hybrid Photomultiplier Tubes (PMTs) 
(Becker & Hickl, Berlin, Germany) operating in single photon counting mode. The 
microscope was controlled by a software developed using the graphical based LabVIEW 
programming language (National Instruments Corporation, Austin, USA). For these 
experiments the porcine skin was challenged under the same barometric pressure conditions 
employed in the permeation studies (Section 4.3.1). Upon hypobaric treatment, the skin was 
immediately mounted on a glass slide with the SC facing the objective. Z stacks of the 
porcine skin samples were acquired using Bio-Rad software (Philadelphia, USA) and were 
taken from the SC to the dermis (1 - 100 µm deep), with steps every 2 µm. Two dimensional 
images were generated by raster scanning the excitation beam across the skin sample utilizing 
the afocal scanning system. Measurements of the hair follicle infundibula were performed 
using an in-house developed software that was based on the graphical based LabVIEW 
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programming language (National Instruments Corporation, Austin, USA) that allowed the 
assessment of the length and depth of the follicular structures. 
 
4.3.5.2  Atomic force microscopy analysis 
 
Atomic force microscopy (AFM) has been widely used to characterize the morphology of 
corneocytes (Ritcher et al., 2001; Kashibuchi et al., 2002). Corneocytes were collected from 
the porcine skin surface (n = 6) treated under the same barometric stress conditions employed 
in the permeation studies by the removal of 4, 6 and 10 tape strips (Scotch 845 book tape, 
3M, Bracknell, UK) from the same cutaneous site, a method that had been previously 
described by Fredonnet et al., (2014). The tape was then fixed on a glass slide and atomic 
force microscopy images were obtained from a Nanoscope V multimode scanning force 
microscope (Digital Instruments, Bresso, Italy). Imaging was performed in tapping mode in 
air. Aluminium coated Si3N4 cantilevers with integrated pyramidal tips (NSC15/Al, 
MikroMasch, Wetzlar, Germany) with a reported resonance frequency of 325 kHz and high 
spring constant of 40 N/m were used. After acquisition, the images were flattened and 
analysed using section analysis with the Gwyddion software (Czech Metrology Institute, 
Brno, Czech Republic). 
 
4.3.5.3  Histological studies 
 
Porcine and rat skin samples challenged under the same barometric stress conditions 
employed in the permeation studies were carefully cut in small pieces and fixed with 10% of 
buffered formalin during 24 h at room temperature and subsequently embedded in Tissue-
Tek-O.C.T. as previously reported (Hoppert, 2003). Cross-section slices of 20 mm thickness 
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were obtained using a Bright Model OTF cryostat (Bright Instruments, Huntingdon, UK). 
The samples were stained following the Ellis Hematoxylin and Eosin (H&E) staining 
protocol (Ellis, 2010) and dehydrated with different volumes of ethanol (75%, 95%, and 
100%) and xylene for 5 min each, before being mounted in DPX and covered with glass 
cover slips. The samples were analysed using a Leica DM 200 Led light microscope (Leica 
Microsystems, Wetzlar, Germany) equipped with a Leica digital camera (Model DFC 295) at 
4, 10 and 40 magnifications. Images were processed using Las v4.4 Imaging Software (Leica 
Microsystems, Wetzlar, Germany). 
 
4.3.6 Statistical analysis 
 
All data were presented as mean ± standard deviation and statistical analysis of data was 
performed using SPSS version 16.0, as described previously in Section 2.3.4. In all cases, a 
statistically significant difference was defined as p < 0.05 and denoted as: * p < 0.05, ** p < 
0.01 and *** p < 0.001. The number of replicates was 4 or 5 in the permeation studies and 
drug quantification within the skin layers, 15 in the follicular infundibula characterisation 
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4.4 Results and Discussion 
 
4.4.1 Tetracaine permeation studies  
 
The data confirmed that tetracaine transport rate through the synthetic membrane (Figure 4.3 
a) and porcine skin (Figure 4.3 b) were acting as a rate limiting barrier and hence, the linear 
portion of the permeation data was adequate to calculate steady-state permeation. The 
experiments applied an infinite dose of the drug that was saturated in an aqueous solution 
which is known not to interact with the membrane (as demonstrated in Section 2.4.3) and as 
the calculation of the total drug transport through the membrane in each experiment 
suggested that no drug depletion occurred, it was thought that tetracaine was constantly 
supplied in the transport studies at unity to the barrier. Sink conditions in the receiver 
compartment were maintained for each experiment, i.e., tetracaine concentration in the 
receiver fluid did not exceed 10% of the saturated solubility at each experimental pH (Howes 
et al., 1996). Therefore, it was assumed that the cumulative rate of drug passing the 
membrane could be considered to be the steady-state flux in the exponential portion of the 
cumulative drug concentration vs time plots.  
 
The transport data showed that tetracaine steady-state permeation was significantly greater   
(p < 0.001) when the silicone membrane was challenged under hypobaric stress (20.2 ± 3.1 
µg.cm-2.min-1 vs 9.5 ± 1.3 µg.cm-2.min-1 at atmospheric pressure), but this effect was not 
mirrored in the porcine skin and the rate of mass transfer was found to be statistically 
equivalent (p  > 0.05). A steady-state flux of 1.91 ± 0.2 µg.cm-2.min-1 under hypobaric driven 
delivery vs and 1.42 ± 0.7 µg.cm-2.min-1 at atmospheric pressure was obtained. The lack of 
change in tetracaine permeation through porcine stressed skin was attributed in these 
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preliminary studies to solvent back diffusion into the donor fluid, which was visually 
apparent at the end of the experimental period. This led to the use of the sponge in the 
receiver compartment in the subsequent studies as this negated the back diffusion effects. The 
observed back flow was thought not to be caused by a disruption of the mechanical integrity 
of the skin induced by hypobaric treatment, since application of similar sub-atmospheric 
pressure has been shown not to compromise barrier integrity (Pedersen et al., 2006), but a 
consequence of the presence of a large volume of liquid under the skin which did not 
represent in vivo conditions.  
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Figure 4.3. Tetracaine permeation profile under atmospheric (1010 mBar) and hypobaric (500 
mBar) pressure through a) silicone membrane and b) porcine skin over 7 h. Each point 
represents mean ± standard deviation (n = 5). 
a) 
b) 
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The use of the adapted methodology showed in general that the transmembrane penetration 
and drug deposition within specific skin strata was increased under hypobaric driven delivery 
(Figure 4.4). The rate of mass transfer through the biological membrane was found to be 4-
fold greater when compared to that obtained under atmospheric conditions. In addition, the 
ability of hypobaric stress to localise the drug within the epidermal tissue was found to be 
significantly greater (p < 0.001) when compared to the amount found in the SC and dermal 
tissue. It was registered an enhancement ratio of 25.6, 8.8 and 9.9 respectively (Figure 4.4). 
The enhanced drug deposition within the skin tissue was thought to be caused by a temporary 
alteration of the skin properties. As such, the mechanical and physiologic changes in the 
barrier were further investigated and related to the ability of the drug to cross the skin by the 
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Figure 4.4. In vitro profile of tetracaine deposition in porcine skin layers and transdermal 
permeation under atmospheric (1010 mBar) and hypobaric (500 mBar) pressure conditions. 
Each point represents mean ± standard deviation (n = 5). ER (Enhancement ratio) represents 
the ratio between the amount of drug found under hypobaric and atmospheric conditions. 
Student’s t-test with * p < 0.05, *** p < 0.001. 
 
4.4.2 Dextran permeation studies  
 
The application of topical hypobaric stress did not alter the amount of FDs found in the SC, 
but there was a different skin deposition of FD-4 when the barrier was challenged by 
mechanical stress stimuli (Figure 4.5 a). The FD-4 dextran demonstrated a 3-fold greater 
deposition within the dermal tissue. On the other hand, the amount of FD-10S retained in the 
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dermal tissue was found to be equivalent (p < 0.05) under both barometric conditions (Figure 
4.5 b). The transdermal delivery of FDs was found to be significantly greater (p < 0.01) when 
compared to atmospheric conditions (2.9 and 19.6-fold increase, respectively) (Figure 4.5 a 
and b). Interestingly, the effect of hypobaric stress was more pronounced upon the 
transdermal delivery of the higher molecular weight dextran (10 kDa). The enhanced 
cutaneous and transdermal bioavailability was not thought to be attributable to chemical 
degradation since it has been previously shown that FDs of various molecular weights were 
stable after the permeation through pig, mouse and rat skin under similar experimental 
conditions (Ying-Zhe et al., 2009; Fang et al., 2004; Woan-Ruoh et al., 2008; Lombry et al., 
2000). 
 
The dextran permeation through rat skin was studied to investigate a possible magnification 
of the follicular route upon hypobaric driven delivery. Previously, permeation studies using 
FDs through rat skin, porcine skin and in vitro cultured human epidermis model suggest that 
the follicular route is the primary permeation pathway for dextrans between 4 - 10 kDa 
(Ying-zhe et al., 2009; Fang et al., 2004; Todo et al., 2010). This was recently confirmed in a 
novel follicle-plugging method, which showed that the permeation of 4 kDa dextran was 
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Figure 4.5. Ex vivo profile accumulation of FD-4 (a) and FD-10S (b) in rat skin layers and 
transdermal permeation under atmospheric (1010 mBar) and hypobaric (500 mBar). Each 
point represents mean ± standard deviation (n = 4) for atmospheric conditions and (n = 5) for 
hypobaric conditions. ER (Enhancement ratio) represents the ratio between the amount of 
drug found under hypobaric and atmospheric conditions. Student’s t-test with ** p < 0.01 and 
*** p < 0.001. 
a) 
b) 
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4.4.3 Dextran permeation pathways  
 
To evaluate the effects of hypobaric driven delivery upon dextran cutaneous diffusion routes, 
cryostat sections of skin with and without hypobaric treatment were viewed by fluorescence 
microscopy. A mounting medium with DAPI was employed to allow the visualization of 
cellular structures which were displayed by the blue color. Skin control samples where no 
dextran had been applied (Figure 4.6 a and b) exhibited some fluorescence at an excitation of 
490 nm (green color) which was thought to be due to the skin’s chromophores that fluoresce 
at this wavelength has previously shown by Hanson and Bardeen (2009). However, there was 
a significant increase in the fluorescence intensity in deeper skin layers exposed to hypobaric 
treatment (Figure 4.6 d and f) compared to the samples under atmospheric conditions (Figure 
4.6 c and e). Moreover, a greater fluorescence signal was evident around the perifollicular 
region, which suggests that hypobaric treatment influenced drug transport across the hair 
follicle structures. The lower molecular weight FD dextran gave a broad and continuous band 
of fluorescence signal that extended from the SC into deeper layers of the skin (Figure 4.6 d). 
This may indicate that the 4 kDa dextran was transported more efficiently not only through 
the follicular route but also through the transcellular and/or intercellular regions. In contrast, 
the fluorescence signal of the 10 kDa dextran was mainly localized around the perifollicular 
region, suggesting that the follicular pathway was the main route utilised by this permeant to 
diffuse through the hypobaric stressed skin. These data suggested that the specific effects of 





Chapter 4: Modifying xenobiotic passage into the skin through the application                  123 


























Figure 4.6. Fluorescence microscopic examination after topical administration of FD-4 and 
FD-10S dextran under atmospheric conditions (1010 mBar) and hypobaric stress conditions 
(500 mBar): control samples at atmospheric (a) and after hypobaric treatment (b); topical FD-
4 delivery under atmospheric conditions (c) and upon hypobaric stress treatment (d); topical 
FD-10S delivery under atmospheric conditions (e) and upon hypobaric stress treatment (f). 























Foll icular duct 
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4.4.4 Skin morphology and physiology 
 
4.4.4.1 Hair follicle  
 
Multiphoton microscopy has been widely used to analyse the skin tissue (Lin et al., 2007; 
Hanson et al., 2002; Sun et al., 2003). This imaging technique was selected because is 
possible to rapidly obtain two dimensional reconstructions of individual hair follicles. 
Furthermore, no staining or mechanical sectioning is involved, since the endogenous 
fluorophores in the hair follicle can easily produce strong two photon excited fluorescence 
signals without the need of contrast agents. These signals are ideally suited to determine the 
size of the follicular orifice, as previously reported for mouse skin (Lyubovitsky et al., 2007). 
In this study, the follicular infundibula was significantly longer (p < 0.001) upon hypobaric 
stress treatment. It registered an average horizontal planner length of 243 ± 23.9 µm and 151 
± 40.5 µm after hypobaric and under atmospheric conditions, respectively (Figure 4.7 c and 
f). In addition, there was a significantly decrease (p < 0.01) in the depth of the follicular 
structures after the application of barometric stress (159 ± 14.5 µm after hypobaric pressure 
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Figure 4.7. Multiphoton microscopic images of porcine follicular infundibula a) 3D 
reconstruction under atmospheric conditions (1010 mBar) b) top view (singe Z-stack cross-
section at 1010 mBar) c) side view at 1010 mBar with an average length of 151 ± 40.5 µm 
and depth of 190 ± 30.1 µm  d) 3D reconstruction after applying hypobaric pressure (500 
mBar) e) top view after hypobaric pressure (Z-stack cross-section) f) side view after 
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A greater horizontal planner length of the follicular infundibula with concomitant decrease in 
the depth of the follicular structure was believed to be due to the stretching and vertical 
displacement of the skin when exposed to hypobaric stress. Previously, the follicular 
infundibula orifice was studied using cyanoacrylate porcine ear skin (Jacobi et al., 2007). The 
horizontal planner length of the follicular infundibula was reported to be between 170 and 
200 µm, which is in good agreement with the values obtained under atmospheric conditions.  
Several studies by Lademann et al., (2008 and 2001) have suggested that a large fraction of 
the hair follicles are not accessible to drug penetration. It was demonstrated that drug 
transport only occurred through the “active” (open) hair follicles that are characterized by 
hair growth and/or sebum production. This can be explained by the fact that plugs from shed 
corneocytes and dry sebum, which block some of the hair follicles, are pushed out by 
growing hair or flowing sebum (Otberg et al., 2004). Previously, mechanical peeling has 
been shown to open closed follicles and facilitate drug passage into the cutaneous tissue 
(Lademann et al., 2008). In a similar manner, Toll et al., (2004), reported that the pre-
treatment of the skin with cyanoacrylate skin surface stripping resulted in drug targeting into 
the dermal tissue by a facilitated follicular transport of nanosized compounds. The 
application of hypobaric stress is commonly used to open and clean clogged hair follicles in 
clinical practise (Davis et al., 2010). This previous work and the new data derived in this PhD 
then suggest that hypobaric pressure may be opening up the follicles and hence facilitating 
xenobiotic percutaneous penetration. It is important to note in the current project, that the 
penetration of nanosized systems is possible via the follicular pathway through the skin has 
previously suggested for other nanosized delivery systems (Alvarez-Román et al., 2004; Vogt 
et al., 2005). As such, the increase in tetracaine permeation and deposition within the 
different skin layers caused by the application of barometric pressure could be attributable at 
least in part, to the follicular transport of the nanosized drug aggregates. It is therefore 
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hypothesized that hypobaric driven delivery could reverse the reduction in drug permeation 





The average size of the porcine corneocytes was significantly lower (n = 15 p < 0.001) upon 
hypobaric treatment with a length and width at 31.5 ± 8.2 µm and 26.2 ± 6.8 µm vs 41.5 ± 
5.5 µm and 37.2 ± 7.2 µm under atmospheric conditions respectively (Figure 4.8). The 
diffusional barrier characteristics of the skin result from the properties of the lipids and the 
path length for diffusion. The latter depends on the number of corneocytes, their cohesion and 
size. Previously, a reduction in the corneocytes packing with a concomitant increase in the 
size of corneocytes gaps was shown to facilitate percutaneous penetration and drug 
deposition into deeper skin layers (Zhai et al., 2011; Schafer-Korting et al., 2007). In 
additional work, a decrease in corneocyte size was thought to result in greater drug 
permeation rates through the skin by a facilitated transcellular and intercellular cutaneous 
drug diffusion pathways (Hadgraft et al., 2009).  Transepidermal water loss as a measure of 
the water vapour flux crossing the skin to the outside environment has been previously used 
as an indicator of the skin barrier function. It was shown that an increase in TEWL is directly 
related to a decrease in corneocyte size and hence, in a shorter permeation path length 
through the cutaneous tissue (Rougier et al., 1988; Machado et al., 2010). The application of 
similar sub-atmospheric pressure to that employed in this study has been reported to cause an 
increase TEWL with concomitant morphological alteration of the corneocytes due to 
mechanical stretching (Pedersen et al., 2006; Corcuff et al., 1991).  
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Figure 4.8. Atomic force microscopy analysis of in vitro porcine skin corneocytes at a) 
atmospheric conditions (1010 mBar) with average length of  41.5 ± 5.5 µm and width of 37.2 
± 7.2 µm and b) within 25 min of applying hypobaric pressure (500 mBar) with average 
length  of 31.5 ± 8.2 µm and width of 26.2 ± 6.8 µm. 
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It can be hypothesized that the decrease in corneocyte size upon hypobaric treatment was 
caused by an increase in TEWL during the permeation studies and therefore a lower water 
content of the tissue. A shorter permeation path length may explain the facilitated dextran 
transport through the intercellular and transcellular route as shown by fluorescence 
microscopy (Figure 4.6). The intercellular route could also facilitate tetracaine delivery 
through the skin, but probably not via aggregate permeation as they had a size of (156.5 ± 
15.5 nm) and the gaps between porcine corneocytes have been previously reported to be ca. 
19 nm (van der Merwe et al., 2006). It was thought unlikely that a 30% reduction in 
corneocyte size would lead to the transport of a large aggregate through these gaps which will 
have been enlarged. 
 
4.4.4.3  Skin morphology and thickness 
 
The hypobaric stressed porcine skin was found to be significantly thinner (p < 0.05) 
following the transport studies. A skin thickness of 0.89 ± 0.1 mm upon the application of 
hypobaric treatment vs 1.1 ± 0.1 mm under atmospheric pressure conditions was registered. 
Conversely, when rat skin was treated with the same hypobaric conditions used in the in vitro 
permeation studies and subsequent in vivo experiments (Chapter 6) there was no significant 
alteration (p > 0.05) in membrane thickness. Skin thinning upon the application of hypobaric 
stress has been previously reported in the literature. A 7% and 17% skin thickness reduction 
was observed upon the application of 200 and 350 mBar of sub-atmospheric pressure from a 
suction device (Hendricks et al., 2003). The decrease in skin thickness may translate in a 
shorter diffusion path length across the skin and thus facilitate solute mass transport (equation 
1.1). Moreover, the vertical displacement of the skin upon hypobaric treatment could result in 
a greater diffusional area (Figure 4.9 b, f). The change in the morphological characteristics of 
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the hypobaric stressed skin was shown to be reversible and the initial morphology was 
restored ca. 15 - 30 min after the hypobaric stress was removed (Figure 4.9 d, h).  A linear 
stress-strain relationship up to 350 mBar has been previously demonstrated using a suction 
device (Childers et al., 2001). 
 














Figure 4.9. Vertical displacement of porcine (PS) and rat skin (RS) upon the application of the hypobaric conditions employed in the in vitro 
permeation studies a) PS control under atmospheric conditions (1010 mBar) e) RS control under atmospheric conditions (1010 mBar) b) PS 
immediately upon the application of 500 mBar for 7 h, f) RS immediately upon the application of 500 mBar for 1 h, c) and g) PS and RS       
after 10 min of hypobaric stress d) and h) PS and RS after 30 min of hypobaric stress. 
CONTROL DOSE APPLICATION 10 min   30 min 
 a b c d 
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4.4.4.4   Skin integrity 
 
Light microscopy was used to visualize the histological changes to porcine and rat skin upon 
hypobaric treatment. Dermal-epidermal detachment was observed in few localized areas of 
both porcine (Figure 4.10 d) and rat skin samples (Figure 4.11 d). However, the majority of 
the skin maintained its morphological and structural characteristics (Figure 4.10 f and Figure 
4.11 f) when compared to the control samples (Figure 4.10 c and 4.11 c). Minor changes were 
observed regarding cell cohesion, with some areas of the SC detaching or peeling off from the 
adjacent layer. However, this was most probably due to sample handling, since this was 
observed in the control skin samples. The small amount of dermal-epidermal detachment was 
thought unlikely to influence drug delivery via the skin as the SC seems to remain intact upon 
hypobaric driven delivery. 
 
Previous in vivo work in human subjects has shown a rapid repair of the dermal-epidermal 
adherence after 2 h (Beerens et al., 1975; van der Leun et al., 1974). This process was also 
observed when employing porcine and rat animal models (Nanchahal and Riches, 1982; Pang 
et al., 1978). One of the major concerns when employing physical enhancement methods to 
deliver therapeutic agents across the cutaneous tissue is the effects upon skin integrity and 
reversibility. The data generated in this Chapter suggested that the enhanced topical 
bioavailability of the test agents was accompanied by reversible changes in the morphological 















Figure 4.10. Porcine skin histology a), b) and c) control under atmospheric conditions 4 ×, 10 × and 40 × respectively d), e) and f) after 
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Figure 4.11. Rat skin histology a), b) and c) control under atmospheric conditions 4 ×, 10 × and 40 × respectively, d), e) and f) after hypobaric 
treatment of 500 mBar for 1 h at 4 ×, 10 × and 40 × respectively. SC, stratum corneum, E, epidermis, D, dermis and arrow indicates epidermal-
dermal detachment. 
 100 µm 
100 µm 
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    50 µm 
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This chapter has provided new insights into the effects of local hypobaric treatment upon the 
skin and the transport of molecules through the tissue. A novel device that can pressure seal 
the donor compartment of a traditional Franz diffusion cell (Franz 1975) and a ‘fit for 
purpose’ method that allowed the characterization of percutaneous penetration were 
developed. The use of the adapted Franz cell demonstrated that the application of topical 
hypobaric stress improved the delivery of both small molecular weight and macromolecular 
size xenobiotics. The enhanced tetracaine epidermal deposition was accompanied by an 
enlargement of the follicular infundibula (p < 0.001), reduced corneocyte size (p < 0.001) and 
skin thinning (p < 0.05) and this suggested that the transcellular and follicular routes of 
penetration could both be facilitated and therefore explain the enhanced drug penetration 
and/or site specific drug accumulation in the skin’s strata. 
 
It was hypothesized that hypobaric driven delivery could reverse the reduction in drug 
permeation of a molecular aggregated system such as tetracaine (as described in Chapter 3), 
by facilitating drug movement of the aggregates into the skin. Histological studies showed 
that these changes were accompanied by dermal-epidermal detachment in few localized 
areas. However, this was thought unlikely to influence drug transport as the SC seems to 
remain intact. In order to move this concept forward, a greater understanding of the 
relationship between cutaneous bioavailability upon hypobaric driven delivery and the drug’s 
physicochemical properties is required. Consequently, in the next phase of this work, three 
model agents (tetracaine, diclofenac diethylamine and aciclovir) were employed in an 
aggregated/non-aggregated state and permeation studies were conducted under differential 
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barometric pressure to further explore this novel method to facilitate percutaneous 
penetration into the skin. 
 
  































In order to deposit therapeutically relevant levels of drugs within the different skin strata, 
complementary strategies employing chemical and physical methods have been employed 
(Mitragotri, 2006; Megrab et al., 1995; Prausnitz et al., 2004; Arora et al., 2008; Kalia et al., 
2004). However, this needs a finely tuned approach system and at the present only limited 
success in retaining therapeutic molecules within the skin has been achieved (Brown et al., 
2006). Drug localization of this type is desirable in the treatment of dermatological conditions 
such as skin cancer, psoriasis, eczema and microbial infections where the origin of the 
disease lies within the skin tissue (Brown et al., 2006).  
 
One strategy that has shown encouraging results in terms of skin strata targeting is opening 
the follicular route. These structures circumvent the formidable barrier posed by the SC when 
passing molecules into the skin. However, despite the fact that the corneocytes of the 
follicular epithelium are not completely differentiated, suggesting that the skin barrier is more 
permeable in this area and permitting drug diffusion directly into the viable epidermis 
(Rancan et al., 2009), the follicular structure also forms a relatively tight barrier that requires 
open up (Knorr et al., 2009). This could be achieved by the application of hypobaric stress 
(Chapter 4). The main mechanism by which hypobaric driven delivery promotes drug 
localisation was thought to be due to a facilitated follicular penetration of topically applied 
nanosized aggregates.  
 
The aim of this study was therefore to investigate the effects of local hypobaric treatment 
upon localization of actives within the cutaneous tissue and relate these findings with the 
presence or absence of drug aggregates in the application system. In addition, the findings of 





these studies were compared to products containing the same drugs to understand the 
influence of the formulation components on the barometric enhanced delivery process. For 
this purpose, tetracaine (TC) (M.W.; 264.36, pKa 2.48 ± 0.03 and 8.56 ± 0.02 (Section 
3.4.1)), diclofenac diethylamine (DDEA) (M.W.; 369.29, pKa 4 (Djordjevic et al., 2005)) and 
aciclovir (ACV) (M.W.; 225. 21, pKa 9.25 (Freeman et al., 1986)) were selected based upon 
their different physicochemical properties. The chemical structure of these drugs was 
predicted to cause molecular aggregation in solution (Miller et al., 1993; Fernandez, 1980; 
Kitagawa et al., 2004; Kriwet and Muller-Goymann, 1993; Karen et al., 2001). Therefore, 
photon correlation spectroscopy was employed to determine the critical aggregation 
concentration at which nanosized aggregates were formed and zeta potential measurements 
provided details regarding surface potential of the supramolecular structures formed in the 
administration vehicle. A hydroxypropyl methylcellulose (HPMC) gel formulation was then 
prepared for each active with a drug load above and below the experimentally determined 
critical aggregation concentration. Transport studies were conducted through porcine skin 
under atmospheric pressure using a traditional Franz diffusion cell and hypobaric stress 
conditions were tested using the adapted cell described in Section 4.3.1 and cutaneous 
bioavailability for each drug was assessed by tape stripping and tissue homogenisation 
methodologies. Porcine ear skin was chosen in the current work because this barrier is 
especially suitable for studying follicular uptake as the ear cartilage prevents contraction of 
tensile fibres and closure of follicles, which greatly reduces follicular transport, when 












Acetonitrile and methanol both HPLC grade, grade A glass pipettes, clear glass HPLC vials 
crimpable lids and 0.45 µm nylon filter papers were purchased from Fischer Scientific 
(Leicester, UK). Tetracaine base and aciclovir base both BP grade (99.9%) were supplied by 
Sigma Aldrich (Dorset, UK). Diclofenac diethylamine BP grade (99.9%) was obtained from 
Chemos Group (Regenstauf, Germany). Concentrated hydrochloric acid and sodium 
hydroxide was from Fluka (Dorset, UK). Sodium acetate was provided by Alfa Aesar 
(Heysham, UK). Deionised water was obtained by purification using an Elgstat water purifier 
(Elga Ltd, Buckingham, UK). Hydroxypropyl methyl cellulose grade 65SH viscosity 50 cP 
with the brand name of Metolose was supplied by Shin-Etsu Chemical Ltd (Tokyo, Japan). 
Ametop® gel (tetracaine 4% w/w), Voltarol® emulgel (diclofenac diethylamine 1.16% w/w) 




5.3.1 Aggregation characterization 
 
5.3.1.1 Photon correlation spectroscopy characterization 
 
Changes in derived count rate were tracked using photon correlation spectroscopy (PCS) 
(Malvern Nanoseries Zetasizer, Malvern Instruments Ltd, Malvern, UK). Measurements were 
taken at a scattering angle of 173°. Refractive index and viscosity constants were set at 1.33 
and 0.88 mPa.s, respectively. Samples were filtered through a 0.45 µm cellulose nitrate filter 





prior to the analysis. The scattering information was determined in an aqueous vehicle 
(acetate buffer 0.1 M) at increasing molar concentrations at the pH of the commercial 
product: pH 9 for tetracaine (79.3% unionized) and pH 7.4 for diclofenac diethylamine 
(100% ionized) and aciclovir (80% unionized), respectively. In addition, studies at pH 5 
(100% unionized) were performed for aciclovir. Control solutions were prepared in the same 
manner as for the test systems, but without the addition of drug. A discontinuity in the slope 
indicated the formation of a nanosized aggregate structure in the solution. The concentration 
at which this change occurred was assumed to be the critical aggregation concentration. The 
discontinuity in the linear model applied to the unattenuated derived count rate data was 
confirmed by the application of a second derivative function (OriginPro 9.1 Software, 
OriginLab, Northhampton, USA). The size of the molecular aggregates was detected by 
converting the light scattering signal into a hydrodynamic radius using the Stokes–Einstein 
equation given in Equation 3.1. The zeta potential of the aggregate containing solutions was 
determined in the same vehicle employed for the molecular aggregates analysis and the 
concentration of each drug was set above critical aggregation concentration at pH 7.4 for 
diclofenac diethylamine, pH 5 for aciclovir and at pH 9 for tetracaine.  
 
5.3.1.2 Apparent distribution coefficient 
 
The apparent drug distribution coefficients (Log D) were measured at room temperature, 
below and above the critical aggregation concentration in a two phase n-octanol and acetate 
buffer (0.1 M) system at pH 7.4 for diclofenac diethylamine, pH 5 for aciclovir and pH 9 for 
tetracaine as previously described (Valenta et al., 2000). After phase separation the aqueous 
phase was withdrawn and samples were centrifuged at 13.000 rpm (Biofuge, Heraeus, 
Germany) and aliquots of the liquid phase were then transferred into vials. The samples were 





analysed using the established HPLC methods for each model agent described in Section 
2.3.1. The apparent distribution coefficient was calculated using Equation 3.2. 
 
5.3.2 HPMC gel preparation 
 
HPMC was selected as the gelling agent because it is a non-toxic and non-ionic inert 
polymer, which is extensively used in the preparation of topical pharmaceutical formulations 
(Wu et al., 1998; Wade and Weller, 1995). A 3% HPMC gel was prepared with a drug load 
above and below the experimentally determined critical aggregation concentration for each 
test active. The concentration above the critical aggregation concentration was selected to 
match the concentration of the commercial product where possible. A gel formulation at a 
concentration of 0.5 and 151 mM and 0.12 and 43 mM was prepared for tetracaine and 
diclofenac diethylamine, respectively. Conversely, since no significant aggregation was 
detected at the pH of the aciclovir commercial product (pH 7.4; 222 mM), a 0.15 and 2 mM 
formulation was prepared at pH 5 because it showed the presence of aggregates. The gel was 
prepared by heating 25 mL of distilled water up to 70 °C and 1.5 g of metolose was gradually 
added while stirring until complete dissolution. The required amount of drug was weighed 
and then dissolved in 25 mL of distilled water. Both phases were combined and then stirred 
homogeneously in a stirring plate. The mixture was cooled in a fridge to 0 °C – 5 °C until it 
became transparent. The pH was then adjusted to the required value by adding NaOH (1M) or 
acetic acid as required. Finally, agitation was continued for at least 30 min until room 
temperature was reached. The pH of the gel was then checked by diluting and dispersing it in 
water 10% (w/v) in a manner described elsewhere (Dhawan et al., 2009). Visual inspection 
indicated that the formulated preparations remained physical stable for the entire duration of 
the experimental period and were found to be transparent and uniform in consistency. 





5.3.3 Permeation studies  
 
Adult pig ears were obtained from a local abattoir. The ears were removed from the carcass 
after hair removal. Any ears that were obviously damaged were discarded. The ears were 
cleaned with water, the residual water on the skin surface was immediately removed by 
blotting with tissue, visible residual hairs were trimmed carefully and the ears were stored at  
-20 °C. Freezing has been shown not to compromise the permeability of porcine skin (Weber, 
1993).  Porcine skin was defrosted and the subcutaneous fat carefully removed using a 
scalpel and cut into pieces of a suitable size to be mounted in the Franz diffusion cell 
(University of Southampton, UK) with the SC facing the donor compartment. For each 
experiment five different ears were used. The receptor phase consisted of a sponge 
compartment that was placed underneath the controlling barrier in intimate contact with the 
dermal tissue. Five diffusion cells were used for each experiment. Before the initiation of the 
studies an integrity test was performed, inverting each cell and visually inspecting for any 
signs of leakage. Leaking cells were excluded from the experiments. A 1 g aliquot of each in-
house formulated gel or 1 g of the commercial product was applied to the apical surface of 
the porcine skin to initiate the transport studies. In vitro permeation experiments were 
conducted as method described previously in Section 4.3.1 under atmospheric pressure (1010 
mBar) and under hypobaric pressure (500 mBar) using the pressure cell assembly over a 
period of 24 h. The samples were analysed employing the HPLC methods described in 
Section 2.3.1. The analysis of the chromatograms showed that matrix interference was 
negligible (data not shown) and drug degradation was not detected (< 2% change in peak 
area) for the entire duration of the experimental period.  
 





At the end of the transport studies, the pressure cell was dismantled and skin was removed 
and washed with distilled water to discard any residual donor solution and excess water was 
absorbed with tissue paper. The SC of the skin was removed by tape stripping (ca. 20 strips 
until the skin was translucent) using adhesive tape (Scotch 845 book tape, 3M, Bracknell, 
UK) as reported by Primo (2008) and the first strip was considered as part of the applied 
formulation and hence its removal was part of the formulation wash off (Sheth et al., 1987). 
The remaining tape strips were applied sequentially by pressing the adhesive tape onto the 
skin using a roller to stretch the skin surface (Surber et al., 2001). Once the strips were 
removed they were collected together, weighted and tetracaine and diclofenac diethylamine 
were extracted from the adhesive tape by immersing it in a 90% MeOH and 10% NaCOOH 
(0.1 M at pH 4) solution for 24 h, whereas for aciclovir a 95% hydrochloric acid (0.1 M pH 
3) and 5% MeOH solution was used. The adhesive tape was then removed from the drug 
solvent and discarded. The drug solutions were dried down and the residue was reconstituted 
in acetate buffer (0.1 M) at pH 7.4 for diclofenac diethylamine, pH 5 for aciclovir and in 
acetate buffer (0.1 M) at pH 9 for tetracaine and analysed employing the HPLC methods 
described in Section 2.3.1 for each model agent.  
 
Using the specimens from the stripped skin, the epidermis was separated from the dermis 
using a scalpel as reported by Argenta et al. (2014). Both the epidermis and dermis were 
homogenized (Ultra Turrax, Fisher Scientific, Leicester, UK) in the extraction solutions 
mentioned previously and were left to equilibrate for 24 h. Samples were then centrifuged at 
17000 rpm (Biofuge, Heraeus, Germany) for 15 min, the resultant supernatant was 
evaporated and the residue was reconstituted in acetate buffer (0.1 M) at pH 7.4 for 
diclofenac diethylamine, pH 5 for aciclovir and in acetate buffer (0.1 M) at pH 9 for 
tetracaine and analysed employing the HPLC methods described in Section 2.3.1 for each 





model agent. To assess the extraction recovery efficacy, skin samples were spiked with a 
known amount of each drug and the extraction procedure was conducted as previously 
described. The extraction recovery was measured by comparing the amount of each drug 
added and extracted. The extraction recovery of each drug from the receptor compartment 
was found to be to be 95.3 ± 2.5%, 93.4 ± 1.2% and 96.1 ± 2.9% for tetracaine, diclofenac 
diethylamine and aciclovir, respectively. Whilst the recovery extraction at 24 h period from 
the tape strips and skin tissue was found to be 96.16 ± 1.3% and 93.2 ± 5.2% , 94.4 ± 3.3% 
and  91.9 ± 7.2% , 95.3 ± 3.9% and 95.8 ± 9.1% (n = 5) for tetracaine, diclofenac 
diethylamine and aciclovir, respectively. Drug extraction was within the 100 ± 15% recovery 
rates, which was in line with published regulatory guidelines (Health and consumer 
protection directorate-general, 2006). The effect of local hypobaric stress upon drug 
cutaneous bioavailability was represented by an enhancement ratio (ER) which was 
calculated according to equation 4.1. Epidermal targeting potential (TP) was calculated 
according to equation 5.1, where AE and AD were the amount of drug (µg) per cm2 deposited 
within the epidermal (SC + viable epidermis) and dermal tissue under hypobaric or 
atmospheric pressure conditions. 
 TP =  𝐴𝐸
𝐴𝐷
                                                                                                                 (Equation 5.1) 
 
5.3.4 Statistical analysis 
 
All data were presented as mean ± standard deviation and statistical analysis of data was 
performed using SPSS version 16.0, as described previously in Section 2.3.4. In all cases, a 
statistically significant difference was defined as when p < 0.05 and denoted as: * p < 0.05, 
** p < 0.01 and *** p < 0.001.  The number of replicates was 5 in the permeation studies and 





3 in the apparent distribution coefficient determination, zeta potential and light scattering 
studies. 
 
5.4 Results and Discussion 
 
5.4.1 Aggregation characterization 
 
In order to characterize the aggregation behaviour of each model agent in the vehicles 
employed in the permeation studies photon correlation spectroscopy was used to track 
changes in the derived count rate at the pH of the commercially available product.  A critical 
aggregation concentration of 0.62 ± 0.1 mM and 0.15 ± 0.02 mM was registered at pH 9 and 
7.6 for tetracaine and diclofenac diethylamine, respectively (Figure 5.1 a and b), but no 
aciclovir self-association was detected at pH 7.6 of the commercial product (Figure 5.2 a). 
However, molecular aggregation was detected at pH 5 and a critical aggregation value of 0.3 































Figure 5.1. Graph depicting the changes in total light scattering in an aqueous vehicle for a) 
tetracaine (TC) at pH 9 and b) diclofenac diethylamine (DDEA) at pH 7.6  Each point 
represents mean ± standard deviation (n = 3). Inset graph represents the application of a 
second derivative function that confirmed the discontinuity in the slope of the derived count 
rate data. The critical aggregation concentration was determined to be 0.62 ± 0.1 mM and 




























Figure 5.2. Graph depicting the changes in total light scattering in an aqueous vehicle for 
aciclovir a) pH 7.6 and b) pH 5  Each point represents mean ± standard deviation (n = 3). 
Inset graph represents the application of a second derivative function that confirmed the 
discontinuity in the slope of the derived count rate data. The critical aggregation 
concentration was determined to be 0.3 ± 0.02 mM at pH 5. 
a) 
b) 





The average size of the diclofenac diethylamine molecular aggregates was significantly lower 
(p < 0.001) at 59.3 ± 10.2 nm than tetracaine at 190.2 ± 23.2 and aciclovir at 130.9 ± 17 
(Table 5.1). The relatively high polydispersity index (≥ 0.28) measured for all the test 
systems was indicative of the presence of different sized aggregates in solution (Table 5.1). 
This suggests that above the experimentally determined critical aggregation concentration 
each drug exists in solution as several supramolecular structures of various sizes. The zeta 
potential values obtained for diclofenac diethylamine (-9.19 ± 0.8 mV) indicates that a 
negatively charged aggregate was formed, whilst the values close to neutral for tetracaine 
(0.98 ± 0.5 mV) and aciclovir (-0.62 ± 0.3 mV) suggests that these species are predominantly 
unionized in solution (Table 5.1). The experimentally determined post-aggregation 
distribution coefficient for tetracaine (Log D 2.1 ± 0.16) and diclofenac diethylamine (Log D 
0.58 ± 0.06) were significantly lower (p < 0.05) when compared with the pre-aggregation 
values at 2.6 ± 0.12 and 0.8 ± 0.04, respectively (Table 5.1). It can be hypothesized that the 
aggregated species for these compounds had more favorable interactions with the aqueous 
vehicle in which they were dispersed. This was thought to result in a decrease in the 
hydrophobic characteristics of the molecules presented to the water/oil interface used to 
determine the distribution coefficient. The presence of an organized cluster where the polar 
region groups are displayed to the outer region (as suggested in Section 3.4.2) may provide a 
higher aqueous solubility due to a decrease in the interfacial tension between the aggregate 
surface and water and therefore explain the lower experimental Log D post-aggregation 
values compared to the pre-aggregation ones as previously reported for other molecules 
(Kronberg et al., 2014). In contrast, the post-aggregation distribution coefficient for aciclovir 
(Log D -1.65 ± 0.3) was not significantly different (p > 0.05) when compared to the pre-
aggregation value of -1.48 ± 0.7 (Table 5.1). 
 





Table 5.1. Characteristics of tetracaine (TC), diclofenac diethylamine (DDEA) and aciclovir 
(ACV) molecular aggregates. a hydrodynamic size, b polydispersity index, c  post aggregation 
apparent distribution coefficient and *  pre aggregation apparent distribution coefficient. 
 
 
5.4.2 Permeation studies 
 
The data showed that drug deposition within the different skin strata and transdermal 
permeation under both barometric conditions was equivalent (p < 0.05) when tetracaine, 
diclofenac diethylamine and aciclovir were presented to the skin at a concentration that was 
below CAC (Figure 5.3). In contrast, when the drugs were applied to the skin as an 
aggregated system, i.e. above their CAC, the application of topical hypobaric stimuli was 
found to alter the cutaneous bioavailability of all three agents. Tetracaine transdermal 
permeation increased by 8.9-fold (p < 0.01) compared to the unstressed skin transport 
experiment, but the amount of tetracaine detected within the different cutaneous strata was 
found to be equivalent (p > 0.05) (Figure 5.3 a). All the percutaneous data recorded for 
diclofenac diethylamine was found to be greater (p < 0.01) when the porcine skin was 
challenged with hypobaric stress (Figure 5.3 b). There was a higher retention (p < 0.001) of 
the drug in the epidermal tissue, i.e. a 12 and 16.9-fold increase in diclofenac diethylamine 
was recorded in the SC and epidermis, respectively. In addition, diclofenac diethylamine 
residence in the dermal tissue and transdermal permeation was found to be enhanced by 2.8 
Drug pH   Size a 
(nm) 
P.I. b Zeta potential  
(mV) 
Log D c 
TC 9 190.2 ± 23.2 0.34 0.98 ± 0.5 2.1 ± 0.16 (2.6 ± 0.12)* 
DDEA 7.6 59.3 ± 10.2 0.28 -9.19 ± 0.8 0.58 ± 0.06 (0.8 ± 0.04)* 
ACV 5 130.9 ± 17 0.46 -0.62 ± 0.3 -1.65 ± 0.3 (-1.48 ± 0.7)* 





and 2.4-fold, respectively. In a similar manner to diclofenac, all the percutaneous penetration 
indices recorded under barometric stress conditions were significantly different (p < 0.01) 
compared to atmospheric conditions when aggregated aciclovir was applied to porcine skin 
(Figure 5.3 c). More specifically, there was a 2.1 and 2.5-fold increase in the amount of 
aciclovir deposited in the SC and viable epidermis, respectively. In addition, the amount of 






















Figure 5.3. In vitro percutaneous penetration profile of tetracaine, diclofenac diethylamine 
and aciclovir in porcine skin 24 h after the application of a gel formulated with a drug load 
below (0.5 mM, 0.12 mM and 0.15 mM ) and above (151 mM, 43 mM and 2 mM ) critical 
aggregation concentration under atmospheric (1010 mBar) and hypobaric (500 mBar) 
pressure conditions, respectively. Each point represents mean ± standard deviation (n = 5).ER 
(Enhancement ratio) represents the ratio between the amount of drug found under hypobaric 









Hypobaric driven delivery was shown to be an effective means to achieve ‘targeting’ of 
diclofenac diethylamine and aciclovir within the epidermal tissue after topical application of 
the aggregated agents. This effect followed the trend diclofenac diethylamine > aciclovir with 
a calculated ‘targeting’ potential of 4 and 1.4 for the two agents, respectively (Table 5.2). 
Drug transport into the skin can be achieved via the confluent structure presented by the cells 
and the pores introduced into the skin structure. However, the importance of the passage of 
the drug aggregates suggested that the transappendageal pathway may be the most important 
in terms of hypobaric pressure induced percutaneous penetration changes. Although the data 
generated in Chapter 4 indicated that a facilitated intercellular and transcellular route through 
the alteration of the corneocytes was also possible, the data in this Chapter suggested that the 
follicular route was being used by the drug aggregates to alter skin deposition rather than the 
normal passive diffusion pathway. This was shown by the fact that barometric stress only had 
a significant impact on drug transport in the presence of drug aggregates. The data described 
herein was in good agreement with previously reported studies that demonstrate a much more 
efficient penetration of nanosized systems through hair follicles than small molecules under 
mechanical stress (Lademann et al., 2006). 
 
The hydrophilic characteristics of the diclofenac diethylamine (Log D 0.58 ± 0.06) and 
aciclovir (Log D -1.65 ± 0.3) supramolecular structures would make them more susceptible 
to pass into the epidermis via the follicular route, whereas the lipophilic tetracaine molecular 
aggregates (Log D 2.1 ± 0.16) may reside on the skin and interact with the lipid matrix 
surrounding the corneocytes and/or the lipid components of the follicular structures (Meidan, 





Table 5.2. The deposition of tetracaine (TC), diclofenac diethylamine (DDEA) and aciclovir (ACV) in the epidermal (SC + epidermis) and 
dermal tissue 24 h after a gel formulated with a drug load above critical aggregation concentration was applied to porcine skin under atmospheric 
(1010 mBar) and hypobaric (500 mBar) pressure conditions. Epidermal targeting potential is expressed as a ratio between the amount of drug 








 Skin deposition (µg/cm2)  
 
 

















TC 85.4 ± 2.8 109.1 ± 3.3 204.4 ± 16.5 228.4 ± 12.7 0.4 0.5 
DDEA 205.9 ± 91 3301 ± 1678.5 309.8 ± 12.4 864.2 ± 293.8 0.7 4 
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The smaller size of the diclofenac diethylamine (59.3 ± 10.2 nm) and aciclovir (130.9 ± 17 
nm) drug aggregates would also facilitate their more rapid passage into the skin compared to 
the tetracaine aggregates (190.2 ± 23.2 nm). The accumulation within the superficial layers of 
the SC of nanosized particles up to 200 nm has been previously reported through porcine and 
human skin (Menzel et al., 2004; Lademann et al., 1999) and the same mechanism may 
explain why only tetracaine showed an increased SC residence upon the formation of the 
aggregates even without the application of hypobaric pressure.  
 
The follicular pathway has been shown to be the primary penetration route for nanosized 
systems up to 600 nm (Lademann et al., 2015). As the follicular structure extend deep 
through the skin surface past the dermis (Delgado-Charro and Guy, 2001; Babiuk et al., 
2000) this allows drugs following the follicular route to access both the epidermal and dermal 
tissue (Rancan et al., 2009). From the data in this work, it is hypothesised that the smaller and 
charged characteristics of the diclofenac diethylamine molecular aggregates provided a better 
ability of these supramolecular masses to move by passive diffusion across the follicular 
epithelium into the hydrophilic interfollicular epidermis, which resulted in a greater 
epidermal targeting potential upon hypobaric driven delivery. Interfollicular epidermal 
passage of nanosized systems with a similar size to that recorded for diclofenac diethylamine 
aggregates has been previously reported by Vogt and his colleagues (2006). On the other 
hand, the size of the aciclovir and tetracaine drug aggregates might limit perifollicular 
diffusion at some extent and result in drug transport through the follicular structures directly 









5.4.3 The commercial product 
 
5.4.3.1  Formulation characterization 
 
Tetracaine is commercially available as a gel (Ametop®) that contains 4% (w/w) of the drug 
together with an undisclosed amount of xanthan gum as a gelling agent. The drug is presented 
as a two phase suspension system presumably to allow maximum thermodynamic activity to 
be retained throughout the entire storage and delivery process (Escribano et al., 2005; Paudel 
et al., 2010). Both the in-house produced tetracaine test system and the commercial product 
showed the presence of drug crystals with similar morphology when presented as a two phase 
suspension (Figure 5.4 a and b), hence it was assumed that the excipients in the commercial 
product did not significantly alter tetracaine/vehicle interactions (Higuchi, 1960). Diclofenac 
diethylamine is commercially available as a hydrogel (Voltarol emulgel®) that contains 
1.16% (w/w) of the drug salt together with an undisclosed amount of propylene glycol as a 
cosolvent (Cevc et al., 2001). Microscopic images revealed the presence of drug crystals in 
the in-house formulated diclofenac diethylamine test system (Figure 5.4 c), but this was not 
detected in the commercially available product (Figure 5.4 d), probably due to the use of 
propylene glycol as a cosolvent in the pharmaceutical preparation. Propylene glycol has been 
reported to enhance diclofenac diethylamine solubility (Khalil et al., 2000). Aciclovir is 
commercially available in a cream formulation (Zovirax® cream) that contains 5% (w/w) of 
the drug together with an undisclosed amount of propylene glycol as a cosolvent (Cevc et al., 
2001). In the aciclovir product and the in-house produced aciclovir test system drug 
crystallization was not observed.  















Figure 5.4. Light microscopy (Olympus BX50F, Tokyo, Japan) at a magnification of 40 × of 
the a) tetracaine commercial product, b) in-house tetracaine formulation above its critical 
aggregation concentration c) in-house diclofenac diethylamine formulation above its critical 
aggregation concentration and d) diclofenac diethylamine commercial product. 
 
5.4.3.2  Permeation studies 
 
The characteristics of the excipients and vehicles added to a formulation play a major role in 
determining the rate of uptake, penetration and residence of therapeutic agents through the 
skin (Idson, 1983). Therefore, it was of interest to assess the manner the formulation 
composition influenced the effects of hypobaric stress on the three model compounds. The 
data showed that tetracaine epidermal localisation was significantly lower (p < 0.001) upon 
a) b) 
c) d) 





the application of hypobaric stress (Table 5.3), but the the amount of drug detected in the 
receptor increased by 6.5-fold compared to the unstressed skin transport experiment (Figure 
5.5). The increase in tetracaine transdermal permeation was found to be similar to that 
recorded for the in-house formulated gel. However, the in-house formulated preparation did 
display an enhanced capacity (p < 0.001) to localise drugs within deeper skin layers (Table 
5.2 and 5.3) which resulted in an enhanced transdermal permeation (p < 0.001) (Figure 5.3 a 
and Figure 5.5). This was thought to be a consequence of the use of xanthan gum in the 
commercial product. The negatively charged carboxyl groups presented by the hydrocolloid 
gum have been previously reported to alter drug/drug interactions (Salim et al., 2012). In a 
similar manner, tetracaine-tetracaine self-association process may have been disrupted at 
least at some extent in the commercial vehicle product and therefore affect the ability of the 
drug aggregates to diffuse via the follicular route. All the percutaneous data recorded for 
diclofenac diethylamine was found to be greater (p < 0.01) when the porcine skin was 
challenged with hypobaric stress (Figure 5.5). There was a higher retention (p < 0.001) of the 
drug in the epidermal tissue, i.e. an 18.9 and 8-fold increase in diclofenac diethylamine was 
recorded in the SC and epidermis, respectively. In addition, diclofenac diethylamine 
residence in the dermal tissue and transdermal permeation was found to be enhanced by 1.54 
and 5.1-fold, respectively. The ability of the commercial product formulation to deliver the 
drug into the skin was significantly lower (p < 0.05) and diclofenac diethylamine localisation 
in the epidermal tissue was proportionally lower when compared to that displayed by the in-
house formulated gel. It was registered an epidermal targeting potential of 3.1 and 4, 
respectively (Table 5.2 and 5.3). This was thought to be a consequence of the use of 
propylene glycol in the commercial product, which may have altered drug/skin/vehicle 
interactions. Propylene glycol has been shown to limit the aggregation behaviour of several 
drug compounds and to interact with water molecules (Squillante et al., 1998; Trottet et al., 





2004; Miller et al., 1993; Dixit et al., 2002). It can be hypothesised that diclofenac 
diethylamine self-association was limited at some extent in the commercial vehicle product 
and this may have resulted in a lower follicular mass transport rate under hypobaric stress. In 
addition, it was though that propylene glycol-water structuring in the commercial product 
limited diclofenac diethylamine permeating species to participate in the transport process, 
which resulted in a low partitioning from the delivery vehicle as previously observed by 
Benaouda et al., (2012). 
 
 
Figure 5.5. In vitro percutaneous penetration profile of tetracaine, diclofenac diethylamine 
and aciclovir in porcine skin 24 h after the application of the commercial product, Ametop® 
(TC), Voltarol® (DDEA) and Zovirax® (ACV) under atmospheric (1010 mBar) and 
hypobaric (500 mBar) pressure conditions. Each point represents mean ± standard deviation 
(n = 5). ER (Enhancement ratio) represents the ratio between the amount of drug found under 
hypobaric and atmospheric conditions. Student’s t-test with * p < 0.05, ** p < 0.01, *** p < 
0.001. 
       
 
 
Table 5.3. The deposition of tetracaine, diclofenac diethylamine and aciclovir in the epidermal (SC + epidermis) and dermal tissue 24 h after the 
commercial product Ametop® (TC), Voltarol® (DDEA) and Zovirax® (ACV)  was applied to porcine skin under atmospheric (1010 mBar) and 
hypobaric (500 mBar) pressure conditions. Epidermal targeting potential is expressed as a ratio between the amount of drug retained in the 









 Skin deposition (µg/cm2)  
 
 


















TC 223.2 ± 9.3 100.9 ± 33.6 193.8 ± 56.2 122.2 ± 43.9 1.1 0.8 
DDEA 232.9 ± 37.9 2057. 6 ± 248.5 422 ± 22.8 650.8 ± 91.2 0.6 3.1 
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In a similar manner to diclofenac all the percutaneous penetration indices recorded under 
barometric stress conditions were significantly different (p < 0.01) compared to atmospheric 
conditions when aciclovir was applied to porcine skin (Figure 5.5). More specifically there 
was a 1.7 and 2.35-fold increase in the amount of aciclovir deposited in the viable epidermis 
and dermal tissue, respectively. The ability of the commercial product formulation to deliver 
the drug into the skin was significantly enhanced (p < 0.05), but aciclovir localisation in the 
epidermal tissue was similar when compared to that displayed by the in-house formulated gel. 
It was registered an epidermal targeting potential of 1.3 and 1.4 respectively (Table 5.2 and 
5.3). It can be hypothesised that a better ability of the commercial product to deliver greater 
amounts of aciclovir into the cutaneous tissue was due to the higher concentration of the drug 
in the application vehicle (222 mM vs 2 mM in the in-house formulated gel), which was 





The results from this investigation suggested that the application of local hypobaric stress 
was effective in targeting and retaining topically applied therapeutic agents within the 
epidermal tissue. However, this effect was only observed when the drug was presented to the 
skin as an aggregated system. It was thought that an enhanced follicular transport was the 
main mechanism that hypobaric driven delivery used to promote epidermal localisation. The 
epidermal targeting potential was calculated to be 4, 1.4 and 0.5 for diclofenac diethylamine, 
aciclovir and tetracaine, respectively. The smaller size (p < 0.001) and more hydrophilic 
characteristics (Log D 0.58 ± 0.06) of the diclofenac drug aggregates was believed to 
facilitate drug movement into the interfollicular epidermis, which resulted in the formation of 





an epidermal depot of the drug. The use of propylene glycol as a cosolvent in the commercial 
product was thought to decrease drug epidermal localization due to its ability to alter 
drug/skin/vehicle interactions. 
 
The in vitro data generated in this Chapter supports the hypothesis from Chapter 4 that the 
ability to alter cutaneous drug diffusion paths upon hypobaric treatment could potentially 
represent a new means to enhance topical bioavailability of therapeutic agents in medical 
practice.  To validate this, in vivo studies were required and hence, the next phase of this 
work aimed to satisfy this need using both a drug aggregate and a macromolecule. 
 































One of the major limitations of the in vitro transport data presented in Chapter 4 and 5 
specially when considering the application of barometric stress is the absence of the 
cutaneous microvascular flow, which has been shown to have a significant impact upon drug 
diffusion and distribution within the skin tissue and systemic circulation (Wojciechowski et 
al., 1985). Early studies by Schaefer and Stuttgen (1978) showed the importance of blood 
flow upon skin absorption by comparing in vitro and in vivo dermal levels of topically 
applied hydrocortisone. These workers reported a significantly higher amount of the drug in 
the dermal tissue in the in vitro studies. The co-administration of vasoactive agents (known to 
alter drug absorption into the systemic circulation) has provided further knowledge of the 
function of the local vasculator in drug penetration and distribution (Riviere et al., 1991; 
Singh et al., 1994). Theoretically, vasodilatation should allow a greater absorption of drug 
into the systemic circulation due to an efficient clearance of the penetrant by the skin 
microcirculation and vasoconstriction is expected to have a contrary effect. This hypothesis 
has been experimentally confirmed for a variety of drugs including lidocaine and flurbiprofen 
when co-administered with vasoactive agents (Riviere et al., 1991; Sugibayashi et al., 1999). 
In addition, faster drug uptake and distribution below the site of topical application and at 
contralateral sites due to vasodilation (Cross et al., 1999) and the opposite effect due to 
vasoconstriction (Higaki et al., 2005) have also been reported. It is believed that upon drug 
movement through the epidermis, the permeant is removed by the local blood supply once it 
reaches the dermal tissue or is transported into deeper tissues by diffusion, perfusion or a 
combination of both (Roberts, 1991; Cross and Roberts, 1999; Roberts et al., 2002). The 
orientation of the blood vessels has also been suggested to play a pivotal role in the rapid 
distribution of drugs from the epidermal-dermal interface to deeper cutaneous tissues 





(Roberts and Cross, 1999). It has been proposed that the orientation of the microvascular 
networks produces a “convective force” that generates a localized deep tissue mechanism, 
which is believed to result in a deeper tissue penetration at the site of application and away 
from the site of application for several compounds (Cross and Roberts, 1999; McNeill et al., 
1992; Monteiro-Riviere et al., 1993). However, how hypobaric pressure driven delivery 
affects in vivo drug diffusion through the skin and subsequent clearance by the systemic 
circulation is at the present not well characterised.   
 
There is conflicting evidence concerning the effects of hypobaric stress upon the local 
vasculature. Skagen et al., (1983) applied between 13 mBar and 330 mBar to the skin using a 
suction device and found that sub-atmospheric pressure changes of 53 mBar or more induced 
pronounced vasoconstriction and a corresponding increase in vascular resistance of about 
90% using a 133Xe wash-out technique. These findings were further supported by Kairinos 
and his colleagues (2009) who found a decrease in blood flow upon the application of local 
hypobaric stress to human tissue using radioisotope perfusion imaging. Conversely, an 
increase in blood flow has been reported when laser Doppler flowmetry was employed to 
investigate the cutaneous haemodynamic vascular responses to hypobaric stress stimuli. A 
continuous application of sub-atmospheric pressures between 166 to 660 mBar to the skin 
was reported to significantly increase cutaneous blood flow when compared to baseline 
measurements (Morykwas et al., 1997; Timmers et al., 2005). In addition, it has been shown 
a temporary and controlled dilation of the dermal blood vessels upon the application of sub-
atmospheric pressure between 170 and 510 mBar generated from a suction cup (Aguilar et 
al., 2005). In a follow up study, Childers et al., (2007) demonstrated that the application of a 
hypobaric pressure of 500 mBar resulted in a two-fold dilation of the dermal blood vessels 
with concomitant displacement towards the skin surface. However, a link between cutaneous 





blood flow changes induced by barometric pressure alteration and the penetration of 
xenobiotics into the cutaneous tissue has not been reported and hence this field warrants 
further investigation. 
 
The aim of this Chapter of the PhD thesis was to assess the effects of locally applied 
hypobaric stress upon skin microvascular flow and relate these findings with drug diffusion 
behavior across the skin and subsequent clearance by the systemic circulation. In order to 
achieve this aim Full-Field Laser Perfusion Imaging (FLPI) was used to determine the 
cutaneous haemodynamic vascular responses to hypobaric stress stimuli as previously carried 
out by Leutenegger and colleagues (2011). A radiolabelled (carboxyl-14C) dextran with a 
molecular weight of 10 kDa was selected as the model compound for in vivo permeation 
studies since the follicular route is the main pathway taken by this permeant to access the skin 
tissue (Section 4.4.3). In addition, it was anticipated that a greater understanding of the 
effects of the local vasculature upon skin permeation could be attained by comparing the 
results with the previously in vitro data collected for this agent (Section 4.4.2). Rat was 
chosen as the model for skin permeation due to its good accessibility and common use for in 
vivo permeation studies (Jung and Maibach, 2015; Godin and Touitou, 2007). Although, rat 
skin is more permeable than human skin, the permeation absorption kinetic parameters are 
generally comparable (Jung and Maibach, 2015; Godin and Touitou, 2007; Roberts and 
Mueller, 1990; Sato et al., 1991). Tape stripping and tissue homogenisation methodologies 
permitted the assessment of cutaneous bioavailability and tissue distribution profile by 
scintillation counting (Tsai et al., 1999; Schwarb et al., 1999; Wester et al., 1998). In order to 
investigate if the greater epidermal localization of diclofenac diethylamine upon hypobaric 
driven delivery (Section 5.4.2) would translate in a better anti-inflammatory efficacy a rat 
carrageenan-induced paw oedema model was used. For this purpose an in-house 





hydroxypropyl methylcellulose gel formulated with a diclofenac diethylamine drug load 
above critical aggregation concentration (Section 5.3.2) was selected as the test model. This 
allowed the formation of diclofenac diethylamine nanosized molecular aggregates with an 




Dextran (carboxyl-14C) with an average M.W. of 10 kDa and specific activity of 0.00006 
Ci/mmol was obtained from American Radiolabeled Chemicals, Inc. (St. Louis, USA).  
Diclofenac diethylamine BP grade (99.9%) was obtained from Chemos Group (Regenstauf, 
Germany). Concentrated hydrochloric acid and sodium hydroxide was from Fluka (Dorset, 
UK). Deionised water was obtained by purification using an Elgstat water purifier (Elga Ltd., 
Buckingham, UK). Hydroxypropyl methyl cellulose grade 65SH viscosity 50 cP with the 
brand name of Metolose was supplied by Shin-Etsu Chemical Ltd (Tokyo, Japan). Heparin 
sodium salt from porcine intestinal mucosa grade (I-A) 1800 USP units/mg, urethane, 0.7% 
(v/v) glacial acetic acid, isopropanol, λ carrageenan were purchased from Sigma Aldrich 
(Dorset, UK). Scintillation vials and hydrogen peroxide 30% were obtained from VWR 
International (Leicestershire, UK). Optiphase scintisafe gel was from Fischer Scientific 
(Leicester, UK). Soluene® 350 was provided by Perkin Elmer (Bucks, UK). Isoflurane 100% 














All procedures were conducted in accordance with the U.K. Animal Scientific Procedures 
Act (1986) and Amendments Regulations (2012) and approved by the King’s College 
London Animal Care and Ethics Committee. Sprague Dawley male rats (6 - 9 weeks old, ca. 
220 - 250 g; Charles River, Kent, UK) were caged in groups of 4 with free access to water 
and food. A temperature of 19 - 22 °C was maintained, with a relative humidity of 45 – 65%, 
and a 12 h light/dark cycle. Animals were acclimatized for 7 days before each experiment.  
 
6.3.2 Cutaneous blood flow measurements 
 
Rats were anaesthetized by inhalation of (1 - 3%) isoflurane / (1 – 3%) O2 and cutaneous 
blood flow was assessed in the whole plantar hind paw area using the Full-Field Laser 
Perfusion Imager (FLPI, Moor Instruments, Axminster, UK). Baseline blood flow in both 
hind paws was recorded prior to the application of hypobaric stress to ensure the 
haemodynamic vascular responses were stabilized following the induction of anaesthesia. 
The ipsilateral hind paw was subsequently exposed to 500 mBar for 7 min (group 1 n = 6) 
and 250 mBar for 28 min (group 2 n = 6) employing the adapted pressure cell described in 
Section 4.3.1 that was modified for in vivo purposes to fit the rat’s hind paw (Figure 6.1). The 
contralateral paw was untreated and served as a control. Changes in blood flow after these 
treatments were followed for 15 min. Rats were placed on a heating mat (Harvard Apparatus, 
Cambridge, UK) in the ventral position maintained at 36 °C for blood flow measurements. 
All animals were culled by a schedule 1 method upon termination of the experiment. Results 





were expressed as a measure of % change in blood flow from baseline for the entire recording 
period for 15 min following hypobaric treatment or maximum % increase in blood flow 
(representing maximum vasodilatation from baseline recorded to 0 – 2 min following local 
hypobaric treatment). The mathematical equation 6.1 was used to drive % change in blood 
flow and equation 6.2 to calculate maximum vasodilatation. 
 % 𝐷ℎ𝑎𝑎𝑎𝑎 𝑖𝑎 𝑏𝑏𝑏𝑏𝑏 𝑓𝑏𝑏𝑓 =   (𝐵𝐵𝐵𝐵𝐵  𝑓𝐵𝐵𝑓  − 𝐵𝑚𝑠𝐵𝐵𝐵𝐵𝐵 )
𝐵𝑚𝑠𝐵𝐵𝐵𝐵𝐵
 × 100                                  Equation 6.1 
 
𝑀𝑎𝑀𝑖𝑀𝑀𝑀 𝑣𝑎𝑠𝑏𝑏𝑖𝑏𝑎𝑣𝑎𝑣𝑖𝑏𝑎 =   (𝑃𝐵𝑚𝑘  𝑣𝑚𝑠𝐵𝐵𝐵𝐵𝑚𝑣𝑚𝑣𝐵𝐵𝐵  − 𝐵𝑚𝑠𝐵𝐵𝐵𝐵𝐵 )
𝐵𝑚𝑠𝐵𝐵𝐵𝐵𝐵

























                 Figure 6.1. Adapted pressure cell for cutaneous blood flow measurements. 
 
6.3.3 Pharmacokinetic studies  
 
Animals were anaesthetized by intraperitoneal injection of urethane (0.175 g/100 g) and 
placed on a heating mat (Harvard Apparatus, Cambridge, UK) in the ventral position 
maintained at 36 °C for the duration of the experiments. The dorsal fur was carefully 
removed (to avoid any damage to the skin) with an animal hair clipper and the donor 
compartment of a Franz cell with an available area of 2.1 ± 0.2 cm2 was attached to the 
shaved skin with glue, as previously described (Jing et al., 2011; Woan-Ruoh et al., 2008; 
Ren-Jiunn et al., 2007). Rats were bled by tail veil puncture and ca. 100 µL of blood was 
collected to a heparinized tube. To initiate the finite dose studies (Howes et al., 1996) a 300 
µL of 14C- labeled dextran in phosphate buffer (0.79 µCi equivalent to 1.428 pM) was added 
to the donor compartment. Permeation studies were conducted under atmospheric pressure 
(1010 mBar) for 7 h (n = 5). The same procedure was followed for the hypobaric pressure 





condition studies, but in this case the assembled pressure cell (Section 4.3.1) was 
immediately attached to the top of the donor compartment (Figure 6.2) and a sub-atmospheric 
pressure of 500 mBar was applied for the first hour (n = 5) of the experimental period.  At 
different time points the rats were bled by tail vein puncture and ca. 100 μL of blood was 
collected to a heparinized tube. Blood withdrawn did not exceed 10% of the 6.86 ± 0.53 
mL/100 g rat blood volume per day as previously determined by Probst et al., (2006). All 
animals were culled by a schedule 1 method upon termination of the experiment. Blood 
samples were transferred to 20 mL scintillation vials and solubilized with 1 mL of tissue 
solubilizer and shaken overnight at 55 °C. Before adding the scintillation cocktail, samples 
were decolorized by adding 0.3 mL of 30% H2O2 and isopropanol as an antifoaming agent. 
Samples were shaken at 55 °C for at least 3 h to expel H2O2 content and then mixed with 20 
mL of scintillation cocktail acidified with 0.7% (v/v) glacial acetic acid to eliminate any 
chemiluminescence and kept in the dark for 24 h before counting (Al-Jamal et al., 2012). 14C 
radioactivity was quantified for each sample using a LS6500 multi-purpose scintillation 
counter (Beckman Coulter, Brea, USA) with a defined limit of detection of 3 × background 
level measurements. Total radioactivity in the blood was calculated based on the total blood 
volume of 6.86 ± 0.53 ml/100 g previously reported for Sprague Dawley male rats (Probst et 
al., 2006). The results were expressed as amount of 14C- dextran (fg) per mL of blood (n = 5). 
 
 
















                       Figure 6.2. Adapted pressure cell for in vivo permeation studies. 
 
6.3.4 Cutaneous bioavailability and tissue distribution  
 
At the end of the transport studies, the dorsal skin underneath the Franz cell donor 
compartment and organs (heart, bladder, kidneys, liver and spleen) were collected, rinsed 
with distilled water and weighed. The SC was removed by tape stripping using adhesive tape 
(Scotch 845 book tape, 3M, Bracknell, UK). Each tape strip was weighted prior to application 
onto the skin and after removal in order to guarantee that the collected amount of SC was 
uniform throughout the samples (Weigmann et al., 1999; Marttin et al., 1996). The first strip 
was discarded (Sheth et al., 1987) and the adhesive tape was pressed onto the skin using a 
roller to stretch the skin surface and ensure a constant pressure during the procedure (Surber 
et al., 2001). The tape strips were dissolved in 15 mL of tissue solubilizer and left at room 
temperature for 2 days, as previously conducted by Rougier and Lotte (1993). A 2 mL aliquot 





was then transferred to 20 mL scintillation vials and mixed with 15 mL of scintillation 
cocktail acidified with 0.7% (v/v) glacial acetic acid to eliminate any chemiluminescence 
(Al-Jamal et al., 2012). The stripped skin and whole organs were homogenized using a tissue 
homogenizer (Ultra Turrax, Fisher Scientific, Leicester, UK) in phosphate buffer (0.2 mL per 
100 mg of tissue). An aliquot of 200 µL was transferred using a positive displacement pipette 
to 20 mL scintillation vials and 1 mL of tissue solubilizer was added and samples were 
shaken overnight at 55 °C. Samples were then processed as described in section 6.3.3. The 
extraction recovery of 14C-labeled dextran from the process was found to be 95.6 ± 3.3%. 
Drug extraction was within the 100 ± 15% recovery rates, which was in line with published 
regulatory guidelines (Health and consumer protection directorate-general, 2006). The results 
were expressed as amount of 14C- dextran (fM) per cm2 or per gram of tissue (n = 5). The 
effect of local hypobaric stress upon 14C-labeled dextran cutaneous bioavailability was 
represented by an enhancement ratio (ER) which was calculated according to equation 4.1. 
 
6.3.5 Anti-inflammatory assay 
 
The anti-inflammatory activity of diclofenac diethylamine formulated in a hydroxypropyl 
methylcellulose gel with a drug load above critical aggregation concentration (Section 5.3.2) 
was studied in a rat carrageenan-induced paw oedema under atmospheric (1010 mBar) and 
hypobaric (500 mBar) pressure conditions. Rats were randomly divided in 6 groups (n = 5) 
and the experimenter was blinded towards the different barometric pressure conditions 
applied to the ipsilateral hind paw at the time of the study. The contralateral paw was 
untreated for the duration of the experiments. Animals were anaesthetized by inhalation of (1 
- 3%) isoflurane / (1 – 3%) O2 and placed on a heating mat (Harvard Apparatus, Cambridge, 
UK) in the ventral position maintained at 36 °C for the duration of the anaesthesia. The 





contralateral and ipsilateral hind paw thickness in the dorsal plantar axis was measured with a 
caliper (Mitutoyo, Kanagawa, Japan) and the point of measurement was pre-marked as 
reference for subsequent measurements (Morris, 2000). The first and the second groups 
served as control and 1 g of in-house formulated gel (no drug was added) was topically 
applied under atmospheric and hypobaric pressure conditions (500 mBar for 30 min using the 
adapted pressure cell described in Section 6.3.1). In the third and fourth groups, 1 g of the 
formulated gel containing diclofenac diethylamine was topically applied to the hind paw 
glabrous skin under both barometric conditions whereas in the fifth and sixth groups the same 
formulation was delivered to the paw non glabrous skin. Carrageenan paw oedema was 
induced by sub-plantar injection (0.1 mL of 1% w/v carrageenan in 0.9% saline) after 30 min 
of topical application of the formulated gel and anaesthesia was interrupted. Animals were 
allowed to recover and changes in paw thickness were determined by three replicate 
measurements carried out at 60 min intervals. All animals were culled by a schedule 1 
method upon termination of the experiment. The results were expressed as paw swelling % 
(PS) which was calculated according to equation 6.3, where Te is the mean paw edema 
thickness at a specific time point after carrageenan induced inflammatory response and Ti is 




 ×  100                                                                                                (Equation 6.3) 
 
6.3.6 Statistical analysis 
 
Statistical evaluation was carried out using a statistical package for social sciences software 
(SPSs version 16.0, SPSS Inc., Chicago, USA). All data were checked in terms of normality 





(Kolmogorov-Smirnov test) and homogeneity of variances (Levene's test) prior to analysis. 
Data statistical analysis was performed using Student’s t-test, Mann-Whitney U-test or two-
way analysis of variance followed by Bonferroni’s comparison post-hoc test. In all cases, a 
statistically significant difference was defined as when p < 0.05 and denoted as: * p < 0.05, 
** p < 0.01 and *** p < 0.001. The number of replicates was 6 in the cutaneous blood flow 
measurements and 5 in the transport studies, cutaneous bioavailability, tissue distribution and 
anti-inflammatory assay. 
 
6.4 Results and Discussion 
 
6.4.1 Cutaneous blood flow measurements 
 
Following baseline blood flow measurements, the ipsilateral hind paw was subjected to 
hypobaric treatment (500 and 250 mBar for 7 and 28 min, respectively) whilst the 
contralateral paw remained untreated under atmospheric pressure. It was anticipated that the 
application of different barometric dose treatments to the skin would allow a broader 
understanding of the effects of hypobaric upon the cutaneous microvascular flow. The 
cutaneous vascular response to hypobaric stress treatment was assessed immediately after the 
application of local sub-atmospheric pressure for 15 min using full-field laser perfusion 
imaging, to allow dynamic measurement, at a time period chosen to ensure that the response 
to hypobaric treatment was complete (return to base line levels) (Figure 6.3 a). The 
haemodynamic response to hypobaric stress stimuli resulted in significant increase in blood 
flow (p < 0.001) under both barometric stress conditions. The increase in local blood flow 
declined at ca. 3 min, which was in good agreement with previously reported maximum 
haemodynamic response period under hypobaric stress (Morykwas et al., 1997). Furthermore, 





maximum vasodilation was observed between 0 to 2 min following application of sub-
atmospheric pressure to the ipsilateral hind paw (peak vasodilatation, Figure 6.3 a) and 
determined as the % maximum increase in blood flow from the baseline line obtained under 
atmospheric pressure conditions (Figure 6.3 b). This response was not significantly different 
(p  > 0.05) under both hypobaric conditions, but there was a 51 ± 14.3 and 42.3 ± 8.5% 
increase in the ipsilateral hind paw blood flow from baseline upon treatment with 250 mBar 
and 500 mBar pressure conditions, respectively. The data suggest that haemodynamic 
response was time dependent and did not significantly change with a greater amount of 
mechanical stress as demonstrated elsewhere (Borgquist et al., 2010). Moreover, the 
application of hypobaric stress resulted in an increased blood flow at the contralateral sites of 
hypobaric treatment, as shown in Figure 6.4. The increase in cutaneous blood flow upon the 
application of sub-atmospheric pressures has been attributed to a pressure gradient between 
the surrounding tissues and the site of topical mechanical stress, with blood flow surging to 
the latter to increase perfusion pressure of the tissue, which originates an increase in the 



































Figure 6.3. Hypobaric stress induced vascular response a) representative % change in 
ipsilateral and contralateral (control) hind paw blood flow from baseline to 0 - 15 min 
following hypobaric stress treatment, # peak vasodilatation  b) % change in ipsilateral and 
contralateral (control) paw blood flow from baseline to 0 - 2 min following hypobaric 



















Figure 6.4. Representative full- field laser perfusion imaging pictures alongside grey scale picture showing blood flow at baseline, 2 and 15 min 
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6.4.2 Pharmacokinetic studies 
 
Topical application of local barometric stress resulted in a rapid appearance of the dextran in 
the systemic circulation after 1 h (Figure 6.5) with a detected concentration of 7.2 ± 2.81 
fg.mL-1 of blood. However, as the systemic levels of the rest of the experimental were found 
to be too low to be accurately quantified by liquid scintillation counting (values were below 
the defined limit of detection) parameters such as Cmax and Tmax could not be derived. One 
interpretation of this data was that the in vivo transdermal delivery of the 10 kDa dextran was 
enhanced during topical application of mechanical stress, i.e. for the 1 h duration of 
mechanical stimuli, but the effect was reversed by the re-establishment of atmospheric 
conditions at the surface of the skin. 
 
The in vivo and in vitro transdermal permeation upon hypobaric driven delivery (Section 
4.4.2) was compared through the analysis of the percentage of applied dose that reached the 
systemic circulation and receptor compartment as described elsewhere (Bronaugh and 
Maibach, 1985; Bronaugh and Franz, 1986; Wester et al., 1992; Dick et al., 1995; Dick et al., 
1997; Cnubben et al., 2002; Mavon et al., 2007; Griffin et al., 1999; Griffin et al., 2000). The 
detected amount of dextran corresponded to 0.004 ± 0.001% and 0.051 ± 0.002% of the 
applied dose in the in vitro and in vivo studies, respectively. The in vivo transdermal delivery 
was found to be significantly higher (p < 0.001) when compared to that observed in vitro 
(Figure 6.7) and  resulted in a 13-fold increase in the amount of drug that permeated through 


















Figure 6.5. Blood concentration vs time profile of 14C- labeled 10 kDa dextran in phosphate 
buffer (0.79 µCi equivalent to 1.428 pM) applied topically under atmospheric (1010 mBar) 
and hypobaric conditions (500 mBar). Each point represents mean ± standard deviation (n = 
5). # Values below limit of detection (< 3 × background level measurements). 
 
This was believed to be due to the barometric pressure opening of the follicular pathway (as 
demonstrated in Chapter 4), which combined with an increase in cutaneous blood flow 
resulted in a greater in vivo transdermal permeation. The significant role played by the 
heavily vascularized follicular structures upon rapid transdermal permeation has been 
previously reported when a vasodilator was topically applied in areas with varied follicle 
density (Jepps et al., 2013; Jacobi et al., 2006). It should be noted that urethane anaesthesia 
has been previously reported to decrease blood flow (Iwamoto et al., 1987; Sakaeda et al., 
 #        #        #         #         #        #         #        





1997) and hence clearance of the penetrant by the systemic circulation under both barometric 
conditions may potentially be reduced by the anaesthetic employed in this work. 
 
Compared to existing strategies to enhance percutaneous penetration of macromolecules, the 
transdermal delivery of the dextran in this work was found to be 125 and 19-fold higher when 
compared to in vitro rat skin data that applied iontophoresis delivery and SC removal 
respectively (Wu et al., 2007; Wu et al., 2006). In addition, the amount of absorbed dose 
under hypobaric stress was found to be 7-fold higher to that detected upon in vitro skin 
electroporation delivery of a similar molecular weight dextran (Lombry et al., 2000). 
Conversely, highly invasive methods such as the ablation of the SC by argon-fluoride laser 
were found to be more effective in delivering a 10 kDa dextran through the skin (Fujiwara et 
al., 2005). It is noteworthy that in some cases this comparison may be over exaggerated due 
to the absence of skin microcirculation and hence efficient clearance of the drug from the 
cutaneous tissue in the in vitro studies. Nevertheless, hypobaric pressure was shown to be a 
competitive efficient manner to push macromolecules into the skin. 
 
6.4.3 Cutaneous bioavailability and tissue distribution 
 
At the end of the transport studies, the dorsal skin and organs (heart, bladder, kidneys, liver 
and spleen) were collected and the amount of 14C labeled 10 kDa dextran was quantified in 
the different layers of the skin and tissues in order to determine cutaneous bioavailability and 
organ uptake under differential barometric pressure. The data showed that cutaneous 
bioavailability was significantly greater (p < 0.01) under hypobaric pressure conditions and 
this effect was more pronounced upon dextran localization in deeper skin tissues. The amount 
of dextran found in the SC and dermal tissue was 4.3 and 5.7-fold higher, respectively (Figure 





6.6). The enhanced drug deposition within deeper cutaneous tissues was believed to be due to 
an increase in blood flow volume that has been previously reported to allow deeper tissue 
distribution below the site of topical application (Cross et al., 1999; Singh and Roberts, 1993; 
Singh and Roberts, 1996). In addition, the different anatomical configuration of the cutaneous 
vasculature under differential barometric pressure could have a significant role in the 
distribution of drugs from the epidermal-dermal interface to deeper cutaneous tissues 
(Roberts and Cross, 1999). The application of mechanical stress to the skin (ca. 500 mBar) 
has been shown to result in vertical displacement of dermal blood vessels towards the skin 
surface (Childers et al., 2007). It can be hypothesised that a close proximity of the 
microvascular network to the epidermal-dermal layer combined with an increase in blood 
flow volume produced a “convective force” that generated a localized deep tissue mechanism 
that resulted in a deeper tissue penetration at the site of application, as previously shown by 



























Figure 6.6. In vivo profile of 14C labeled 10 kDa dextran cutaneous bioavailability in rat skin 
layers under atmospheric (1010 mBar) and hypobaric (500 mBar) pressure conditions. Each 
point represents mean ± standard deviation (n = 5). ER (Enhancement ratio) represents the 
ratio between the amount of drug found under hypobaric and atmospheric conditions. 
Students t-test with ** p < 0.01, *** p < 0.001. 
 
The in vivo and in vitro cutaneous bioavailability upon hypobaric driven delivery (Section 
4.4.2) was compared through the analysis of the percentage of applied dose that reached the 
different layers of the cutaneous tissue (Figure 6.7). The detected amount of dextran within 
the SC layer corresponded to 5.76 × 10-4 ± 6.8 × 10-6% and 4.9 × 10-3 ± 2 × 10-3% of the 
applied dose in the in vitro and in vivo studies, respectively. In addition, the determined 
amount deposited within the dermal tissue was equivalent to 3.7 × 10-3 ± 3 × 10-4% and 2.5 × 





10-2 ± 7 × 10-3% of the applied dose in vitro and in vivo, respectively. The in vivo cutaneous 
bioavailability was found to be significantly higher (p < 0.01) when compared to that 
observed in vitro (Figure 6.7). It was registered a 9 and 7-fold increase in the amount of drug 
that was detected in the SC and dermal tissue, respectively. This data underpinned again the 
pivotal role of the cutaneous microcirculation in the diffusion partition process across the 
skin tissue that was not necessarily captured in traditional in vitro excised skin transport 













Figure 6.7. In vitro vs in vivo profile 10 kDa dextran cutaneous bioavailability in rat skin 
layers and transdermal permeation under atmospheric (1010 mBar) and hypobaric (500 
mBar) pressure conditions. Each point represents mean ± standard deviation (n = 5). Students 
t-test with ** p < 0.01, *** p < 0.001. 
 





Organ uptake of the 14C-labeled 10 kDa dextran following topical delivery is shown in Figure 
6.8. The overall biodistribution trend under both barometric conditions was in good 
agreement. There was a higher accumulation (p < 0.01) of the radiolabeled dextran in the 
heart, bladder and spleen with lower amounts detected in the kidneys and liver. However, a 
greater tissue uptake (p < 0.05) under hypobaric driven delivery was observed in all the 
collected organs, which was suggested to be attributable to a greater dextran uptake into the 
systemic circulation due to vasodilatation. A higher dextran systemic level may therefore 
explain the 64.4-fold increase in the amount found in the heart. The greater amount of 
dextran detected in the kidneys and bladder (p < 0.01) when compared to the low liver uptake 
under both barometric conditions suggest that the elimination of the 10 kDa dextran is 
dependent on the renal excretion rather than hepatic accumulation. A minimal dextran 
accumulation in the liver with a significantly higher (p < 0.001) amount detected in the urine 
following intravenous injection of a 4 kDa dextran has been previously described by Mehvar 
and his colleagues (1995). It has been reported in the literature that dextrans with a 
hydrodynamic radius < 2 nm (M.W. < 10 kDa) undergo significant renal clearance due to 
their ability to permeate through the glomerular wall pores (Chang et al., 1975; Chouinard-
Pelletier et al., 2012). Tissue distribution profile has been demonstrated to be dependent on 
the chemical structure of a molecule (van de Water et al., 2006; Li and Liang, 2010). These 
findings suggest that dextran chemical stability in this study was not compromised upon 
topical administration (i.e. presence of cutaneous metabolic systems) under both barometric 
conditions as demonstrated by the similar tissue uptake to that reported in the literature 
following intravenous administration of similar molecular weight dextrans. 














Figure 6.8. Biodistribution of 14C labeled 10 kDa dextran following topical application under 
atmospheric (1010 mBar) and hypobaric (500 mBar) pressure conditions. Each point 
represents mean ± standard deviation (n = 5). Students t-test with * p < 0.05, ** p < 0.01. 
 
6.4.4 Anti-inflammatory assay 
 
Carrageenan-induced paw oedema is a well-established model to evaluate the anti-
inflammatory activity of diclofenac (Halici et al., 2007; Manosroi et al., 2008; Moncada et 
al., 1973). Its pharmacologic action upon topical application is believed to be dependent upon 
tissue localization rather than a systemic effect (Nair and Taylor-Gjevre, 2010; Reiss et al., 
1986; Cross et al., 1998). Therefore, in order to investigate if a greater epidermal localization 
upon hypobaric driven delivery (Section 5.4.2) would translate in a better anti-inflammatory 
efficacy; diclofenac diethylamine was presented to the skin as a nanosized aggregated system 





(Section 5.3.2.). In addition, to elucidate the possible contribution of the follicular route upon 
nanosized cutaneous transport the in-house formulated gel was applied in the glabrous 
(plantar) and non glabrous skin (dorsal). 
 
Intraplantar injection of carrageenan in rats led to a time-dependent increase in paw oedema 
(Figure 6.9 a, b and c). The oedema was significantly reduced (p < 0.01) over the duration of 
the experiment when diclofenac diethylamine was applied under atmospheric pressure both in 
glabrous and non glabrous paw skin. On the other hand, significant oedema decrease (p < 
0.001) was only observed upon 240 min and 180 min when the in house gel was topically 
applied under hypobaric stress to the glabrous and non glabrous skin, respectively. These 
findings suggest that a more rapid onset of anti-oedematous effect was achieved upon topical 
application under atmospheric conditions. To simplify data analysis between topically 
administration to the glabrous and non glabrous skin under differential barometric pressure, 
the area under the curve (AUC) of the % increase in paw swelling effect-time curve was 






























Figure 6.9. Time course for the anti-inflammatory activity of diclofenac diethylamine 
formulated in a hydroxypropyl methylcellulose gel (43 mM) on rat carrageenan-induced paw 
oedema under atmospheric (1010 mBar) and hypobaric (500 mBar) pressure conditions. 
Oedema was measured at 1, 2, 3, 4 and 5 h after the inflammatory challenge on the ipsilateral 
hind paw and is expressed as mean ± standard deviation (n = 5), a) paw swelling (%) upon 
topical administration in ipsilateral hind paw glabrous skin, b) paw swelling (%) upon topical 
administration in ipsilateral hind paw non glabrous skin, c) paw thickness (mm) over the time 
course of the study, d) area under the curve determined using the trapezoidal rule (arbitrary 
units). ** p < 0.01, *** p < 0.001 atmospheric vs control, # p < 0.05, ### p < 0.001 hypobaric 
vs control (Mann-Whitney U-test or analysis of variance, Bonferroni post-hoc test). 
a) b) 
c) d) 





Area under the curve analysis showed that despite of a more rapid onset of action upon 
topical application at atmospheric conditions, diclofenac diethylamine anti-oedematous effect 
was statistically equivalent (p > 0.05) to that observed under hypobaric stress over the time 
course of the anti-inflammatory assay when topically applied to both glabrous and non 
glabrous skin. The results suggest that diclofenac diethylamine had a significant anti-
inflammatory effect on carrageenan-induced paw oedema regardless of topical barometric 
conditions or skin physiology. Edema formation results as a consequence of a synergism 
between inflammatory mediators that increase vascular permeability and/ or mediators that 
increase blood flow (Ialenti et al., 1995). The data suggest that the cutaneous haemodynamic 
response to hypobaric stress did not alter the inflammatory process since the increase in paw 
oedema in the control was not significantly different (p > 0.05) throughout the experimental 
period at both barometric conditions. Although diclofenac diethylamine has been shown to 
provide a good permeation rate across the skin (Sengupta et al., 2015; Fini et al., 1999), it 
was expected that the rate of mass transfer across glabrous skin would be significantly lower 
when compared to non glabrous skin as was observed in previous studies for other molecules 
(Prausnitz et al., 2012; Jacobi et al., 2006). This lack of difference suggests that an excessive 




The results presented herein demonstrated the significant role played by the cutaneous 
microcirculation upon drug localization within the cutaneous tissue and subsequent uptake by 
the systemic circulation under barometric stress. The haemodynamic response to topical 
hypobaric pressure led to a significant increase in skin blood flow at the site of hypobaric 
treatment, which was thought to result in a significant higher dextran cutaneous and systemic 





bioavailability. The in vivo and in vitro data comparison further supported the importance of 
vasodilatation upon hypobaric driven delivery. The anti-inflammatory study showed that 
diclofenac diethylamine had a significantly anti-inflammatory effect on carrageenan-induced 
paw oedema regardless of topical barometric conditions or skin physiology. In conclusion, 
hypobaric driven delivery was shown to be competitive compared to the most prominent 
strategies to deliver drugs into the skin. Whereas these systems target the cutaneous tissue by 
changes in the penetration rate of the agents, the application of hypobaric stress can 
potentially alter cutaneous drug diffusion paths and blood flow which could represent a 
compelling prospect as a means to deliver therapeutic agents in medical practice. It may 
perhaps be more efficient however to use this strategy to enhance the percutaneous 
penetration of macromolecules rather than small molecular weight drugs. 
 



























For many therapeutic agents, percutaneous drug delivery presents many advantages when 
compared to other major routes of administration including oral and parenteral (Guy and 
Hadgraft, 2003; Williams, 2003; Prausnitz et al., 2004; Bronaugh and Maibach, 2005). These 
include the avoidance of first-pass metabolism, the provision of a drug reservoir that can be 
removed from the body and the possibility of a convenient and pain free means to provide 
controlled release of a drug over 24 h from a single application (Joshi and Raje, 2002; 
Roberts et al., 2002). However, drug deliver via the skin has yet to fully achieve its potential 
as an alternative route when compared to oral and parenteral administration because the 
selective permeability of the skin only allows relatively small lipophilic molecular weight 
drugs to penetrate into lower layers (Naik et al., 2000; Barry, 1983). As such, the greatest 
challenge is to widen the range of drugs that can be administered via this route to achieve a 
clinical relevant dose in the body. 
 
The administration of hydrophilic drugs via the skin has been difficult to achieve and the 
delivery of peptides, nano-particulate systems and macromolecules, including new genetic 
treatment employing DNA or small-interfering RNA has posed particular challenges 
(Prausnitz and Langer, 2008). Nevertheless, a variety of chemical and physical methods have 
proved successful in delivering large molecules into the cutaneous tissue, but an ideal system 
has yet to be produced (Arora et al., 2008; Prausnitz and Langer, 2008). Many of the 
challenges related with the strategies already developed are associated with achieving an 
appropriate balance between safety and cost-effectiveness. Their clinical success can be 
limited by their lack of reversibility and cost. Moreover, they usually involve the use of 
cumbersome devices that require the need of trained personnel and hence pose problems 
regarding patient self-administration and compliance. The application of topical barometric 




stress as a strategy to improve percutaneous drug delivery has received little attention and this 
study wanted to explore this enhancement technology further. 
 
The exposure of humans to barometric changes is becoming more common in the modern 
world. For example, the modern jet engine operates most efficiently at altitudes above 30 000 
ft. The atmospheric pressure outside a commercial aircraft with a flight altitude of 35 000 ft is 
3.4 psi (235 mBar), whereas the atmospheric pressure at sea level is 14.7 psi (1010 mBar). A 
standard aircraft is typically pressurized to maintain a cabin altitude of around 5500 ft and the 
passengers in this situation would be expose to a hypobaric pressure of 830 mBar. Whilst 
activities such as deep sea diving and hyperbaric medicine, both of which are becoming more 
popular, can expose the body to pressures of up to 8000 mBar. Physiological changes in 
blood circulation and respiration under hyperbaric and hypobaric pressures have been well 
documented, but the effects on xenobiotic entry into the body have not been systematically 
investigated. Whole body exposure to barometric pressure changes would be expected to 
have very different effects to local pressure changes induced by methods such as suction 
because the latter generates a pressure differential which could draw molecules across the 
barrier and have less profound effects on whole body physiology.  
 
Local barometric pressure changes at the apical surface of the skin have been previously 
reported to alter the mechanical and physiological properties of the cutaneous tissue. Topical 
application of hypobaric pressure generated from a suction cup device has been shown to 
result in a marked increase in TEWL, disorganization of the intercellular lipid bilayers, 
rupture of the corneosomes and thinning of the epidermis (Childers et al. 2007; Pedersen and 
Jemec 2006; Rawlings et al., 1995; Leveque et al., 2002). Furthermore, the application of 
mechanical stress to the skin has been demonstrated to alter cutaneous microcirculation and 




orientation of the local vasculature, albeit with conflicting evidence. Whereas a decrease in 
blood flow has been reported using radioisotope perfusion imaging (Skagen et al., 1983; 
Kairinos et al., 2009), a contrary effect was shown when laser Doppler flowmetry was 
employed to investigate the cutaneous haemodynamic vascular responses to hypobaric stress 
stimuli (Morykwas et al., 1997; Timmers et al., 2005). Further, a vertical displacement of the 
local vasculature towards the skin surface upon the application of a sub-atmospheric of 500 
mBar has been previously reported by Childers et al., (2001). However, a link between skin 
changes induced by barometric pressure alteration and xenobiotic percutaneous penetration is 
less predictable and at the present unknown. As such, the aim of this PhD was to investigate 
the effects of local barometric pressure changes upon cutaneous drug delivery with a view to 
understand if such an approach could be used to design a novel medicinal product.  
 
In order to accomplish this aim three relevant agents (tetracaine, diclofenac diethylamine and 
aciclovir) were selected based upon their different physicochemical properties. This was 
anticipated to allow a broader understanding of the effects of hypobaric driven delivery by 
establishing a relationship between the drug characteristics and the diffusion partition 
behavior through the cutaneous tissue. Thereby, an analytical method for each needed to be 
established and the transport methodology adapted for the specific application to this work 
overall aim. HPLC with ultraviolet detection was selected as the method to be implemented 
for each of the selected actives since their quantification by HPLC was reported to be 
reproducible, accurate and sensitive (Wang et al., 2003; Vemula et al., 2013; Boulieu et al., 
1997). The experimental transport setup was designed to investigate the parameters where 
tetracaine permeation could be determined under equilibrium conditions that allowed ‘free 
diffusion’ through the membrane (Section 1.4.2). Three different set of method parameters 
were optimised 1) the degree of ionization of tetracaine in the donor solution, which was 




achieved by tightly controlling the pH of the drug-saturated vehicles, 2) the effect of 
membrane thickness and 3) the influence of tetracaine donor solution pre-equilibration time. 
This was considered important to access before designing an optimal method for diffusion 
testing due to the complex solution state behavior shown by this active (Menon and Norris, 
1980; Guerin et al., 1980; Umemura et al., 1981; Zhang et al., 2007). 
 
The three verified HPLC methods for each model agent were shown to be ‘fit for purpose’, 
which was underpinned by a sound calibration curve linearity, specificity, repeatability and 
precision in accordance with ICH guideline recommended values (ICH, 1995). Tetracaine 
chemical stability assessment showed that tetracaine was prone to hydrolytic degradation in 
both acidic and basic environments. The analysis of the chromatograms revealed that the 
verified HPLC method was able to detect tetracaine chemical degradation and this was 
suggested to be attributable to the formation of p-n–butylaminobenzoic acid in solution as 
previously described by Menon and Norris, (1980). 
 
Only the permeation data through a 0.25 mm thick silicone membrane was thought to provide 
a suitable representation of tetracaine permeation behaviour across a hydrophobic controlling 
barrier. Changing the pH of the delivery vehicle and thus the degree of ionisation of the 
molecule was found to have a large influence on membrane permeation. A comparison of the 
steady-state flux from the drug saturated vehicles at pH 4 (predominantly ionised form in 
solution) and pH 10 (unionised form dominates in solution) demonstrated a better ability of 
the molecule to cross the barrier when it was presented as a unionised microspecies. This was 
believed to be due to the different degree of ionisation of tetracaine in the vehicles employed 
in the permeation studies. The hydrophobic characteristics of the molecule at pH 10 
suggested a facilitated drug movement across the lipophilic silicone barrier when compared 




to that registered at pH 4, which was in agreement with the pH-partition hypothesis (Shore et 
al., 1957). Surprisingly, lag time was significantly greater (p < 0.01) despite the better 
diffusion and partition characteristics of the unionised form when compared to that observed 
at pH 4. In addition, an increase in the application system pre-equilibration time was 
observed to result in slower drug diffusion through the membrane at pH 4. The data indicated 
that tetracaine permeation through a confluent barrier could not be explained by Higuchi’s 
equation of mass transport (Section 1.4.1). It was hypothesised that the decrease in 
permeation with an increase in donor solution pre-equilibration time and the differences in 
lag time at both pHs was due to drug-drug interactions in solution (Guerin et al., 1980; 
Umemura et al., 1981). A different molecular arrangement in solution of the drug was 
thought to alter tetracaine diffusion behavior through the barrier. This initial part of the work 
provided a suitable testing methodology that was not limited by drug depletion, spent receiver 
saturation or chemical degradation, which was deemed critical for the assessment of the 
effects of hypobaric driven delivery upon drug transport permeation. In addition, it 
demonstrated the importance of molecular aggregation in the transport of tetracaine. 
 
Molecular aggregation in solution was expected to have a significant influence on the 
pharmacological action of a drug since it can change the passive diffusion process through 
the cutaneous tissue and hence altering localisation at a receptor site (Schreier et al., 2000; 
Rossetti et al., 2011; Ueda et al., 2012). This is believed to happen due to intermolecular 
bonding in solution that generates a cluster of molecules that display different 
physicochemical properties to their monomeric counterparts (Florence and Attwood, 1998; 
Potts and Guy, 1995). It was thought that tetracaine self-association could explain the 
deviation from the Higuchi model of mass transport (Section 1.4.1) observed in the transport 
methodology development, albeit further investigations were necessary to confirm this 




hypothesis. For this purpose, a series of aqueous vehicles where the degree of ionization of 
both the tertiary and secondary amine was varied were utilised to understand the properties of 
tetracaine molecular aggregates that may form in topical preparations. These findings were 
linked to drug passive diffusion through a model synthetic membrane and porcine skin. 
 
The aggregation process was found to be more favourable at increasing pH when only the 
tertiary amine was protonated (i.e. at pH 9 of the commercially available formulation) 
whereas drug solutions containing species with some proportion of both the tertiary and 
secondary amine ionized (i.e. pH 4) displayed a significantly greater (p < 0.05) critical 
aggregation concentration. It should be noted that due to the analytical sensitivity of the 
assay, critical aggregation values reported in this work could be challenged since the presence 
of supramolecular structures in solution was only detected when drug aggregates displayed a 
hydrodynamic radius greater than 2 nm. However, in this case it was assumed that the data 
collected in this work provided a good indication of tetracaine molecular structure changes in 
solution. This assumption was supported by comparing the experimentally determined critical 
aggregation values recorded herein with previous reported literature, which suggested a better 
analytical sensitivity of light scattering when compared to other analytical methods. A 
favourable environment for drug-drug interactions was found to result in larger molecular 
aggregates in solution, which exhibited a zeta potential close to neutrality. This was 
suggested to be a result of the uncharged drug microspecies being in majority and these 
species migrating to the surface of the molecule to minimize its surface energy as was 
observed in previous studies for other molecules (Tanford, 1980; Israelachvili, 1985). This 
assumption was underpinned by molecular dynamic studies that suggested that upon self-
association, the protonated tertiary amine is positioned to the outer region of the 
supramolecular structure at pH 4 and hence, when a lower proportion of these species were 




present at a higher pH it makes sense that the drug aggregates would display lower 
electrostatic repulsion. Moreover, the appearance of ‘new’ vibrational bands in the FTIR 
spectra and NMR spectroscopy data further supported this hypothesis. 
 
The analysis of the permeation data suggested that when tetracaine was presented to the 
silicone membrane as an aggregated system, drug diffusion behavior was in good agreement 
with the pH-partition hypothesis (Shore et al., 1957). Wherein, the greater steady-state flux 
was determined at pH 10 when the unionised fraction accounted for ca. 95% of the total 
microspecies in solution. Conversely, the highest rate of mass transfer through porcine skin 
was registered at pH 7.6 when the unionised fraction represented only 9.88% of the tetracaine 
species in solution. The pH of the delivery vehicle was thought to have a negligible influence 
on skin permeability (i.e. SC isoelectric point 4.8 - 6) since the barrier characteristics of the 
cutaneous tissue have been previously reported to remain unchanged when exposed to 
delivery vehicles with pHs between 3.5 and 11 (Thune et al., 1988; Sznitowska et al., 2001; 
Zatz, 1991). This was believed to be due, at least at some extent, to stronger tetracaine/skin 
lipid interactions when the unionised species dominated in solution (Zhang et al., 2007), 
which may have limited percutaneous permeation through the biological membrane. An 
increase in lag time at higher pHs was surprising and it was thought to be a consequence of 
the presence of larger and more strongly bonded drug aggregates in the donor solution. It can 
be hypothesised that large hydrophobic masses (i.e. pH 9 Log D 2.1 ± 0.16; 188 ± 20.4 nm) 
may have difficulty in passing through or leaving a hydrophobic barrier like a silicone 
membrane or the skin despite the ability of the individual molecules to partition into the 
membrane. On the other hand, at lower pHs, the smaller size of the hydrophilic masses (i.e. 
pH 4 Log D -0.9 ± 0.03; 114 ± 8.3 nm) may result in a facilitated passage across the SC 
and/or through the pores introduced into the skin tissue compared to the basic pHs as 




previously reported for other local anaesthetics molecules (Horita et al., 2014). The 
properties of the supramolecular structures appeared an elegant means to explain the changes 
in diffusion speed through the controlling barrier at the different delivery vehicle pHs (Figure 
7.1). The findings from the study highlight the relevance of the complex drug-drug 
interactions upon transcutaneous permeation and how this process may change the topical 




















Figure 7.1. Diagram representing the effects of molecular aggregation upon tetracaine skin transport at different pHs. The presence of larger 
hydrophobic uncharged masses when only the tertiary amine (TCH+) was ionized (at pH 9 of the commercially available formulation) was 
coupled with a significantly slower diffusion rate (243 ± 10.9 min) through the controlling barrier. Whereas when both the secondary (TCH2+) 
and tertiary amine (TCH+) where ionized (pH 4) smaller hydrophilic charged masses were shown to diffuse more rapidly through the skin tissue 
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The primary focus of this study was to investigate the influence of locally applied hypobaric 
stress upon drug delivery into the skin. To accomplished this aim, the work adapted one of 
the most widely used test systems for studying in vitro skin permeability, the Franz diffusion 
cell (Franz, 1975), in order to generate a pressure differential at the apical surface of the skin. 
It was anticipated that the application of topical hypobaric pressure could potentially reverse 
the reduction in the permeation of topically applied aggregated systems through changes to 
the mechanical and morphological properties of the skin. Therefore, the experimental setting 
previously shown to result in optimal self-assembly configuration of tetracaine and hence 
allow a rapidly diffusing species available for transport through the skin was employed in the 
study. It was predicted that the balance between the ionic form (TCH+) and non ionised form 
of the drug (TC) at pH 7.6 allowed the molecule to pass into the skin via the transcellular, 
intercellular and follicular route, thus any changes in these routes induced by local barometric 
stress could potentially be picked up using tetracaine as the test species. Drug movement 
across the skin under hypobaric driven delivery was understood by relating the changes in the 
mechanical and morphological properties of the hypobaric stressed skin and the cutaneous 
deposition profile of tetracaine. 
 
The in-house designed pressure cell system was shown to be ‘fit for purpose’. The transport 
method limited data collection to a single time point and hence, other permeation parameters 
such as lag time and steady-state flux could not be derived from the experimental data. 
However, knowledge that tetracaine established steady-state transport through the skin after 
1h and that its diffusion process was linear for up to 7 h, strengthened the findings presented 
from this method. The use of the adapted cell demonstrated that topical application of 
hypobaric pressure improved drug delivery into the skin in the presence of the nanosized 
aggregates and this resulted in a significantly increase in cutaneous bioavailability (p < 




0.001). Furthermore, drug deposition within the epidermis was found to be proportional 
higher to that found in the SC and dermal tissue (25.6-fold vs 8.8 and 9.9-fold increase, 
respectively). In addition, tetracaine transdermal permeation was improved when hypobaric 
stress was applied to the skin; however with proportionally lower levels of drug crossing all 
the way through the barrier (4-fold higher) when compared to the amount retained within the 
cutaneous tissue.  
 
The mechanical and morphological changes in the hypobaric stressed skin suggested that the 
‘targeted’ tetracaine deposition to the epidermal layer was driven by the enlargement of the 
follicular infundibula (p < 0.001), reduced corneocyte size (p < 0.001) and skin thinning (p < 
0.05). The data suggested that an improved follicular transport and/or a facilitated 
transcellular and intercellular drug diffusion could be possible causes of the enhanced 
cutaneous bioavailability. Although, it was thought that the intercellular pathway could not be 
accessed by the tetracaine supramolecular structures (156.5 ± 15.5 nm) formed in the 
aggregated drug solutions used to administer the active, since the lateral and vertical gaps 
between porcine corneocytes have been previously reported to be ca. 19 nm (van der Merwe 
et al., 2006). The nanosized aggregate systems could have passed into the skin tissue by the 
follicular pathway. This was further supported by fluorescence micrograph pictures that 
revealed that the penetration of dextran nanosized molecules (4 kDa (0.45 nm); 10 kDa (1.9 
nm)) into the hypobaric stressed skin resulted in a greater fluorescence signal around the 
perifollicular area, which suggested that hypobaric treatment affects the performance of the 
hair follicles and hence increased drug transport into the tissue. It is important to note that 
due to the size of the molecular aggregates, drug transport via other pores introduced into the 
skin tissue (i.e. sebaceous and sweat glands) may also provide an effective means to 
circumvent the formidable barrier posed by the SC. However, these structures were difficult 




to visualise by fluorescence spectroscopy and hence their contribution to drug transport under 
hypobaric stress is at the present less clear and therefore should be investigated in further 
studies. 
 
One of the main challenges when developing new means to deliver drugs into the cutaneous 
tissue is the conservation of the skin’s barrier function upon treatment; hence skin integrity 
and the reversibility of any damage should be one of the primary concerns during this 
process. Histological and morphological studies indicated that the enhanced topical 
bioavailability of nanosized drug aggregates and macromolecules was accompanied by 
reversible changes in the mechanical properties of the skin and that the SC remained intact 
upon hypobaric treatment. This was considered to be the major advantage of this means to 
enhance xenobiotic penetration into the tissue compared to technologies such as laser ablation 
and tape stripping of the SC. 
 
Once mechanical stress was shown to be effective in delivering both small and large 
molecules into the skin, it was thought important to investigate how a drug’s physicochemical 
properties influenced the skin tissue distribution upon hypobaric driven delivery. In order to 
achieve this aim three model agents (tetracaine, diclofenac diethylamine and aciclovir) were 
formulated in a gel preparation in an aggregated/non aggregated state. The physicochemical 
characteristics of the drug aggregates and monomeric species was then related to their ability 
to diffuse through the hypobaric stressed skin.  
 
The penetration and permeation profile of the three drugs when it was thought that only the 
monomeric species was applied to the skin was found to be statistically equivalent (p > 0.05) 
under atmospheric and hypobaric pressure conditions. However, when topically applied as an 




aggregated system, hypobaric driven delivery altered the  cutaneous bioavailability of each 
active, albeit at a different extent. This provided a strong basis to suggest that barometric 
delivery was mainly functioning via the opening of the follicular transport route. Hypobaric 
driven delivery seemed to have an effect of ‘targeting’ diclofenac diethylamine and aciclovir 
within the epidermal tissue and this effect was most significant for diclofenac diethylamine 
then aciclovir. The calculated epidermal ‘targeting’ was found to be 4 and 1.4 for each model 
agent respectively, when considering the drug levels in the different layers of the tissue. 
Interestingly, the transdermal permeation followed the opposite trend in terms of the three 
compounds with highest amounts of tetracaine reaching the receptor compartment when 
compared to that registered for aciclovir and diclofenac diethylamine (8.9 vs 2.7 and 2.4-fold 
increase in drug permeation, respectively).  
 
These results might be attributable to the different physicochemical characteristics of each 
active in the delivering vehicle employed in the transport studies. The hydrophilic 
characteristics of the diclofenac diethylamine (Log D 0.58 ± 0.06) and aciclovir (Log D -1.65 
± 0.3) supramolecular structures would make them more susceptible to pass into the 
epidermis via the follicular route, whereas the lipophilic tetracaine molecular aggregates (Log 
D 2.1 ± 0.16) may interact with the lipid matrix surrounding the corneocytes and/or the lipid 
components of the follicular epithelium (Meidan, 2010; Huang et al., 2005; Williams, 2003; 
Hadgraft et al., 1998). It was hypothesised that the smaller and charged diclofenac 
diethylamine molecular aggregates allowed drug movement into the hydrophilic 
interfollicular epidermis most readily, as previously reported for nanosized compounds with a 
similar size (Rancan et al., 2009; Vogt et al., 2006), which resulted in a higher epidermal 
drug localisation upon hypobaric driven delivery (Figure 7.2). On the other hand, the size of 
the aciclovir and tetracaine drug aggregates might limit, at least at some extent, perifollicular 




diffusion into the epidermal tissue. This could have resulted in drug transport through the 
follicular structures directly into the dermis with subsequent diffusion across this layer, which 
may explain the greater transdermal permeation of these actives (Figure 7.2). It is important 
to note that other factors such as cutaneous drug metabolism and binding to cellular 
components of the epidermal tissue (Liu et al., 1991; Hikima et al., 2002; Roberts et al., 
2005) may have limited diclofenac diethylamine permeation into the underlying dermal tissue 
and therefore contribute to the epidermal residence of this agent under hypobaric driven 
delivery.  
 
The effect of the commercial product composition upon topical bioavailability was 
considered important to determine since the excipients added to a formulation play a major 
role in determining the rate of uptake, penetration, and residence of therapeutic agents 
through the skin (Idson, 1983). Therefore, it was of interest to assess the manner the 
formulation composition influenced the effects of hypobaric stress on drug transport. The 
presence of excipients known to alter drug/skin/vehicle interactions was shown to have a 
significant effect upon cutaneous bioavailability under hypobaric stress. For example, the 
epidermal localization of diclofenac diethylamine following topical application of the 
commercial product was proportionally lower to that obtained from the in-house formulated 
gel. This was suggested to be attributable to the use of propylene glycol in the Voltarol 
emulgel® preparation. Propylene glycol may have interacted with water molecules and/or 
created a less favourable environment for drug-drug interaction in the delivery vehicle 
(Squillante et al., 1998; Trottet et al., 2004; Miller et al., 1993; Shigeta et al., 2000; 
Benaouda et al., 2012) and hence reducing the amount of diclofenac permeation species able   
permeate into the skin via the follicular route. This again highlighted the role of the drug 























Figure 7.2. Diagram representing the postulated mechanism of diclofenac diethylamine (DDEA), aciclovir (ACV) and tetracaine (TC) enhanced 
topical bioavailability when administered as an aggregated system under hypobaric pressure conditions. A higher DDEA epidermal ‘targeting’ 
potential was thought to result from a greater transport of the aggregated species through the follicular route (1) followed by drug diffusion into 
the perifollicular epidermis (2). A greater TC and ACV transdermal permeation was thought to result from a facilitated follicular route (1) which 
led to drug transport directly into the dermis. It was believed that the intercellular (3) and transcellular (4) routes were mainly accessed by the 
monomeric species since drug aggregate diffusion via these pathways was limited by the size of the supramolecular structures. SC, stratum 
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The 10 kDa dextran was selected as the model compound for the in vivo transport studies 
since this allowed a greater understanding of the effects of the local vasculature upon skin 
permeation of a nanosized structure (10 kDa dextran has a reported size of 1.9 nm 
(Chouinard-Pelletier et al., 2012)). In addition, the activity of diclofenac diethylamine, the 
agent best localised in the epidermal tissue, was evaluated under differential barometric 
pressure in a rat carrageenan-induced paw oedema to assess if the epidermal localization 
upon in vitro hypobaric driven delivery would translate in an improved anti-inflammatory 
efficacy. These in vivo studies were considered important because the effects of the changes 
in cutaneous microvascular flow could be combined with the changes in skin penetration 
profile caused by hypobaric pressure.  
 
The application of sub-atmospheric pressure induced a haemodynamic response which was 
significantly greater (p < 0.001) compared to atmospheric conditions. This change in skin 
blood flow in combination with the opening of the follicular structures resulted in an 
improved transdermal bioavailability upon hypobaric treatment (Figure 7.3). The 
pharmacokinetic profile suggested that the transdermal delivery was only enhanced during 
topical application of mechanical stress and it was reversible upon re-establishment of 
atmospheric conditions at the surface of the skin. The higher dextran systemic levels resulted 
in a greater tissue uptake (p < 0.05) in the collected organs (Figure 7.3). The biodistribution 
data suggest that topical delivery did not compromise dextran chemical stability as it 
mimicked organ uptake following intravenous administration of a similar molecular weight 
dextran (Chang et al., 1975; Chouinard-Pelletier et al., 2012). In addition, cutaneous tissue 
availability was found to be statistically greater (p < 0.01) under hypobaric pressure 
conditions with proportionally higher amounts of drug found in deeper skin tissues (Figure 
7.3). It can be hypothesised that a different organization of the local vasculature network 




under hypobaric stress with concomitant increase in blood flow allowed deeper tissue 
distribution below the site of topical application as previously reported by other researchers 
(Cross et al., 1999; Singh and Roberts, 1993; Singh and Roberts, 1996). Evidence that the 
changes in local blood flow induced by barometric stress had a role to play in the enhanced 
percutaneous delivery under hypobaric pressure was provided by an in vitro-in vivo data 
comparison. The presence of the cutaneous microvascular flow resulted in a 13-fold increase 
in the amount of dextran that was able to cross all the way through the cutaneous tissue. 
Moreover, it was registered a 9 and 7-fold increase in the amount of drug that was detected in 
the SC and dermal tissue, respectively. It is important to note that changes in tissue integrity 
could have occurred between in vitro and in vivo assays and hence histological examinations 
of in vivo hypobaric stressed skin should be conducted in further studies. 
 
The diclofenac diethylamine anti-inflammatory assay that utilised a carrageenan-induced paw 
oedema model employed two different experimental settings in order to establish if the 
follicular route did have an influence upon diclofenac drug aggregates cutaneous transport. It 
was expected that due to the absence of follicular structures and lower permeability of the 
glabrous skin this would result in a lower anti-oedematous efficacy. However, the data 
suggest that diclofenac diethylamine was effective in reducing oedema formation over the 
experimental period regardless of topical barometric conditions or skin physiology. It can be 
hypothesised that the maximum therapeutic effect was achieved at the drug concentration 
used in this work. There was not the time or resources to tailor the applied dose to optimise 
the model. It is therefore suggested that lower concentrations of the drug should be employed 













Figure 7.3. Diagram representing the effects of topical hypobaric stress upon skin barrier properties and local vasculature. An enhanced 
cutaneous and systemic bioavailability of 10 kDa dextran with concomitant improvement in tissue distribution under hypobaric pressure 
conditions (500 mBar) was coupled with an increase in skin blood flow and facilitated cutaneous drug diffusion paths. An enhanced follicular 
transport (1 and 2) into the epidermal and dermal tissue was thought to be the main pathway for drug entry into the cutaneous tissue rather than 
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The data obtained from the PhD suggested that hypobaric driven delivery was an effective 
means to enhance percutaneous penetration. In addition, the data generated suggested that 
hypobaric stress was competitive with some of the most prominent alternatives (e.g. 
iontophoresis and electroporation). Whereas the clinical success of such approaches is usually 
restricted due to the disruption of the mechanical integrity of the skin, the application of 
hypobaric pressure was shown to only induce reversible effects and hence it may potentially 
represent a cost-effective means of delivering therapeutic agents in medical practise. 
However, clinical application will be dependent upon the ability of such a novel means to 
deliver relevant drug dose levels to human skin that are able to exert a topical and/or systemic 
pharmacological effect. It is important to note that both animal membranes employed in this 
project display different anatomical and morphological characteristics to that of human 
cutaneous tissue (e.g. larger diameter of the follicular opening in porcine skin and greater hair 
follicle density in rat skin) and hence drug transport upon the application of hypobaric stress 
may be over exaggerated in the studies presented herein. Therefore, further investigations 
employing human skin and using a wide range of hypobaric treatment doses would be 
valuable in order to find the optimal conditions for increasing permeation in medical practise. 
In addition, the use of other skin sources with varied hair follicle density (e.g. hairless rat skin 
and rabbit skin) may be useful to understand in greater detail the contribution of the follicular 
pathway upon hypobaric driven delivery. 
 
In the first part of the project it was demonstrated that molecular aggregation could modify 
the rate of mass transport through the skin and hence change the topical bioavailability of 
therapeutic agents. The data suggested that the presence of tetracaine unionized microspecies 
in the delivery vehicle led to the formation of larger supramolecular structures that resulted in 
a delayed diffusion through the skin. It can be hypothesised that this could be one possible 




reason that may contribute to tetracaine slow onset of topical anaesthesia when using the 
commercially available formulation (Ametop®). Therefore, it is proposed that a compromise 
between aggregate formation and the permeation rate for this molecule is required or a 
strategy to modulate this process should be sought to improve its clinical efficiency. This 
work is of particular relevance since the concept of optimising drug delivery to the skin by 
controlling drug aggregation has received little attention to date. Nevertheless, drug-drug 
interactions are known to occur in topical pharmaceutical preparations intended to be 
administered to the skin (Walters, 2002) and a large majority of pharmaceutical active 
compounds display amphiphilic properties that can lead to molecular aggregation (Berge et 
al., 1977). It is therefore suggested that this process should be studied while developing 
topical pharmaceutical preparations and the feasibility of adding compounds known to 
modulate drug aggregation such as electrolytes (Attwood and Udeala, 1975), surfactants 
(Rossetti et al., 2011; Shao et al., 1993) or polymers (Pygall et al., 2011) to the delivery 
vehicle should be investigated in greater detail. 
 
In the later part of the study, the application of topical hypobaric treatment has been 
demonstrated to improve the delivery of large molecules to the skin. The delivery of peptides, 
proteins and antigens via the skin is an attractive proposal when considering the treatment 
and prevention of diseases (Glen et al., 2000). The findings from this part of the project could 
have a significant clinical impact in the treatment of chronic diseases, such as diabetes, 
osteoporosis and growth hormone deficiency. The glycaemic control required to attenuate 
associated complications of diabetes mellitus often involves several daily subcutaneous 
injections of peptides such as insulin (5.8 kDa) or enenatide (4.1 kDa) that can result in poor 
patient compliance (Shivanand, 2010). The required daily dose of exenatide (10 µg) 
compares to the transdermal permeation of the 4 kDa dextran reported herein whilst insulin 




recommended systemic levels (272 ug) are considerably greater (Section 4.4.2). Likewise, 
parathyroid hormone (9.4 kDa) recommended systemic therapeutic levels (40 µg) for the 
treatment of osteoporosis are significantly higher compared to the transdermal permeation of 
a 10 kDa dextran registered in this study (Section 4.4.2). However, the development of a 
patch based formulation that can operate under differential barometric pressure may obviate 
this problem due to avoidance of peptide gastrointestinal degradation and first pass 
metabolism as reported elsewhere (Bastaki, 2005). In addition, an increased surface area 
available for drug diffusion and duration of hypobaric treatment might result in improved 
therapeutic systemic levels. Moreover, a patch-based formulation provides a needle free 
alternative that could improve patient adherence and compliance. It is anticipated that patient 
control over hypobaric treatment dose could result in a modulated rate of delivery which 
could be beneficial in glycaemic control. Other applications are also feasible, such as the 
topical delivery of human growth hormone (22 kDa), but further investigations using higher 
molecular weight dextrans would be needed in order to examine "cut-off" value of these 
technology. 
 
Vaccine delivery via the skin is a very attractive approach because it targets the cutaneous 
antigen-presenting cells (APCs) that may generate a strong immune response at much lower 
doses when compared to deeper injection (Prausnitz and Langer, 2008). It has been reported 
that cutaneous vaccination can allow antigen dilution up to one fifth and hence may provide 
the possibility to reduce vaccine cost (Nasir, 2008) and increase availability (Nel et al., 
2006). However, designing a cost-effective product to deliver a vaccine to the cutaneous 
tissue remains a challenge. There have been a number of devices engineered to deliver 
vaccines, but these tend to be costly due to the complexities of depositing large molecules to 
the skin. Recently, trans-follicular vaccination has been shown to be a promising approach to 




vaccine delivery (Mittal et al., 2013; Mittal et al., 2015; Combadiere et al., 2010; Baleeiro et 
al., 2013). The main aim of such a technology is to deliver antigens to the abundant 
perifollicular APCs without compromising the SC barrier function (Fan et al, 1999). 
Nanosized systems have been shown to be ideal vehicles for trans-follicular delivery, since 
they preferentially accumulate and penetrate deeper into hair follicles than conventional 
formulations (Lademann et al., 2015). Some experiments suggest that vaccination via this 
route may favor a CD8+ preferred response which would be appealing for developing 
vaccines against intracellular pathogens, cancer or virus infection (Combadiere et al., 2010). 
Thereby, a facilitated follicular route of nanosized compounds under hypobaric driven 
delivery could represent a compelling prospect as a novel means do induce skin vaccination. 
It is anticipated that the possibility of administering hypobaric driven vaccine patches by 
minimally trained personnel or patients themselves could not only facilitate compliance but 
also eliminate the risks involved with the use of hypodermic needles (Prausnitz and Langer, 
2008). In addition, such a novel means could become a simple, low-cost solution to the 
current challenges to transdermal vaccination.  
 
This research project has examined the potential of hypobaric driven delivery as a means to 
enhance percutaneous delivery of therapeutic agents. It was shown that hypobaric stress 
significantly improved the delivery of large molecules into the skin. The assessment of the 
mechanical and physiologic properties of hypobaric stressed skin not only provided a better 
understanding of the effects of topical mechanical stress upon the local vasculature and 
cutaneous diffusion paths but also allowed to gain a mechanistic insight into the contribution 
of such processes upon hypobaric driven delivery. The findings from this project could assist 
in the development of a novel pressure induced transdermal patch that could potentially be 
applied for the treatment of chronic diseases and for vaccine delivery. 
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